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Abstract 
The collecting duct of the distal nephron marks the final location where 
adjustments to Na
+
 excretion can be made, therefore determining the final 
concentration of Na
+
 conserved in the extracellular fluid which plays a role in 
governing overall blood volume and pressure. This transport of Na
+
 is subject to 
hormonal regulation but the signalling pathways underpinning this regulation 
however, are not fully understood. In this thesis the signalling pathways allowing 
both basal and insulin-stimulated Na
+
 absorption were explored in the murine 
collecting duct cell line, mpkCCDcl4. The effects of two insulin-sensitizing drugs, 
TZDs, on ENaC-mediated Na
+
 transport were investigated and the signalling 
pathways underlying two other hormonal regulators of ENaC, dexamethasone and 
vasopressin, were also examined. 
 
Unstimulated monolayers of mpkCCDcl4 cells generated spontaneous Na
+
 
absorption which was quantified by measuring equivalent short circuit current 
(Ieq). Selective inhibition of PI3-kinase, mTORC2 and SGK1 left ~80 % of the 
current intact, indicating these signalling molecules are not required for basal Na
+
 
transport. Acute addition of insulin stimulated Ieq and this occurred with a 
concomitant increase in mTORC2, SGK1 and Akt activity. Inhibition of PI3-
kinase abolished the insulin-stimulated response as well as phosphorylation of 
downstream substrates, indicating a crucial role of PI3-kinase. Inhibition of 
mTORC1 with rapamycin did not alter basal or insulin-stimulated Na
+
 transport. 
The mTOR inhibitors TORIN1 and PP242 could therefore be used to evaluate the 
role of mTORC2. These inhibitors greatly reduced insulin-stimulated ENaC-
mediated Na
+
 transport and also abolished SGK1 and mTORC2 activity, 
indicating a novel role of mTORC2. An inhibitor of SGK1, GSK650394A 
abolished insulin-stimulated Na
+
 transport and specifically inhibited SGK1 
acitivty demonstrating the importance of SGK1 in insulin signalling. The inhibitor 
Akti-1/2 also abolished insulin-mediated Na
+
 transport but this compound 
inhibited both Akt and SGK1 activity. The TZDs pioglitazone and rosiglitazone 
xviii 
 
did not alter basal or insulin-stimulated Na
+
 transport and had no effect on SGK1 
activity indicating these drugs do not alter Na
+
 absorption in this cell line. 
 
Dexamethasone stimulated ENaC-mediated Na
+
 transport in a similar manner to 
insulin and this could be blocked with rapamycin. This drug did not alter 
phosphorylation of NDRG1 indicating that dexamethasone stimulates Na
+
 
transport in an mTORC1-dependent manner but without altering SGK1 activity. 
Arginine vasopressin also stimulated Ieq but did so by reducing Rt with an 
associated depolarisation of Vt. Ieq could be blocked with amiloride and 
vasopressin-stimulated Ieq was insensitive to TORIN1 and PP242. Vasopressin 
suppressed SGK1 phosphorylation of NDRG1 but did stimulate protein kinase A 
(PKA) activity. Therefore vasopressin stimulates Ieq via a PKA-dependent but 
mTOR- and SGK1-independent pathway. 
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Chapter 1 - Introduction 
 
 
 
 
 
 
 
 
 
 
2 
1.1 Thesis overview 
The regulation of body fluid and volume is fundamental to blood pressure 
regulation. The kidneys play a vital role in this by filtering blood and selectively 
absorbing and secreting electrolytes, water, nutrients and hormones as well as 
waste products. Alterations to electrolyte transport along the nephrons in the 
kidney, in particular Na
+
 transport, have a critical effect on water movement. The 
final adjustments to Na
+
 retention are made in the collecting duct of the nephron 
and are subject to hormonal control and these hormones alter the activity of 
epithelial sodium channels, ENaCs. 
 
Whilst the natriferic effects of these hormones have been clearly demonstrated the 
signalling pathways underpinning these responses are not so clear. The scope of 
this thesis has been to investigate the signalling pathways allowing both 
spontaneous and insulin-stimulated Na
+
 transport in the collecting duct cell line, 
mpkCCDcl4. The effects of two other hormones, dexamethasone and arginine 
vasopressin were also examined. The mpkCCDcl4 cell line has previously been 
shown to exhibit spontaneous Na
+
 absorption that can be hormonally regulated 
(Bens et al., 1999, Shane et al., 2006, Nofziger et al., 2005, Robert-Nicoud et al., 
2001). Here the basal properties of these cells have been confirmed as well as the 
effect of acute stimulation with insulin (Chapter 3). Furthermore the effects of two 
TZDs upon basal and insulin-stimulated Na
+
 transport as well as SGK1 activity 
were investigated (Chapter 3). The role of PI3-kinase and mTORC1 under both 
basal and insulin-stimulated conditions were examined (Chapter 4). Using two 
novel inhibitors, Akti-1/2 and GSK650394A, the relative importance of both Akt 
3 
and SGK1 in spontaneous and insulin-stimulated Na
+
 transport was investigated 
(Chapter 5). Finally, the novel inhibitors PP242 and TORIN1 were used to target 
mTORC2 to investigate the role of this signalling molecule in basal Na
+
 
absorption as well as under insulin-stimulated conditions (Chapter 6). The 
stimulatory effects of the glucocorticoid dexamethasone and the peptide hormone 
arginine vasopressin on basal Na
+
 absorption were also quantified and the effects 
of TORIN1 and PP242 investigated (Chapter 6). 
 
This introduction provides a brief and general overview of the structure and 
function of the kidneys as well as a description of salt transport that takes place 
across the epithelia lining the distal nephron. The epithelial Na
+
 channel ENaC is 
then discussed in more detail, in particular previous studies regarding hormonal 
control of this channel and the signalling pathways proposed to be involved. 
Whilst this introduction provides a broad overview of previous work carried out, 
each chapter begins with a more specific introduction relevant to the particular 
signalling molecule(s) of interest. Similarly, each chapter closes with a specific 
discussion relevant to the data presented but an overall general discussion is given 
at the end of this thesis. Values of electrical parameters measured in larger scale 
experiments can be found in the appendix (Chapter 9). 
 
 
 
 
4 
1.2 Salt transport in the kidney 
1.2.1 Structure and function of the kidneys 
The kidneys are bean-shaped organs that lie behind the peritoneum of the 
abdominal cavity. They have several important functions in the body including 
excretion of metabolic breakdown products and toxins from the blood and the 
regulation of water and electrolyte balance (Koeppen and Stanton, 2007a). The 
kidneys also regulate acid base balance as well as the production or activation of 
hormones involved in erythropoeisis and the regulation of blood pressure and 
flow (Boron and Boulpaep, 2009b). Despite accounting for only 0.5 % of total 
body weight together, the kidneys receive ~ 25 % of the body’s cardiac output 
(Koeppen and Stanton, 2007a). Blood enters the kidney via the renal artery at the 
hilus and subsequently splits into smaller arteries that extend into the medulla and 
cortex. These arteries finally split into afferent arterioles that feed blood into the 
nephrons of the kidney. 
 
The nephron is the functional unit of a kidney and consists of a renal corpuscle 
(including a glomerulus, Bowman’s capsule and Bowman’s space) and a looped 
tubule. There are around one million nephrons in each human kidney and their 
function is to filter the blood across the glomerulus in the renal corpuscle into the 
Bowman’s capsule leading to the tubule where urine is formed (Boron and 
Boulpaep, 2009b). The filtrate is mainly composed of electrolytes including Na
+
, 
K
+
 and Cl
-
 since larger proteins cannot permeate across the glomerulus. The 
kidney filters ~ 180 L of blood per day but only ~ 2 L of this will leave the body 
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as urine. Therefore one of the main functions of the renal tubule is the 
reabsorption of electrolytes and water (Koeppen and Stanton, 2007a). This 
reabsorption takes place along the tubule of the nephron which can be split up into 
different subsections starting with the proximal convoluted tubule which exits the 
Bowman’s capsule followed by the proximal straight tubule (Koeppen and 
Stanton, 2007a). This leads into the loop of Henle which stretches down into the 
medulla and loops back up to the cortex where it becomes the distal convoluted 
tubule, the connecting tubule and collecting duct (cortical, outer medullary and 
inner medullary). The collecting duct stretches back down through the medulla 
and feeds into the renal pelvis leading to the ureter which connects to the bladder 
(Boron and Boulpaep, 2009b). The absorption of fluid and electrolytes along the 
tubule of the nephron occurs across epithelial cells lining the tubule. 
 
1.2.2 Epithelia 
Epithelial cells form a continuous sheet that lines the multiple segments of the 
renal tubules and it is across these cells that electrolytes and water are reabsorbed 
(Koeppen and Stanton, 2007b). Epithelia are characterised by tight junctions that 
couple cells together and this gives rise to polarised epithelia. Coupled cells have 
an apical membrane on one side of the tight junction facing the lumen of the 
tubule and a basolateral membrane on the other facing the extracellular fluid 
(Wills et al., 1996). This polarity allows differential expression of transport 
proteins including ion channels and solute transporters. In the body it is the 
epithelium that comes into contact with the outside world, lining the airways and 
alveoli, oesophagus, stomach, intestine as well as the tubules of the kidney 
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(Butterworth et al., 2009). These cells act as a barrier to the external environment 
but also allow selective movement of electrolytes and non-electrolytes between 
the external and internal compartments (Wills et al., 1996). Epithelia can be 
classed as “leaky” or “tight” depending on the permeability of the tight junctions. 
Along the nephron beginning at the proximal convoluted tubule, epithelia are 
leaky but become tighter towards the distal nephron (Boron and Boulpaep, 
2009c). This has bearing on transport since water and electrolytes can travel in 
both a transcellular (via transporters across the membrane) and a paracellular (via 
tight juntions) manner (Koeppen and Stanton, 2007b). The distal nephron is lined 
with tight epithelia which gives rise to transcellular electrolyte transport (Boron 
and Boulpaep, 2009c). 
 
1.2.3 Salt transport along the nephron 
The absorption of Na
+
 in the kidney is the most important determinant of the 
extracellular fluid and blood volume. This is due to Na
+
 movement creating a 
negative lumen which favours Cl
-
 absorption and the combined movement of 
NaCl creates an osmotic gradient that water will follow (Butterworth et al., 2009). 
The kidney can alter how much salt and therefore water is reabsorbed and this will 
also determine urine concentration. Along the nephron Na
+
 mainly moves across 
the epithelium in a transcellular manner, passively crossing the apical membrane 
of the epithelia via transporters specific to the segment of the tubule (Koeppen 
and Stanton, 2007b). This passive movement occurs due to a favourable 
electrochemical gradient for Na
+
 entry into the cell, generated by a low 
intracellular concentration of Na
+
 and a negatively charged cytosol with respect to 
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the lumen. Once inside the cell, Na
+
 is extruded across the basolateral membrane 
by Na
+
 / K
+
 ATPase pumps where three Na
+
 leave the cell in place of two K
+
 
entering; this action maintains the driving force for Na
+
 entry (Boron and 
Boulpaep, 2009c). The intracellular K
+
 then recycles out of the cell via ion 
channels in the basolateral and / or apical membrane depending on the segment of 
the nephron.  
 
The bulk of Na
+
 absorption along the nephron occurs across the proximal 
convoluted tubule, around 67 % of the filtered load, followed by a further 25 % in 
the thick ascending limb of the Loop of Henle. Only around 8 % of the filtrate 
remains as it moves into the distal tubule and collecting ducts (Boron and 
Boulpaep, 2009b). The proximal tubule and Loop of Henle are subject to 
tubuloglomerular feedback where increased fluid and Na
+
 reaching the distal 
nephron will signal a decrease in the glomerular filtration rate. In contrast, 
transport across the distal nephron, in particular the collecting duct, are finely 
controlled by various hormones and bioactive factors (Koeppen and Stanton, 
2007b). The transport of Na
+
 across the collecting duct marks the final location 
where adjustments to Na
+
 retention can be made (Pratt, 2005). The epithelium of 
this part of the tubule is characteristically very tight, and large potential 
differences across the membrane arise (Boron and Boulpaep, 2009c).  The 
pathway for apical Na
+
 entry in this part of the tubule is via the epithelial Na
+
 
channel, ENaC, and similar to the proximal parts of the tubule, Na
+
 / K
+
 ATPase 
pumps mediate extrusion of Na
+
 out of the cell and into the blood (Kellenberger 
and Schild, 2002). Figure 1.1 shows the major ion transporters present in principal 
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cells of the collecting duct. The apically expressed ENaCs mark the rate-limiting 
step of Na
+
 transport and are a target of hormones and other factors that regulate 
the fine control of Na
+
 and fluid balance in the final segment of the tubule (Bhalla 
and Hallows, 2008). The importance of these channels in regulating blood 
pressure has been highlighted by the discovery that several monogenic forms of 
hypertension are caused by mutations in the genes encoding ENaC (Hummler and 
Horisberger, 1999), this is discussed in more detail below. 
 
 
Figure 1.1 Ion transporters in principal cells of the collecting duct.  
Simplified schematic showing ion transporters present in principal cells of the collecting duct. In 
the apical membrane ENaC mediates Na
+
 entry into the cell and Na
+
 is then extruded across the 
basolateral membrane via the Na
+
 / K
+
 ATPase. The K
+
 that enters via the pump can leave via 
basolaterally expressed K
+
 channels or via the Rat Outer Medullary K
+
 channel (ROMK) in the 
apical membrane. Water is absorbed via the apically expressed Aquaporin 2 (AQP2) and the 
basolaterally expressed Aquaporin 3 (AQP3) and Aquaporin 4 (AQP4). 
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1.3 ENaC 
1.3.1 Expression and function 
The epithelial Na
+
 channel, ENaC, is primarily expressed in lung, colon, sweat 
and salivary ducts as well as the distal nephron (Garty and Palmer, 1997). These 
channels are located in the apical membrane of the epithelia lining these tissues 
and mark the initial step of transcellular Na
+ 
transport. In the lung this Na
+
 
transport, in tandem with Cl
-
 secretion via the cystic fibrosis transmembrane 
conductance regulator (CFTR), maintains the surface liquid lining the airways 
allowing normal respiratory function (Kellenberger and Schild, 2002). 
Furthermore, these channels play a vital role in clearing the fluid-filled foetal lung 
at birth (Kamynina and Staub, 2002). ENaC also functions to absorb salt from the 
secretions of exocrine glands including sweat, mammary and salivary glands 
(Garty and Palmer, 1997). In the kidney, ENaC is responsible for salt reuptake 
from the filtrate in the lumen and therefore plays an important role in the 
maintenance of overall blood volume and pressure. ENaC is highly sensitive to 
the K
+
-sparing diuretic amiloride (and its analogues) and triamterene (Snyder, 
2002). 
 
ENaC is composed of three subunits: α, β and γ which share ~ 30-35% amino acid 
sequence homology (Canessa et al., 1994). α-ENaC was initially cloned from rat 
colon and generated a small, amiloride-sensitive current when expressed in 
oocytes (Canessa et al., 1993, Lingueglia et al., 1993). β- and γ-ENaC were 
identified through functional complementation of α-ENaC in oocytes (Canessa et 
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al., 1994). Only α-ENaC can form a functional channel on its own, but when 
expressed with both β- and γ-ENaC, a 100-fold potentiation in amiloride-sensitive 
current was observed over that recorded from α-ENaC expressed alone (Canessa 
et al., 1994). Each subunit is made up of two membrane spanning domains, 
intracellular N- and C-termini and a large extracellular loop that contains several 
glycosylation sites (Snyder et al., 1994). 
 
Whilst α-, β- and γ-subunits are required to form a functional ENaC, the 
stoichiometry of this channel remains unclear. Several studies have concluded that 
there are twice as many α-subunits as β- and γ-subunits and the channel is 
tetrameric in structure with a stoichiometry of 2α:1β:1γ (Firsov et al., 1998, 
Kosari et al., 1998, Anantharam and Palmer, 2007). However, several other 
studies have found similar levels of all three subunits and propose a nonamer 
structure with a stoichiometry of 3α:3β:3γ (Snyder et al., 1998, Eskandari et al., 
1999, Staruschenko et al., 2005). The recent elucidation of the crystal structure of 
the acid-sensing ion channel 1 (ASIC1) in chicken, which is structurally related to 
ENaC, gives evidence that ENaC is in fact a heterotrimer with a stoichiometry of 
α:β:γ (Jasti et al., 2007). A δ-ENaC subunit has also been discovered and can 
form functional amiloride-sensitive channels alone but similar to α-ENaC, is 
potentiated with co-expression of β- and γ-ENaC (Waldmann et al., 1995). The 
expression of δ-ENaC is quite distinct from the other subunits, it is found in the 
testis, ovary, pancreas and to a lesser extent in the heart and brain (Waldmann et 
al., 1995). 
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ENaC is highly selective for Na
+
 over K
+
 (100:1), whilst more selective for Li
+
 
over Na
+
 (~1.5:1) (Palmer, 1992). The selectivity of the channel is partly due to 
the pore size allowing only the dehydrated form of Na
+
 and Li
+
 to be transported 
and not other larger cations. Therefore ENaC allows apical entry of Na
+
 into a 
cell, down its electrochemical gradient but does not allow K
+
 to leak back out of 
the cell (Snyder, 2002). The single channel conductance of ENaC is ~ 5 pS, it 
exhibits slow gating kinetics and is voltage-independent (Garty and Palmer, 
1997).  
 
1.3.2 The role of ENaC in maintaining blood pressure 
Na
+
 is the main component of the extracellular fluid and its movement can 
determine movement of water, therefore Na
+
 absorption in the kidney is a key 
regulator of blood volume and pressure (Guyton et al., 1972). With ENaC-
mediated Na
+
 transport in the collecting duct providing the final renal adjustment 
to Na
+
 balance, dysregulation of this transport can give rise to increased blood 
pressure (Warnock and Rossier, 2005). The critical role that ENaC plays in the 
regulation of blood pressure is highlighted by the clinical conditions that arise 
with mutations to genes encoding ENaC subunits. Gain of function mutations in 
ENaC subunits lead to a rare form of hypertension known as Liddle’s syndrome, 
whilst loss of function mutations produce pseudohypoaldosteronism type 1 (PHA-
I) characterized by salt wasting and low blood pressure. 
 
Liddle’s syndrome is an autosomal dominant form of salt-sensitive hypertension 
and is characterised by early onset hypertension often accompanied by metabolic 
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alkalosis and hypokalaemia (Rossier and Schild, 2008). Plamsa renin activity is 
reduced and aldosterone levels are low, this condition is sometimes known as 
pseudoaldosteronism (Lifton et al., 2001). The first study that linked Liddle’s 
syndrome with ENaC showed that the original kindred had a truncation in the 
carboxy-terminal of the β-subunit (Shimkets et al., 1994). Four additional 
kindreds revealed mutations in the same location on the β-subunit (Shimkets et 
al., 1994) and truncation of this terminal in the γ-subunit has also been shown to 
cause this form of hypertension (Hansson et al., 1995). The importance of the C-
terminal truncation was further demonstrated in a study where ENaC activity was 
increased in oocytes expressing COOH-mutated ENaC subunits (Schild et al., 
1996). Another study showed that oocytes expressing a truncated β-ENaC 
displayed a five-fold increase in amiloride-sensitive current accompanied with a 
two-fold increase in surface expression, indicating an increased number of 
channels and individual channel activity giving rise to the response (Firsov et al., 
1996). Staub et al. proposed that deletion of a proline-rich motif (PPPxY) in the 
COOH terminal of either β- or γ-ENaC prevented binding of a ubiquitin ligase 
known as Nedd-4 (Staub et al., 1996). This group demonstrated that the PPPxY 
motif, or PY motif, in the COOH terminal of ENaC subunits was a binding site 
for WW domains present in Nedd-4, thereby linking the ubiquitin ligase with 
ENaC (Staub et al., 1996). Since ubiquitination of proteins promotes 
internalisation and degradation, an inhibition of this process would lead to 
reduced internalisation of the subunits resulting in an increase in the number of 
channels in the membrane and therefore increased Na
+
 absorption (Rossier and 
Schild, 2008). A mouse model of Liddle’s syndrome where the C-terminus of β-
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ENaC has been deleted demonstrated that these mice developed normal blood 
pressure but when given a high salt diet developed high blood pressure and other 
symptoms synonymous with salt sensitive hypertension (Pradervand et al., 
1999b). An important feature of this mouse model is that mineralocorticoid 
regulation of ENaC was maintained, indicating that aldosterone exerts its actions 
via an alternate mechanism (Dahlmann et al., 2003). Together these studies 
highlight the role of ENaC in the regulation of blood pressure as shown by the 
gain of function mutation that gives rise to Liddle’s syndrome. 
 
Loss of function mutations in genes encoding the subunits of ENaC have also 
been shown to give rise to pseudohypoaldosteronism type I (PHA-I) (Schafer, 
2002). This disease is characterised by early onset salt-wasting, hypotension with 
hyperkalaemia and metabolic acidosis along with high levels of renin and 
aldosterone in the plasma (Lifton et al., 2001). There are two forms of PHA-I: an 
autosomal dominant form which is less severe and most commonly caused by 
mutations in the mineralocorticoid receptor (Geller et al., 1998); and an autosomal 
recessive form which has been linked to mutations in ENaC subunits (Hummler 
and Horisberger, 1999). Mutations have been found in the extracellular loop of the 
α- and γ-subunit (Firsov et al., 1999, Strautnieks et al., 1996) as well as in the N 
terminal of the α- and β-subunit (Chang et al., 1996). Firsov et al. demonstrated 
that mutations in the two cysteine-rich domains of the extracellular loop of ENaC 
subunits expressed in oocytes caused inactivation of the channel thought to be due 
to abnormal trafficking of ENaCs to the membrane (Firsov et al., 1999). Another 
group showed that expressing ENaC subunits with a mutated glycine in the N 
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terminal in ooctyes reduced amiloride-sensitive currents via alterations to open 
probability rather than channel surface expression (Gründer et al., 1997). Unlike 
in Liddle’s syndrome where the mutations were all in the PY motifs of the C 
terminus, the mutations that lead to PHA-I are not so conserved. Further 
investigation into the mechanism that allows these mutations of ENaC subunits to 
reduce Na
+
 absorption is clearly warranted. These findings again highlight the 
importance of ENaC in maintaining blood volume and pressure. 
 
Animal models where each of the subunits of ENaC were individually knocked 
out or disrupted have also revealed the importance of this Na
+
 channel. α-ENaC-/- 
mice suffer from respiratory distress syndrome and neonatal death (Hummler et 
al., 1996). Amiloride-sensitive currents were abolished revealing that functional 
ENaCs cannot be formed without the α-ENaC subunit. Due to the early death of 
these mice, determination of kidney function could not be fully addressed. 
However, in ENaC transgenic rescue mice where α-ENaC is expressed at a 
constitutively low level revealed that 50% of mice developed severe PHA-I and 
died within 2 weeks. The surviving mice displayed compensated PHA-I with 
normal acid / base and electrolyte values but had greatly increased plasma 
aldosterone levels (Hummler et al., 1997). These provide further evidence for the 
role of ENaC in the regulation of blood pressure. Mice with disrupted β-ENaC 
expression displayed a mild PHA-I phenotype but when challenged with a low 
salt diet, developed acute clinical symptoms of PHA-I indicating a role of β-ENaC 
in salt conservation (Pradervand et al., 1999a). γ-ENaC-/- mice die within 36 h due 
to severe PHA-I with urinary salt wasting and hyperkalaemia revealing that this 
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subunit plays a critical role in Na
+
 transport in the kidney (Barker et al., 1998). 
These data indicate that all three subunits of ENaC play an important role in 
regulating Na
+
 transport in the kidney whereas only α-ENaC appears to be critical 
for respiratory function. 
 
1.4 Mechanisms that regulate ENaC activity 
There are several factors that can modulate ENaC activity and they do so either by 
changing the number of ENaCs in the membrane, N, or by changing the open 
probability of the channel, Po (Butterworth et al., 2009). The former can be due to 
insertion of new channels into the membrane; either from a subapical pool of pre-
formed channels (Butterworth et al., 2005) or from delivery of newly synthesised 
channels (Boyd and Náray-Fejes-Tóth, 2005). Changes to the internalisation and 
degradation of ENaC mark another mechanism that can alter the surface 
abundance of these channels (Flores et al., 2003). Alterations to the open 
probability and the single channel conductance can also modulate ENaC activity 
(Tong et al., 2004b). A number of hormones and factors act to increase ENaC 
activity by the above mechanisms and these will be discussed below. 
 
1.4.1 Hormonal Regulation 
In response to a drop in blood volume and pressure hormones are released by the 
body to stimulate the kidney to increase Na
+
 absorption and subsequently fluid 
uptake (Boron and Boulpaep, 2009c). Two hormones most commonly associated 
with hormonal control of salt and water uptake in the distal nephron are the 
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mineralocorticoid aldosterone and the peptide hormone vasopressin (Kellenberger 
and Schild, 2002). The peptide hormone insulin has also been found to stimulate 
Na
+
 absorption in the distal nephron but the physiological role for this remains 
uncertain (Shane et al., 2006).  
 
1.4.1.1 Aldosterone 
Aldosterone is a steroid hormone synthesised in the adrenal cortex of the adrenal 
glands located above the kidneys. It is the final effector in the renin-angiotensin-
aldosterone axis and is released into the blood in response to a decrease in blood 
volume and pressure (Booth et al., 2002). Aldosterone exerts its effects in 
aldosterone-sensitive tissues including the renal distal tubule and collecting duct, 
the colon and the salivary ducts (Stockand, 2002). These tissues are lined with 
epithelia that contain ENaC in the apical membrane and it is modulation of this 
channel that aldosterone mainly targets. Aldosterone is thought to exert its effects 
by influencing gene expression although it has also been linked to the activation 
of certain signalling pathways. Aldosterone diffuses into the cell, binds the 
cytosolic mineralocorticoid receptor (MR) and the bound receptor complex then 
translocates into the nucleus. Here the bound receptor binds DNA binding sites, 
either steroid response elements (SREs) which promote activation of gene 
expression or negative steroid response elements (nSREs) which repress gene 
expression (Booth et al., 2002). More recent studies have found that steroid-bound 
receptors can also exert their effects via protein-protein interactions rather than 
binding DNA directly (Stockand, 2002).  
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There are two types of steroid receptor in kidney tissue, one with a high affinity 
for mineralocorticoids (MR) and one with a high affinity for glucocorticoids 
(GR). MR are found in aldosterone-sensitive tissues whereas GR are ubiquitously 
expressed (Booth et al., 2002). Glucocorticoids can bind both receptors and 
plasma levels of the endogenous glucocorticoid cortisol are nearly 100 fold 
greater than plasma levels of aldosterone. An enzyme present in aldosterone-
sensitive tissues known as 11-β-hydroxysteroid dehydrogenase type 2 (11β-
HSD2) acts to break down cortisol into cortisone which cannot bind MR and this 
action underpins the epithelial-specific action of aldosterone (Funder et al., 1988). 
Certain forms of hypertension are caused either by increased concentrations of 
aldosterone or cortisol abnormally stimulating Na
+
 transport by activating the MR. 
This is true in apparent mineralocorticoid excess (AME) syndrome, a clinical 
condition where patients present with early onset hypertension associated with 
hypokalaemia and metabolic alkalosis (New et al., 1977). This disease was shown 
to be caused by an absence of 11β-HSD2, with mutations found in the genes 
encoding this enzyme in AME patients (Mune et al., 1995). With a lack of 11β-
HSD2 activity, cortisol cannot be converted to cortisone resulting in excess 
binding of the MR (Ulick et al., 1979) and an abnormal stimulation of ENaC 
resulting in increased blood pressure. 
 
The effects of aldosterone on Na
+
 transport in the aldosterone-sensitive distal 
nephron (ASDN) can be split temporally into three phases: a lag period of 20-60 
min; an early phase 1-3 h of increased Na
+
 transport and a late phase after 3 h 
exposure of a maintained increase in Na
+
 transport (Loffing et al., 2001). The 
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early phase of increased Na
+
 transport is thought to be due to the transcription of 
immediate early genes that act to traffic pre-made transport proteins, including 
ENaC, to the cell membrane (Stockand, 2002). The late phase is associated with 
the transcription of the transport machinery including ENaC, Na
+
 / K
+
 ATPase 
and energy producing enzymes (Loffing et al., 2000, Masilamani et al., 1999). 
 
Whilst it has become clear that aldosterone can repress nearly as many genes as it 
can induce (Robert-Nicoud et al., 2001), several proteins encoded by early 
induced genes have received a great deal of interest due to their role in the 
regulation of Na
+ 
transport. These include: the serum and glucocorticoid-regulated 
kinase, SGK1; the Kirsten Ras GTP-binding protein 2A, Ki-Ras2A; and the 
glucocorticoid-induced leucine zipper protein, GILZ. Expression of these proteins 
is upregulated in renal epithelia following exposure to aldosterone and co-
expression of each of these proteins in oocytes expressing ENaC or in renal 
epithelia can increase ENaC activity (Stockand et al., 1999, Chen et al., 1999, 
Soundararajan et al., 2005). The signalling molecules involved in the aldosterone 
response can be seen in the schematic in Figure 1.2 Signalling pathways allowing 
hormonal regulation of ENaC in the collecting duct. 
. 
 
Out of these three aldosterone-induced proteins, SGK1 has been the main focus of 
several studies, (for review see Loffing and Korbmacher, 2009, Lang et al., 2009). 
Initially identified in a rat mammary tumour cell line, the expression of this kinase 
was shown to increase in response to both serum and glucocorticoid exposure 
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(Webster et al., 1993a). Subsequently SGK1 expression was also shown to 
increase in response to aldosterone in renal epithelia (Chen et al., 1999). Co-
expression of SGK1 with ENaC subunits in oocytes led to a marked stimulation of 
ENaC-mediated Na
+
 transport suggesting a role for this kinase in the regulation of 
ENaC (Chen et al., 1999, Shigaev et al., 2000). SGK1 activity requires 
phosphorylation of key residues by two kinases: phosphoinositide-dependent 
kinase 1, PDK1; and the mammalian target of rapamycin complex 2, mTORC2; 
both of which lie downstream of the phosphoinositide-3-kinase (PI3-kinase) 
(Kobayashi and Cohen, 1999, García-Martínez and Alessi, 2008). Aldosterone has 
been proposed to mediate its early effects on Na
+
 transport by inducing expression 
of SGK1 which has been shown to phosphorylate, and therefore inhibit, the 
ubiquitin ligase Nedd4-2 (Flores et al., 2005). 
 
Ki-Ras2A stimulates ENaC activity by stabilizing the channel in an open state 
(Stockand et al., 1999) however the mechanism by which it does this remains 
elusive. Ki-Ras2A can stimulate both PI3-kinase and mitogen-activated protein 
kinase (MAPK) signalling pathways, however only inhibition of PI3-kinase but 
not MAPK suppresses the natriferic response (Tong et al., 2004a). It is important 
to note that as Ki-Ras2a stimulates PI3-kinase activity this mechanism could feed 
into the SGK1 pathway and mark a point of convergence between two 
aldosterone-induced proteins (Booth et al., 2002). 
 
GILZ was originally discovered as a glucocorticoid-induced early response gene 
in T-lymphocytes (D'Adamio et al., 1997). It was subsequently shown to be an 
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aldosterone-induced protein in rat cortical collecting tubules as well as a murine 
collecting duct cell line (Muller et al., 2003, Robert-Nicoud et al., 2001). 
Overexpression of GILZ was found to increase ENaC-mediated Na
+
 transport in 
oocytes expressing ENaC subunits as well as in a collecting duct cell line 
(Soundararajan et al., 2005). This increase in Na
+
 transport was demonstrated to 
be due to inhibition of the extracellular regulated kinase (ERK) pathway 
(Soundararajan et al., 2005). The ERK pathway has been previously shown to 
play a role in ENaC-mediated Na
+
 transport as the addition of epidermal growth 
factor (EGF), which activates the ERK pathway, inhibits amiloride-sensitive 
currents (Shen and Cotton, 2003). GILZ is thought to inhibit this effect and this 
was demonstrated by Soundararajan and colleagues who showed that 
overexpression of GILZ in a murine collecting duct cell line, pre-stimulated with 
EGF, increased Na
+
 transport whilst at the same time decreased the 
phosphorylation of ERK (Soundararajan et al., 2005). ERK has been shown to 
inhibit ENaC activity via different mechanisms including degradation of β- and γ-
subunits downstream of protein kinase C (Booth and Stockand, 2003b) and 
downregulation of α-ENaC expression (Zentner et al., 1998, Lin et al., 1999). 
More recently ERK has been shown to phosphorylate residues on the PY motifs 
of both the β- and γ-subunits of ENaC which would facilitate their interaction 
with Nedd4 proteins and increase internalisation therefore reducing ENaC-
mediated Na
+ 
transport (Shi et al., 2002). Therefore, similar to SGK1, GILZ acts 
to disinhibit ENaC and it does this by preventing the effects of ERK on the Na
+
 
channel.  
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Figure 1.2 Signalling pathways allowing hormonal regulation of ENaC in the collecting duct. 
Schematic showing proposed signalling pathways allowing alterations to ENaC activity by the 
hormones: aldosterone (aldo), dexamethasone (dex), insulin and arginine vasopressin (AVP). 
Aldosterone and dexamethasone bind cytosolic receptors and migrate into the nucleus where they 
mediate expression of proteins including SGK1, KiRas2A and GILZ as well as increasing the 
transcription of α-ENaC. KiRas2a directly interacts with PI3-kinase therefore linking aldosterone 
action with the PI3K/SGK1/Nedd4-2 pathway; increased levels of SGK1 also feed into this 
pathway. GILZ inhibits the ERK pathway which lies downstream of protein kinase C (PKC) by 
downregulating expression of ENaC subunits but also by increasing the interaction of ENaC with 
Nedd4-2, thereby increasing internalisation. Insulin signals via PI3-kinase resulting in activation 
of SGK1 which phosphorylates Nedd4-2 preventing it from tagging membrane-bound ENaC for 
internalisation and degradation. AVP signals via protein kinase A (PKA) which has also been 
shown to phosphorylate SGK1 and inhibit Nedd4-2 marking SGK1 as a convergence point 
between aldosterone, insulin and AVP. Downstream of AVP, PKA has also been shown to 
phosphorylate Nedd4-2 marking a further convergence point. 
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1.4.1.2 Arginine Vasopressin (AVP) 
Whilst aldosterone is the major hormonal regulator of salt transport in the distal 
nephron, the peptide hormone arginine vasopressin (AVP) is a major stimulus for 
water uptake in the distal nephron as well as increasing salt uptake. AVP, also 
known as anti-diuretic hormone, is synthesised in the hypothalamus and released 
from the posterior pituitary in response to hypovolaemia and increased plasma 
osmolality (Boron and Boulpaep, 2009d). When AVP is released into the systemic 
circulation it binds V2 receptors in the basolateral membrane of the epithelia 
lining the collecting tubules and ducts (Loffing and Korbmacher, 2009). The 
bound G-protein coupled receptor stimulates adenylyl cyclase to produce cyclic 
adenosine monophosphate (cAMP) which in turn activates protein kinase A 
(PKA). PKA phosphorylates unidentified proteins that promote the trafficking and 
fusion of vesicles containing the aquaporin 2 (AQP2) water channels to the apical 
membrane, thus increasing water absorption from the filtrate (Boron and 
Boulpaep, 2009d). This cAMP-dependent pathway also increases the activity of 
ENaC by stimulating insertion of ENaCs into the apical membrane from a 
subapical pool rather than changes to Po (Butterworth et al., 2005). It has been 
proposed that PKA phosphorylates SGK1 (Perrotti et al., 2001) to exert its effects, 
marking a convergence point with aldosterone signalling (see Figure 1.2). It has 
also been proposed that PKA can phosphorylate Nedd4-2 in a similar manner to 
SGK1 and this provides another mechanism by which PKA could stimulate ENaC 
activity by increasing internalisation of the channel (Snyder et al., 2004b). 
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1.4.1.3 Insulin 
Insulin is a peptide hormone synthesised in the pancreas and is released in 
response to increased blood glucose levels and acts to stimulate the uptake of 
glucose from the blood into the liver, muscle and fat (Boron and Boulpaep, 
2009a). Insulin has also been found to stimulate Na
+
 absorption in the distal 
nephron, first discovered in diabetic patients where Na
+
 content in urine was 
increased when insulin treatment was halted (Atchley et al., 1933). Insulin-
induced Na
+
 transport was subsequently demonstrated to be mediated via apical 
ENaCs in the distal nephron, in particular in the collecting duct (Marunaka et al., 
1992, Shane et al., 2006). Insulin binds its tyrosine kinase receptor in the 
basolateral membrane of the epithelia lining the distal nephron which stimulates a 
PI3-kinase signalling cascade. It is stimulation of this pathway that leads to 
increased Na
+
 absorption as inhibiting PI3-kinase abolishes the response as 
demonstrated in renal epithelia cell lines (Staruschenko et al., 2007, Blazer-Yost 
et al., 2003). PI3-kinase phosphorylates phosphatidylinositol- 4,5-bisphosphate 
(PIP2) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3) which triggers a 
signalling cascade leading to the phosphorylation mTORC2 (Mora et al., 2004). 
mTORC2 phosphorylates SGK1-Ser
422
 on the hydrophobic domain and this 
phosphorylated residue becomes a substrate for PDK1 which then phosphorylates 
SGK-Thr
256
 thereby activating SGK1 (Pearce et al., 2010). As described above, 
SGK1 has been shown to phosphorylate residues on the ubiquitin ligase Nedd4-2 
which then prevents it tagging membrane-bound ENaCs for internalisation and 
degradation (Flores et al., 2005). Lee and colleagues have also proposed that 
downstream of PI3-kinase, activated Akt (Lee et al., 2007) can also phosphorylate 
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Nedd4-2 and reduce ubiquitination of ENaC (see Figure 1.3 for a more detailed 
diagram of insulin signalling). Whilst decreased ENaC removal from the 
membrane provides a mechanism to account for the increase in ENaC-mediated 
Na
+
 transport, several other studies have reported that insulin exerts its effects on 
ENaC by insertion of channels from an intracellular pool (Blazer-Yost et al., 
2004) or by increasing Po of the channel (Marunaka et al., 1992).  
 
 
Figure 1.3 Schematic of insulin signalling in the collecting duct. 
Insulin binds its receptor in the basolateral membrane of a principal cell. This results in 
autophosphorylation of the receptor / ligand complex which recruits PI3-kinase to the membrane. 
PI3-kinase generates PIP3 triggering a signalling cascade leading to phosphorylation of mTORC2. 
SGK1 is phosphorylated by mTORC2 then by PDK1, activating SGK1 which can phosphorylate 
and therefore prevent the ubiquitin ligase Nedd4-2 targeting ENaCs for degradation resulting in 
increased Na
+
 transport. It has also been proposed that Akt can be phosphorylated and activated in 
a similar manner to SGK1 and also phosphorylate Nedd4-2. 
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Whilst the signalling pathway underpinning the natriferic response to insulin in 
the distal nephron remains uncertain, it is clear that insulin can stimulate Na
+
 
uptake. Patients suffering type II diabetes, where cells lose responsiveness to 
insulin and can no longer clear increased blood glucose levels following a meal, 
can be treated with thiazolidinediones, TZDs, (Stumvoll and Häring, 2002). These 
drugs sensitize cells to insulin, but as the disease progresses this can be 
supplemented with insulin itself. Recently, side-effects of these drugs have been 
discovered, including fluid retention which can lead to oedema and congestive 
heart failure (Tang and Maroo, 2007). Initial studies proposed that abnormal 
stimulation of ENaC was the cause of this fluid retention (Guan et al., 2005) via 
an SGK1-dependent pathway (Hong et al., 2003). However, further studies have 
not found data consistent with this idea (Nofziger et al., 2005) and the roles that 
SGK1 and ENaC play in mediating these complications is undecided. 
 
1.4.2 Other factors 
As well as hormonal regulation, ENaC activity can be modulated by several other 
factors. These include self-inhibition by increases in either [Na
+
]i (Awayda, 1999)  
or [Na
+
]o (Van Driessche and Lindemann, 1979), changes in [H
+
]i (Harvey et al., 
1988) and intracellular levels of nucleotides (Thomas et al., 2001). The 
phosphoinositides phosphatidylinositide 4,5-bisphosphate (PIP2) and 
phosphatidylinoside 3,4,5-trisphosphate (PIP3) (Record et al., 1998) have also 
been shown to modulate ENaC activity. These lipid second messengers have been 
shown to directly bind ENaC and alter open probability as well as altering the 
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number of channels in the membrane (He-Ping et al., 2002). Bioactive factors 
including prostaglandins and endothelin have also been shown to alter ENaC 
activity (Guan et al., 1998, Bugaj et al., 2008). Protein kinase C (PKC) has also 
been proposed to regulate ENaC activity, the first such evidence came from a 
study that demonstrated acute addition of phorbol esters, activators of PKC, 
inhibited ENaC-mediated Na
+
 transport in A6 cells (Yanase and Handler, 1986). 
PKC has been reported to exert acute effects on ENaC activity due to either 
decreased Po or increased internalisation of the channels, as well as long term 
effects due to a decrease in levels of ENaC subunits (Stockand et al., 2000). 
Booth and Stockand proposed that long-term inhibition of ENaC activity by PKC 
is due to activation of the MAPK pathway as inhibitors of MAPK prevented 
inhibition of ENaC activity by PKC (Booth and Stockand, 2003a). Furthermore 
MAPK has been shown to phosphorylate residues on β- and γ-ENaC just proximal 
to the PY motif that increases the subunits interation with Nedd4-2 (Shi et al., 
2002). Another mode of regulation which has been the focus of recent research is 
the role of protealytic cleavage in the activation of ENaC (Vuagniaux et al., 2000, 
Hughey et al., 2003). Several studies have demonstrated that proteolytic cleavage 
of the extracellular loops of both α- and γ-subunits of ENaC results in an increase 
in Po (Hughey et al., 2003, Diakov et al., 2008).  
 
Trafficking and degradation of ENaCs encompasses another important regulation 
of ENaC activity. Following the discovery that mutation or deletion of the PY 
motif on β- or γ-ENaC caused Liddle’s syndrome (Shimkets et al., 1994, Hansson 
et al., 1995), a severe monogenic form of salt-sensitive hypertension, several 
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studies carried out investigations into the mechanism by which ubiquitination 
could modulate ENaC activity (Staub et al., 1996, Debonneville et al., 2001, 
Kamynina et al., 2001b). The E3 ubiquitin ligase Nedd4 was found to interact 
with ENaC subunits in vitro (Staub et al., 1996) and in vivo (Staub et al., 1997) 
via their WW domains. This suggested that ENaC was subject to ubiquitination 
and that this could regulate the number of channels in the plasma membrane and 
therefore ENaC activity. This was demonstrated in expression studies where co-
expression of ENaC subunits with Nedd-4 in oocytes inhibited amiloride-sensitive 
currents (Goulet et al., 1998). Oocytes expressing a mutated β-ENaC with a 
truncated C-terminus displayed increased amiloride-sensitive currents that were 
not inhibited by co-expression of Nedd-4 (Goulet et al., 1998). This demonstrated 
that Nedd-4 requires the C-terminal of β-ENaC to exert its inhibitory effects 
which supports the hypothesis that Nedd-4 interacts with PY motif in the C-
terminus of ENaC targeting it for degradation. Indeed inhibitors of the 
proteosomal and lysosomal pathways were found to increase the half life of ENaC 
subunits expressed in MDCK cells; demonstrating that both the proteasome and 
the lysosome play a role in ENaC degradation (Staub et al., 1997). In humans 
there are two related Nedd-4 proteins: hNedd4-1 and hNedd4-2 and Kamynina et 
al. demonstrated that only Nedd4-2 interacts with PY motifs on ENaC subunits 
and not Nedd4-1 (Kamynina et al., 2001b) 
 
SGK1 via its own PY motif was found to interact with Nedd4-2 and 
phosphorylate it at two conserved sites. If these sites were mutated, SGK1 could 
no longer stimulate ENaC activity suggesting SGK1 modulates ENaC via 
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interactions with Nedd4-2 (Debonneville et al., 2001). This would suggest that 
both the early action of aldosterone, which increases the abundance of SGK1 
(Chen et al., 1999, Náray-Fejes-Tóth et al., 1999); and the action of insulin, which 
stimulates a PI3-kinase pathway giving rise to increased SGK1 activity (Shane et 
al., 2006); is due to decreased Nedd4-2 interaction with ENaC giving rise to an 
increase in ENaC activity. Another hormonal regulator of ENaC vasopressin is 
known to bind basolateral V2 receptors and increase cellular levels of cAMP 
which activates PKA and stimulates ENaC activity by increasing the number of 
channels in the plasma membrane (Snyder, 2000). In transfected FRT cells cAMP 
was found to prevent Nedd4-2 inhibition of ENaC-mediated Na
+
 transport and 
when Nedd4-2 was silenced, cAMP could no longer stimulated amiloride-
sensitive currents (Snyder et al., 2004a). PKA was shown to phosphorylate 
Nedd4-2 at the same residues that SGK1 phosphorylated it and this provided 
evidence that aldosterone-, insulin- and vasopressin-mediated regulation of ENaC 
converge at the ubiquitin ligase Nedd4-2. 
 
The mechanism by which phosphorylation of Nedd4-2 reduces interaction with 
ENaC subunits was subsequently shown to be due to 14-3-3 binding proteins 
preferentially binding the phosphorylated Nedd4-2 (Bhalla et al., 2005). In 
oocytes expressing ENaC subunits, co-expression with Nedd4-2 abolished 
phenamil-sensitive currents and this was relieved by expressing SGK1 and further 
potentiated by including 14-3-3 (Bhalla et al., 2005). Furthermore, oocytes 
expressing a mutant 14-3-3 protein in oocytes with ENaC and SGK1 abolished 
SGK1-stimulated ENaC activity (Ichimura et al., 2005). In murine collecting duct 
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cells, silencing of the 14-3-3β isoform prevented aldosterone-induced amiloride-
sensitive currents and was the first study showing the regulation of ENaC by 14-
3-3 proteins in a native collecting duct cell line (Liang et al., 2006). This study 
provided further evidence that SGK1-induced phosphorylation of Nedd4-2 
increases its interaction with 14-3-3 proteins thereby reducing its interaction with 
ENaC. Together these data highlight a model by which hormones act to regulate 
ENaC activity and do so by preventing internalisation and degradation of the 
channel. 
 
As well as Nedd4-2 tagging ENaC with ubiquitin to target it for internalisation 
and degradation, it has been proposed that ENaC once internalised can be recycled 
and returned to the membrane (Butterworth et al., 2009). In murine collecting 
duct cells Butterworth et al. demonstrated that increased ENaC activity in 
response to AVP was due to insertion of channels from a subapical pool since 
inhibition of both exocytosis and endocytosis abolished this response whereas 
inhibition of translation did not (Butterworth et al., 2005). Endocytosis of ENaC 
was shown to be clathrin-mediated as ENaC immunoprecipitated with both epsin 
and adaptor proteins in mpkCCDcl4 cells and epsin also downregulated ENaC 
activity when co-expressed in oocytes (Wang et al., 2006). A study using MDCK 
cells stably expressing ENaC with various PY motif mutations demonstrated via 
immunofluorescence and live-imaging that Nedd4-2 and its interaction with the 
PY motif is critical for endocytosis and subsequent recycling of ENaC at the cell 
membrane (Lu et al., 2007). Therefore ubiquitination of ENaC not only results in 
degradation of the channel, it also acts as a signal for the channel to be 
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endocytosed to a subapical pool which can then be recycled back to the cell 
membrane. 
 
Clearly there are many factors that govern ENaC activity including hormonal and 
non-hormonal mediators. These agents act by altering either the number of 
channels in the membrane or the open probability of ENaC giving rise to a 
channel that has many levels of regulation. 
 
1.5 Signalling pathways underpinning hormonal control 
of ENaC 
Both aldosterone and insulin have been proposed to mediate increases in Na
+
 
transport in a PI3-kinase dependent manner. Studies in renal epithelial cell lines 
where PI3-kinase was inhibited using chemical agents prevented the increase in 
Na
+
 transport brought about by these hormones (Blazer-Yost et al., 1999, Blazer-
Yost et al., 2003). These studies highlighted that the spontaneous absorption of 
Na
+
 also appeared to be dependent on the activity of PI3-kinase since these 
inhibitors blocked basal currents (Păunescu et al., 2000). In the H441 human 
airway epithelial cell line and A6 toad kidney cell line, AVP-stimulated Na
+
 
transport was also shown to be PI3-kinase dependent since LY-294002 inhibited 
the natriferic response (Thomas et al., 2004, Edinger et al., 1999).  
 
Vasopressin exerts its effects on ENaC activity in the collecting duct by binding 
basolateral receptors which stimulates an increase in levels of intracellular cAMP 
31 
which in turn activates PKA resulting in an increase in ENaCs in the apical 
membrane (Snyder et al., 2004a, Morris and Schafer, 2002). Studies looking at 
the regulation of Na
+
 transport by AVP have proposed that similar to insulin, AVP 
increases SGK1 activity (Perrotti et al., 2001) which would then increase 
phosphorylation of Nedd4-2 and decrease its interaction with the subunits of 
ENaC. In contrast to this, Thomas et al. found that in H441 cells PKA did not 
increase SGK1 abundance indicating a lack of a role for this signalling molecule 
(Thomas et al., 2004). Another study also showed that in MDCK cells expressing 
SGK1, cAMP did not increase SGK1 activity but did increase cAMP activity 
shown by an increase in CREB phosphorylation (Shelly and Herrera, 2002). 
Snyder et al. showed that PKA could phosphorylate Nedd4-2 at the same residues 
that SGK1 could and that Nedd4-2 marked the convergence point between AVP 
and insulin. 
 
Whilst the evidence supporting the involvement of SGK1 in mediating the 
natriferic response to AVP is inconclusive, the evidence supporting a role for 
SGK1 in mediating the effects of both aldosterone and insulin is strong (Wang et 
al., 2001, Faletti et al., 2002, Shane et al., 2006). Wang et al. showed that in A6 
cells, the glucocorticoid dexamethasone increased SGK1 phosphorylation and this 
was potentiated with the addition of insulin indicating that both these hormones 
could increase the activity of this signalling molecule (Wang et al., 2001). 
Similarly Tong et al. found that aldosterone increased phosphorylated SGK1 
indicating an increase in active levels of this kinase (Tong et al., 2004a). As well 
as clearly increasing SGK1 activity, both aldosterone and insulin increase ENaC-
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mediated Na
+
 transport which can be mimicked with expression studies using 
SGK1. Overexpression of wild-type SGK1 in A6 cells greatly potentiated 
amiloride-sensitive short circuit current compared to control cells (Faletti et al., 
2002). The addition of insulin to control cells significantly stimulated the current; 
however in cells overexpressing a kinase dead form of SGK1, insulin could not 
stimulate the current demonstrating a role for SGK1 in the natriferic response to 
insulin (Faletti et al., 2002). Furthermore in FRT cells expressing ENaC subunits, 
silencing SGK1 expression abolished the insulin-induced amiloride-sensitive 
current (Lee et al., 2007). Similar to PI3-kinase, SGK1 has also been shown to be 
required for spontaneous Na
+
 absorption since a kinase-dead form represses all 
ENaC-mediated Na
+
 transport (Alvarez De La Rosa and Canessa, 2003). Whilst 
these studies provide convincing data concerning the crucial involvement of 
SGK1 in Na
+
 transport across the distal nephron, studies examining SGK1
-/-
 mice 
do not support this hypothesis. These mice do not show any overt phenotype until 
they are exposed to a low-salt diet where they then develop salt-sensitive 
hypertension (Wulff et al., 2002). The role that SGK1 plays in mediating both 
basal and hormone-stimulated Na
+
 transport therefore remains uncertain and 
warrants further investigation. 
 
The activity of SGK1 has been demonstrated to require phosphorylation of two 
residues by the kinases PDK1 and mTORC2 (Kobayashi and Cohen, 1999). 
Importantly, phosphorylation of SGK1 by mTORC2 is absolutely crucial for its 
activity (García-Martínez and Alessi, 2008). Whilst the role that mTORC2 plays 
in SGK1 activity seems clear, the importance of mTORC2 in mediating signalling 
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pathways involved in Na
+
 transport is not understood. If SGK1 is required for 
hormonal stimulation of Na
+
 transport then mTORC2 should equally be so, 
therefore further work on this kinase is clearly warranted. mTORC2 and PDK1 
also phosphorylate and activate Akt, a downstream target of PI3-kinase (Alessi et 
al., 1996, Sarbassov et al., 2005). Recently, Akt has also been proposed to 
mediate Na
+
 transport in a similar manner to SGK1 by phosphorylating the 
ubiquitin ligase Nedd4-2 (Lee et al., 2007). However, conflicting data does not 
support a role for Akt in either basal or insulin-stimulated Na
+
 transport (Arteaga 
and Canessa, 2005). Clearly the signalling pathways underpinning both 
spontaneous and hormonally stimulated Na
+
 transport are not fully understood. 
With the unmistakable importance of ENaC-mediated Na
+
 transport as a factor in 
blood pressure regulation as well as possible side effects in the treatment of type 
II diabetes, understanding these signalling pathways is of crucial importance. 
 
1.6 Thesis Aims 
Na
+
 transport in the distal nephron, in particular the collecting duct is subject to 
hormonal regulation by aldosterone, vasopressin and insulin. Whilst these 
responses have been demonstrated (Shane et al., 2006), the underlying signalling 
pathways involved in mediating these responses are not as clear. The role of 
insulin particularly has received less attention, yet for type II diabetic patients 
abnormal stimulation of Na
+
 transport through treatment with insulin is a serious 
side effect worth consideration. Further understanding of how insulin could 
produce side effects of increased blood pressure as a function of stimulating Na
+
 
34 
transport can only be elucidated if the signalling pathway underlying this process 
is understood. Furthermore, insulin-sensitizing drugs, TZDs, have been reported 
to cause side effects of fluid retention leading to complications including oedema 
and heart failure. Abnormal stimulation of ENaC in the collecting duct has been 
proposed to be responsible yet conflicting data leaves the subject unresolved 
(Guan et al., 2005, Nofziger et al., 2005). 
 
Previous studies examining the roles of PI3-kinase and SGK1 in hormonal 
stimulation of Na
+
 transport have utilised oocyte expression systems and the A6 
amphibian kidney cell line (Chen et al., 1999, Blazer-Yost et al., 2003). Whilst 
these studies have provided valuable information, how well they relate to 
mammalian systems is not clear. The creation of novel small molecule inhibitors 
has allowed a method by which to target specific proposed mediators of these 
signalling pathways (Feldman et al., 2009, Thoreen et al., 2009, Barnett et al., 
2005, Sherk et al., 2008, Folkes et al., 2008). Furthermore with the development 
of mammalian collecting duct cell lines these inhibitors can be tested in a native 
system (Bens et al., 1999). The main focus of this thesis is to determine the 
importance of PI3-kinase, mTORC2, SGK1 and Akt in mediating both 
spontaneous Na
+
 transport and the stimulation of this transport brought about by 
insulin. This has been carried in a murine collecting duct cell line using novel 
small molecule inhibitors. The role that two TZDs, pioglitazone and rosiglitazone, 
play in altering both basal and insulin-stimulated Na
+
 transport as well as SGK1 
activity was also investigated. The responses to two other hormonal regulators of 
Na
+
 transport were also examined: the glucocorticoid dexamethasone and the 
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peptide hormone arginine vasopressin. By using novel small molecule inhibitors, 
the pathways underlying these responses were investigated allowing a comparison 
of signalling pathways by three different hormones in a mammalian system. 
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Chapter 2 - Materials and Methods 
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2.1 Cell culture 
To study the signalling pathways allowing hormonal regulation of ENaC-
mediated Na
+
 transport in the collecting duct, a murine collecting duct cell line 
mpkCCDcl4 was used. This cell line was chosen as it represented a mammalian 
system in which the expression of native transporters including ENaC and Na
+
 / 
K
+
 ATPase were retained following immortalization (Bens et al., 1999, Summa et 
al., 2001). These cells were also reported to respond to the hormones aldosterone, 
insulin and vasopressin (Bens et al., 1999, Shane et al., 2006). During the course 
of the present study however, it became clear that the mpkCCDcl4 cells required 
supraphysiological doses (5 µM) of aldosterone to stimulate ENaC-mediated Na
+
 
transport and this highlights a limitation of using this cell line. Whilst this finding 
allowed us to investigate the signalling pathway allowing GR-mediated Na
+
 
transport it did not allow us to target the more physiological MR-mediated Na
+
 
transport. This finding highlights an inherent problem when utilising cell lines 
from the distal nephron and it is of note that there a large number of studies 
investigating the effects of aldosterone using this hormone at very high 
concentrations (≥ 1 µM) (Fakitsas et al., 2007, Summa et al., 2001, Robert-
Nicoud et al., 2001, Stockand et al., 1999, Helman et al., 1998). These cells did 
however form highly-resistive monolayers and generated spontaneous ENaC-
mediated Na
+
 absorption that responded to both insulin and vasopressin. Thus the 
mpkCCDcl4 cell line provided a useful model to investigate ENaC-mediated Na
+
 
transport so long as its limitations were noted and understood.  
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2.1.1 Routine culture 
mpkCCDc14 cells were routinely cultured in Dulbecco’s Modified Eagle Medium 
(DMEM) / F12 Ham’s media 1:1 mix (Invitrogen, UK) supplemented with 
hormones, growth factors and serum (Table 2.1) as specified by Bens et al. 
(1999). Fully supplemented media, hereafter called complete media, was used to 
culture the cells which were seeded and grown in 75cm
2
 filter capped culture 
flasks (Greiner Bio-one, Frickenhausen, Germany). Cells were incubated at 37°C 
in a humidified atmosphere of 13% O2, 5% CO2 and 82 % N2 and were used at a 
passage no greater than 45. Cells were passaged twice weekly at ~95% confluence 
using a Trypsin / EDTA solution (Sigma Aldrich, Poole, UK) to lift cells from the 
flask. Complete media was used to inactivate the trypsin / EDTA solution and 
cells were spun at 1200 rpm for two minutes before resuspension in complete 
media and counted using plastic haemocytometers (ISL “Fast Read”, Paignton, 
UK). Cells were then seeded into fresh flasks at a known density with media 
being replaced every two days. 
 
2.1.2 Cell culture for experimental use 
For experiments, cells were seeded onto permeable filters with 0.4 µM pore size 
(Corning Costar, NY, USA). Cell were seeded at either at 0.5 x 10
6
 cells on 12 
mm Snapwell membranes for Ussing chamber recordings or at 1 x 10
6
 cells on 24 
mm Transwell membranes for protein lysates. These cells were maintained in 
complete media for 6 days with media changes every two days. The media was 
then replaced with basal media supplemented only with charcoal stripped serum 
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and antibiotics, (Table 2.1) for 24 hours. This was then replaced with basal media 
completely free from serum (Table 2.1) for a further 18-24 hours prior to use in 
experiments. 
 
 
Table 2.1 Media compositions for mpkCCDc14 cell culture 
 
* Sigma Aldrich (Poole, UK) † Invitrogen (Paisley, UK) 
Supplement Complete Charcoal-
stripped 
Serum-free 
Fetal Bovine Serum (FBS) * 2% - - 
Charcoal Stripped FBS * - 2% - 
Sodium selenite * 5ng / ml - - 
Insulin * 5µg / ml - - 
Transferrin * 5µg / ml - - 
Triiodothryonine (T3) * 1nM - - 
Dexamethasone*  - - 
Epidermal Growth Factor 
(EGF) † 
10ng / ml - - 
Glutamine * 2mM - - 
Penicillin * 100 units /ml 100 units / ml 100 units / 
ml 
Streptomycin * 100µg / ml 100µg / ml 100µg / ml 
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2.2  Ussing chamber recordings 
2.2.1 Ussing Chamber setup 
Ussing chambers were used to record either short circuit current (ISC) or 
transepithelial voltage (Vt), across a monolayer of mpkCCDcl4 cells grown on 
snapwells as described above. Cells that displayed a Rt of < 1kΩ were not used as 
this demonstrated that the cells had not formed a tight epithelia typical of the 
collecting duct. The filter membranes were secured within the chamber creating 
completely separate apical and basolateral baths. Each side of the chamber was 
filled with 15ml KREBS buffer (Table 2.2) which was gassed continuously with 
95% O2 and 5% CO2 (BOC, UK). The temperature of the buffer was maintained 
at 37°C by water jackets that surrounded the chambers, connected to a water bath 
(GRANT instruments, Cambridge, UK). Voltage and current Ag / AgCl 
electrodes were held in a 3% Agar / 3M KCl gel and attached to the apical and 
basolateral sides of the chamber, respectively. The tips of the electrodes were 
attached to crocodile clips connected to the pre-amplifier. BNC cables then 
connected the pre-amplifier (WPI model DVC-3, Herts, UK) to the amplifier 
(WPI DVC 1000, Herts, UK) which was in turn, connected to a Powerlab (AD 
instruments, Oxfordshire, UK) which converted the analogue voltage signal to a 
digital one. This was then connected to a PC via a USB cable which allowed 
recording using the Chart 5 software package (AD instruments, Oxfordshire, UK). 
A schematic diagram of the Ussing chamber setup can be seen in Figure 2.1. 
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Prior to recording under experimental conditions, empty snapwells were mounted 
in Ussing chambers and 15 ml KREBs buffer was added to both baths. Any 
offsets to the liquid junction potential brought about by the empty setup were 
compensated. Buffer was aspirated, blank snapwells removed and snapwells 
containing monolayers of cells were mounted in the chambers with fresh KREBs 
buffer and Vt was recorded under open circuit conditions. Once Vt had stablilised 
recordings of either ISC or Vt were made as described below. 
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Figure 2.1 Schematic diagram of a modified Ussing chamber.  
Monolayers of cells were mounted in the central chamber which separated the apical and 
basolateral baths. KREBS buffer bathed the cells, kept at 37°C by the surrounding water jacket 
and gassed with 95 % O2 and 5 % CO2. Voltage and current electrodes were attached to both sides 
of the chamber and were connected to a pre-amplifier connected to an amplifier. This was then 
connected to a Powerlab and finally a computer. 
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Table 2.2 Composition of KREBS buffer used in all Ussing experiments. 
Chemical Concentration 
(mM) 
KCl 4.7 
CaCl2 2.5 
MgSO4 1.2 
KH2PO4 1.2 
NaCl 112.0 
NaHCO3 25.0 
Glucose 11.6 
 
The pH of the KREBS solution was maintained at pH 7.4 in the Ussing chambers 
by constantly gassing the solution with 5 % CO2. All chemicals were from Sigma 
Aldrich (Poole, UK). 
 
2.2.2 Short circuit current recording 
Experiments examining the effects of PPARγ agonists were carried out in 
collaboration with Dr. Sarah Inglis where Vt was clamped to 0 mV allowing a 
direct measurement of the short circuit current (ISC). ISC is defined as the current 
that must be passed in order to maintain Vt at 0 mV and gives a measure of the net 
ion transport across the monolayer. As these cells generated a large Vt clamping 
this to 0 mV imposed an altered electrochemical gradient than that which existed 
under the more physiological open circuit conditions. It was therefore decided that 
all further experiments would be carried out under open circuit conditions where 
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Vt would be recorded using a pulse protocol and the equivalent short circuit 
current Ieq could be calculated. 
2.2.3 Transepithelial voltage recording 
In the present study Vt was measured using a reference electrode in the basolateral 
bath and a recording electrode in the apical bath. Using this configuration, 
movement of cations e.g. Na
+
 from the apical to basolateral baths would give rise 
to a negative Vt. Once Vt had stabilised, a current clamp protocol was employed: 
the current was clamped to -10 µA for 20 sec then returned to 0 µA (open circuit 
conditions) for 40 sec with continuous recording of the Vt at 4 Hz. This was 
maintained throughout the experiment and allowed an indirect method of 
measuring the current passing across the monolayer, which could be calculated 
using Ohm’s Law. Having measured Vt at 0 current clamp and then clamped at -
10 µA, ΔVt can be calculated. The transepithelial resistance can therefore be 
calculated according to Ohm’s law: 
I
V
R
t
t


  
where ΔI = -10 µA. 
The equivalent short circuit current, Ieq, can be therefore be calculated using Vt 
recorded under open circuit conditions and Rt: 
R
V
I
t
t
eq
  
Since baseline Vt is negative by convention with a basolateral earth, baseline Ieq 
will therefore be negative. Using this definition, an increase in the movement of 
cations e.g. Na
+
 moving from the apical to basolateral bath or anions e.g. Cl
-
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moving from the basolateral to apical bath would produce a more negative current 
indicated by a downward deflection on a trace. Likewise, Ieq would become more 
positive if these ionic movements were reversed.  
 
2.3 Western blotting 
2.3.1 Preparation of Samples 
Cells were seeded onto Transwells (Section 2.1.2.) and on the 8
th
 day of culture 
when cells had been exposed to serum-free media for 18-24 h, the media was 
replaced with serum-free media containing the vehicle/drug of interest and 
returned to the incubator for the experimental time period. Cells were then 
removed, placed onto ice and washed three times with ice-cold phosphate 
buffered saline (PBS). 175 µl of lysis buffer (Table 2.3) was added to each well 
and cells were resuspended by scraping. Lysis buffer contained both protease and 
phosphatase inhibitors to prevent sample degradation. The lysate was then 
sonicated for ~10 s (Soniprep150, London, UK) and spun down at 4°C at 
14000 rpm for 10 min to remove cell debris. The mass of protein in the raw lysate 
was then determined using the Bradford method (2.3.2). After determining the 
mass of protein in the lysate, samples were made up to a specific concentration by 
adding 2 x sample buffer (Table 2.4) and then bringing each sample to a defined 
final volume with deionised H2O . Samples were heated to 100°C for five minutes 
to denature the protein and then either ran in a gel straight away or frozen for later 
use. 
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Table 2.3 Composition of Lysis Buffer. 
Chemical Name Concentration 
Tris HCl pH7.5 50.0 mM 
EDTA 1.0 mM 
EGTA 1.0 mM 
Sodium Ortho Vanadate 1.0 mM 
Glycerol Phosphate 10.0 mM 
Sodium Fluoride 50.0 mM 
Sodium Pyrophosphate 5.0 mM 
Sucrose 270.0 mM 
Triton x100 1.0 % (v/v) 
 
All chemicals were from Sigma Aldrich (Poole, UK). 
 
One complete mini protease inhibitor (Roche, Mannheim, Germany) + 10 µl β-
mercaptoethanol (Sigma Aldrich, Poole, UK) was added to 10 ml of lysis buffer 
stock and then frozen and used as required. 
 
Table 2.4 Composition of Sample Buffer 
Chemical Name Concentration 
Tris HCl pH 6.8 66.0 mM 
Glycerol 26.3 % (v/v) 
SDS 2.1 % (v/v) 
Bromophenol Blue 0.01 % (v/v) 
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2.3.2 Bradford Assay 
The protein lysate was diluted 1:10 with deionised water and 5 µl added in 
duplicate to a 96 well plate. Protein standards made up with bovine serum 
albumin at concentrations: 0.05; 0.1; 0.2; 0.3; 0.4; 0.5; 0.7; and 1.0 µg / µl in 
deionised water as well as a water control were added in triplicate to the plate to 
allow construction of a standard curve. 100 µl of Protein Assay Dye Reagent 
(BIORAD, Hertfordshire, UK) (diluted 1:4 with deionised water and filtered 
through Whatman no.1 filter paper) was added to the protein samples and 
incubated for 5 min at room temperature. The absorbance of the samples at 595nm 
was read using a microplate reader (MRX, Guernsey, UK). These values were 
then entered into an Excel worksheet and the protein mass of the samples were 
calculated. 
 
2.3.3 Gel Casting 
A 10 % resolving gel (Table 2.5) was poured into glass plates (BIORAD, 
Hertfordshire, UK) with 1 mm spacers and allowed to set with 500 µl of butanol 
added to the surface to ensure removal of air bubbles. Once set, the butanol was 
poured off and the gel washed thoroughly with deionised water. A 5 % stacking 
gel (Table 2.6) was then poured on top of the resolving gel and the comb carefully 
inserted making sure of no air bubbles. This was left to set and the gel was then 
used for electrophoresis or wrapped up in damp tissue paper and kept in the fridge 
overnight for use the next day. 
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Table 2.5 Composition of 10% Resolving Gel  
 Concentration 
Bis / acrylamide 10.0 % (v/v) 
Tris HCl pH8.5 380.0 mM 
SDS 0.1 % 
Ammonium persulfate 0.1 % 
TEMED 0.4 µl / ml 
 
 
Table 2.6 Composition of 5% Stacking Gel 
 Concentration 
Bis / acrylamide 5.0 % 
Tris pH 8.5 750.0 mM 
SDS 1.0 % 
Ammonium persulfate 1.0 % 
TEMED 1.0 µl / ml 
 
2.3.4 SDS-Gel Electrophoresis 
Gels were clipped into place in gel tanks (Novex mini cell XCell II, Invitrogen, 
Paisley, UK) with running buffer (Table 2.7) added so that it was just above the 
level of the wells. The specified mass of protein was added to each well with a 
visible rainbow marker and a biotinylated marker added to allow visualization of 
protein movement. The tanks were sealed and set at 200 V to run for 50 min.  
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Table 2.7 Composition of Running Buffer. 
Running Buffer Concentration (mM) 
Trizma Base 24.8 
Glycine 191.8 
SDS 3.5 
 
2.3.5 Western Blotting 
Gels were removed from the tank and rinsed with deionised water. Pieces of 
Hybond-P PVDF membrane (8 x 7 cm, GE Healthcare, Buckinghamshire, UK) 
were prepared by soaking in methanol for 15 s, submerging in transfer buffer 
(Table 2.8) for 5 minutes to allow equilibration and then carefully placed onto the 
surface of the gel. An 8 x 8 cm piece of blotting paper, briefly wetted in transfer 
buffer, was then placed on top of the PVDF. The gel was then flipped over and 
another piece of blotting paper (GE Healthcare, Buckinhamshire, UK) placed 
gently on the surface of the gel, creating a “sandwich”. Care was taken to remove 
any visible air bubbles. Sponges presoaked in transfer buffer were then placed 
into a transfer cassette (XCell II blot module, Invitrogen, Paisley, UK) with the 
“blot sandwich” in the middle. If two gels were being transferred, a sponge was 
placed between them. The cassette was placed into the gel tank and the sealed 
inner chamber was filled with transfer buffer. The outer chamber surrounding the 
cassette was filled with deionised water ~1 cm from the top of the tank. Gels were 
transferred at 30 V for 2 h. 
 
 
50 
Table 2.8 Composition of Transfer Buffer. 
 Concentration 
Trizma Base 19.8 mM 
Glycine 150.5 mM 
Methanol 20.0 % (v/v) 
 
2.3.6 Blocking and antibody treatment 
Once transfer was complete the membrane was quickly moved to a small 
container and submerged in ~15 ml of blocking solution (5% dried skimmed milk, 
Tesco, UK) in tris-buffered saline with Tween (TBS-T, see Table 2.9). This was 
placed on a rocker (Bibby Stuart, UK) for 1 h to allow the milk protein to block 
non-specific binding sites on the membrane. The primary antibody was then made 
up in 5% milk / TBS-T unless otherwise stated at the appropriate concentration in 
a 50 ml falcon tube. The membrane was removed from the blocking solution and 
placed protein side up in the 50 ml tube with primary antibody and placed on a 
rotating roller (Bibby Scientific, UK) overnight at 4°C. The following day, the 
blot was removed from the primary antibody and washed for 3 x 10 min in TBS-T 
on a rocker at room temperature. The primary antibody was then frozen and 
would be re-used for a specified number of repeats. The secondary antibody was 
then made fresh on the day in 5% milk / TBS-T and was added after the wash 
steps for 1 hour. The blot was then washed for 3 x 10 min in TBS-T to remove the 
secondary antibody.  
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Table 2.9 Composition of TBS-T. 
 Concentration 
Trizma Base 19.8 mM 
NaCl 136.9 mM 
Tween 20 0.1 % (v/v) 
The solution was brought to pH 7.6 with concentrated HCl. 
 
2.3.7 ECL and exposure 
The blot was then dabbed dry on tissue paper and 3 ml of the pre-mixed ECL 
solution (Table 2.10) was pipetted carefully on top of the membrane. This was 
given ~1 min to react and then the excess was dabbed off the membrane which 
was then placed into a plastic bag with excess solution being pressed out. The 
membrane was then taken to the dark room where it was placed into a cassette 
(Amersham Biosciences, UK) and a piece of film (Konica Minolta Medical Film 
AX, Japan) laid on top for an appropriate period of time. The film was then 
developed in the x-ograph machine (Compact X4, Wiltshire, UK). 
 
Table 2.10 Composition of ECL 
Solution I Concentration Solution II Concentration 
Luminol 2.5 mM H2O2 0.02 % (v/v) 
p-coumaric acid 0.4 mM Tris HCl pH 8.5 1000.0 mM 
Tris HCl pH 8.5 1000.0 mM 
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2.3.8 Densitometry and Analysis 
The exposed film was captured using GeneGenius CCD camera system (Syngene, 
Cambridge) using the GeneSnap acquisition software. Densitometric readings 
were carried out using the associated analysis software GeneTools. These values 
were entered into an Excel worksheet for analysis. 
 
2.3.9 Antibodies 
Throughout this thesis the following antibodies were used. Phosphorylation of 
NDRG1 (n-myc downstream regulated gene 1) at Thr
346/356/366
 was used to 
monitor SGK1 activity. These specific residues have been shown to be 
phosphorylated by SGK1 and not other closely related kinases (Murray et al., 
2004). Phospho-PRAS40-Ser
246
 was used to monitor Akt activity as this kinase 
has been shown to be a specific substrate for Akt (Kovacina et al., 2003). The 
abundance of the respective total protein for NDRG1 and PRAS40 was also 
monitored. These antibodies were produced in the Medical Research Centre 
Protein Phosphoylation Unit, Dundee and were a kind gift from Sir Professor 
Phillip Cohen. 
 
Phospho-Akt-Ser
473
 was used to monitor PI3-kinase downstream signalling. This 
site is specifically phosphorylated by the mammalian target of rapamycin complex 
2, mTORC2, and could therefore be used to monitor its activity. Phospho-P70-
S6K-Thr
389
 was used to monitor mTORC1 activity as it has been previously 
shown to be a substrate for this kinase (Proud, 2007). The abundance of total Akt 
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and P70-S6K was also monitored. These antibodies were from Cell Signalling 
Technology – New England Biolabs, Herts, UK. 
 
2.4 Pharmacological agents 
Throughout this research project a number of small molecule inhibitors and 
hormones were used in both Ussing chamber experiments and western analysis of 
protein phosphorylation. Details of these drugs and hormones are found below in  
Table 2.11 and Table 2.12 respectively. 
 
Table 2.11 Small molecule inhibitors used in experiments 
Compound Function Vehicle Conc. (µM) Reference 
Wortmannin * PI3-kinase 
inhibitor 
DMSO 0.1 (Wymann et al., 1996) 
PI103 * PI3-kinase 
inhibitor 
DMSO 1.0 (Fan et al., 2006) 
GDC-0941 † PI3-kinase 
inhibitor 
DMSO 1.0 (Garcia-Echeverria and 
Sellers, 2008) 
Rapamycin * mTORC1 inhibitor DMSO 0.1 (Proud, 2007) 
Akti-1/2 * Akt 1 / 2 inhibitor DMSO 1.0-10.0 (Barnett et al., 2005) 
GSK650394A † SGK1 inhibitor DMSO 1.0-10.0 (Sherk et al., 2008) 
TORIN1 ** mTOR inhibitor DMSO 1.0-10.0 (Thoreen et al., 2009) 
PP242 † mTOR inhibitor DMSO 1.0 (Feldman et al., 2009) 
Amiloride * ENaC inhibitor H2O 10.0 (Canessa et al., 1994) 
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Table 2.12 Hormones used in experiments 
Hormone Vehicle Conc. (nM) Reference 
Insulin *** H2O 20.0 (Record et al., 1998) 
Dexamethasone *** Basal Media 200.0 (Chen et al., 1999) 
Arginine vasopressin (AVP) 
*** 
H2O 10.0 (Bugaj et al., 2009) 
Pharmacological agents from: 
* Merck, Beeston, UK 
†  GDC-0941, GSK650394A and PP242 were generous gifts from Professor D.R. 
Alessi, MRC Protein Phosphorylation Unit, University of Dundee, UK 
** TORIN1 was a generous gift from Professor D.M. Sabatini, Whitehead 
Institute for Biomedical Research, Cambridge, MA, USA 
*** Sigma Aldrich, Poole, UK 
2.5 Statistical Analyses 
Data recorded from Ussing chambers in the Chart 5 software were copied into 
Microsoft Excel worksheets and experiments were time-matched to allow 
comparison of data. Densitometry data collected from western analysis were also 
entered into Microsoft Excel worksheets where data could be compiled for mean 
results. All data are presented as mean ± S.E.M. and values of n refer to the 
number of times an experiment was repeated using a different passage of cells. 
The statistical significance between mean values was assessed using Student’s 
unpaired t-test or using a one- or two-way ANOVA where appropriate using 
GraphPad Prism. For calculation of statistical significance of the pooled 
densitometric analysis of western blots, raw values were compared. 
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Chapter 3 - Basal Na+ transport in 
mpkCCDcl4 cells, the response to 
insulin and the effects of PPARγ agonists  
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3.1 Introduction 
3.1.1 mpkCCDc14 cells 
A difficulty faced when trying to investigate the hormonal regulation of ion 
transport in epithelia in vitro is finding a cellular system that has retained the ion 
transport properties and regulation typical of the native system. Na
+
 transport 
across the late distal tubule of the nephron and the collecting duct is governed by 
the hormones aldosterone and arginine vasopressin as well as insulin 
(Kellenberger and Schild, 2002). It has been suggested that these hormones alter 
the rate of Na
+
 absorption by increasing the number of ENaCs in the apical 
membrane (Blazer-Yost et al., 1998, Snyder, 2000); and that aldosterone can also 
increase protein synthesis of ENaC subunits (Alvarez De La Rosa et al., 2002). 
The first models used for investigating Na
+
 transport were the frog skin (Herrera 
et al., 1963) and the toad urinary bladder (Herrera, 1965). Both of these tissues 
exhibit high epithelial resistance, generate a spontaneous Na
+
 current and are 
regulated by hormones such as aldosterone and insulin. These tissues provided a 
wealth of information regarding the nature of transepithelial Na
+
 transport and its 
modulation by various hormones. However, although these tissues exhibited Na
+
 
transport across tight epithelia, they were not related specifically to Na
+
 transport 
in the distal nephron. Therefore the emergence of cultured kidney cells provided 
models related to specific parts of the nephron allowing more detailed 
experimental studies of ion transport in the nephron. 
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The A6 toad kidney cell line has been used extensively to model the distal tubule 
of the nephron (Fidelman et al., 1982, Handler et al., 1981a, Kemendy et al., 
1992). The use of cultured cells offers certain advantages, for instance, cells for 
one entire study can be derived from the same precursor cells, therefore reducing 
genetic variability. Factors such as the environment in which the epithelia grow 
can be tightly regulated and cell culture can allow genetic manipulation i.e. 
transfecting in (Faletti et al., 2002) or silencing genes of interest (Lee et al., 
2007). However the limitations of many immortalised cell lines are that they have 
lost certain features of the native tissue such as high transepithelial resistance or 
regulation of Na
+
 transport by various hormones (Chen et al., 1998). Stable and 
transient transfection of cell lines, including COS-7, HEK-293 and Fisher rat 
thyroid cells, with ENaC and related proteins have also been studied (Lee et al., 
2007, Lu et al., 2010). Therefore although transfected cell cultures and amphibian 
cells lines can provide invaluable information regarding interactions within these 
systems, they might not provide as accurate a comparison as mammalian models 
could. For example in expression studies where an interaction between ENaC and 
overexpressed protein are observed, it is difficult to determine whether this would 
happen in the native system where the protein of interest may be expressed at a 
very low level (Alvarez De La Rosa and Canessa, 2003).  
 
The murine M1 cell line was the first example of an immortalised mammalian 
cortical collecting duct cell line that retained well-differentiated epithelia and 
exhibited high transepithelial resistance as well as expressing ENaC and CFTR 
channels (Stoos et al., 1991, Helms et al., 2003). However, despite these qualities, 
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this cell line lacked a mineralocorticoid receptor (MR)-mediated response to 
aldosterone which led another research group to stably express MR in these cells, 
M1-MR
+
 (Náray-Fejes-Tóth et al., 2004b), allowing the control of Na
+
 transport 
by aldosterone. The mpkCCDcl4 murine cell line was derived from collecting 
duct principal cells through targeted oncogenesis in transgenic mice (Bens et al., 
1999). This strategy allowed differentiated epithelia, which importantly retained 
many of the key features of collecting duct cells, including high transepithelial 
resistance and amiloride-sensitive electrogenic Na
+
 transport that could be 
hormonally regulated by aldosterone, vasopressin and insulin. This cell line was 
therefore chosen to investigate the role of insulin in the regulation of Na
+
 transport 
in collecting duct principal cells. 
 
3.1.2 Previous studies on the effect of insulin on Na+ transport 
The first observation that insulin was involved in Na
+
 transport was in 1933 when 
Atchley et al. observed that halting insulin treatment in type II diabetic patients 
significantly increased the level of sodium excreted in the urine (Atchley et al., 
1933). The reintroduction of insulin treatment reversed this effect. Miller and 
Brogdonoff in 1954 showed that treating normal subjects, undergoing either a 
solute (glucose) diuresis or water diuresis, with insulin reduced the levels of 
sodium excreted in the urine (Miller and Bogdonoff, 1954). The addition of 
insulin to isolated perfused dog kidneys also produced a decrease in sodium 
excretion in the urine (Nizet et al., 1971). Whilst these studies clearly 
demonstrated the role of insulin in stimulating sodium reabsorption, they did not 
define the mechanism by which it was being mediated.  
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The groundbreaking work of Ussing and Koefoed-Johnsen in 1958, allowed a 
technique, Ussing chamber recording, by which sodium transport across a 
membrane could be recorded. Hererra et al. (1963) applied similar techniques in 
experiments using frog skin and showed that application of insulin increased short 
circuit current. Similar results were obtained using toad urinary bladder (Herrera, 
1965). A further study identified that insulin only exerted natriferic effects when 
applied to the serosal side of the bladder (Cox and Singer, 1977), consistent with 
finding that the majority of insulin receptors are found on the serosal / basolateral 
membrane (Blazer-Yost et al., 1992). Experiments carried out in A6 cells 
demonstrated that these cultured cells generated a spontaneous Na
+
 current which 
could be stimulated by insulin (Handler et al., 1981b, Fidelman et al., 1982). 
More recent studies utitlising mammalian cell lines including the M1 cell line 
(Nofziger et al., 2005) and the mpkCCDc14 cell line (Shane et al., 2006, Nofziger 
et al., 2005) also confirm the natriferic effect of insulin. These extensive studies 
clearly demonstrate that insulin can stimulate Na
+
 transport, particularly in the 
collecting duct of the nephron.  Patch clamp analysis of A6 cells concluded that 
insulin was increasing the open probability of the amiloride-sensitive sodium 
channel, ENaC, without affecting single-channel current or conductance 
(Marunaka et al., 1992). However, a study using blocker-induced noise analysis 
demonstrated that insulin mainly acts to increase the number of ENaCs in the 
membrane, more so than alterations to Po (Blazer-Yost et al., 1998). Whilst the 
final effects on ENaC were not certain, the mechanism by which insulin could 
alter ENaC activity also remained unclear.  
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3.1.3 PPARγ agonists 
During the late 1990s, a new class of drugs were made available for the treatment 
of type-II diabetes called thiazolidinediones (TZDs) or glitazones (Lehmann et al., 
1995). These drugs are agonists of the peroxisome proliferator-activated receptor 
γ (PPARγ) and act to sensitize cells to insulin thereby increasing glucose uptake in 
insulin-sensitive tissues (Stumvoll and Häring, 2002). PPARγ is a nuclear receptor 
that is highly expressed in adipose tissue but is also found in the vasculature as 
well as the kidney (Vallon et al., 2009). PPARs form heterodimers with retinoid X 
receptors (RXRs) and together act to regulate transcription of a number of genes 
(Stumvoll and Häring, 2002). These include genes encoding proteins that are 
involved in both lipid and glucose metabolism as well as proteins that are 
involved in molecular cascades including inflammation (Buckingham and Hanna, 
2008). Whilst these drugs have been shown to lower blood glucose effectively, 
these anti-diabetic drugs have also been found to produce side effects including 
fluid retention leading to complications such as oedema and congestive heart 
failure (Tang and Maroo, 2007). For these reasons, TZD treatment has been 
withdrawn in 10-15% of cases (Buckingham and Hanna, 2008).  
 
The physiological basis of this fluid retention remains unclear but it has been 
proposed that abnormal stimulation of ENaC in the distal nephron leads to 
increased Na
+
 absorption and therefore water absorption (Zhang et al., 2005, 
Guan et al., 2005, Hong et al., 2003). PPARγ were found to be expressed along 
the nephron from human kidney samples but most abundantly in the collecting 
duct (Hong et al., 2003). Mice treated with either pioglitazone or rosiglitazone 
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increased in body weight within four days and this was associated with an 
increase in total body water volume (Guan et al., 2005, Zhang et al., 2005). 
Furthermore, these studies revealed that selective knockout of PPARγ in the 
collecting duct of mice prevented increases in body weight with TZD treatment. 
These data suggest that a collecting duct specific mechanism was involved in the 
fluid retention associated with TZD treatment. It was postulated that altered 
ENaC-mediated Na
+
 absorption could be responsible since there is high 
expression of this channel in the collecting duct (Hong et al., 2003). Consistent 
with this, Hong and colleagues demonstrated that treating a human collecting duct 
cell line with TZDs for four hours increased the membrane abundance of α-ENaC 
(Hong et al., 2003). 24 h treatment with these drugs resulted in an increased 
expression of α-ENaC mRNA and the authors concluded that PPARγ-agonists 
were mediating Na
+
 absorption in a similar manner to aldosterone (Hong et al., 
2003). Consistent with this data, two other studies revealed that treatment of 
primary cultures of collecting duct cells from mice with TZDs stimulated 
amiloride-sensitive Na
+
 transport (Guan et al., 2005, Zhang et al., 2005). 
Furthermore, cultured cells from PPARγ-/- mice did not show this increase in Na+ 
transport. SGK1 activity and mRNA expression in a human collecting duct cell 
line was also shown to be upregulated in response to TZD treatment (Hong et al., 
2003). Further evidence for a role of SGK1 was demonstrated in SGK1
-/-
 mice 
who did not gain weight with pioglitazone treatment (Artunc et al., 2008). It was 
therefore postulated that PPARγ agonists were signalling via SGK1 to upregulate 
Na
+
 absorption in a manner analogous to insulin / aldosterone regulation of ENaC. 
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Whilst these studies provided a great deal of evidence for PPARγ-agonist-
mediated fluid retention being the result of increased ENaC activity in the 
collecting duct, a number of further studies were not in agreement with this 
hypothesis (Nofziger et al., 2005, Song et al., 2004, Vallon et al., 2009). Song et 
al. showed that rats treated with rosiglitazone stimulated Na
+
 and water 
reabsorption but found increased mRNA expression of other transporters 
including Na
+
 / K
+
 ATPase, NKCC2 and NHE3 but not of ENaC (Song et al., 
2004). Interestingly this study showed that rosiglitazone-treatment actually 
lowered mean arterial blood pressure which seems at odds with increased Na
+
 and 
water absorption. In three different kidney cell lines: A6, M1 and mpkCCDcl4, 
Nofziger and colleagues demonstrated that two TZDs did not alter ENaC-
mediated Na
+
 transport under basal or insulin-stimulated conditions (Nofziger et 
al., 2005). Very strong evidence for a lack of ENaC in mediating fluid retention in 
response to PPARγ-agonists came from a study that showed rosiglitazone could 
still stimulate fluid retention in mice with a selective knockout of α-ENaC in the 
collecting duct (Vallon et al., 2009). Furthermore this study demonstrated that in 
patch clamp recordings from split-open tubules from the collecting duct, TZD 
treatment did not alter ENaC activity (Vallon et al., 2009). Collectively these 
studies reveal that the mechanism underpinning TZD-induced fluid retention is 
not fully understood and the role that ENaC as well as SGK1 play in this response 
is inconclusive, clearly warranting further study. 
 
The aim of the first experiments in this thesis were to confirm that mpkCCDcl4 
cells could generate spontaneous Na
+
 transport as described previously (Bens et 
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al., 1999) and to further characterize some basic pharmacological properties of 
this transport. Furthermore, the responsiveness of these cells to insulin was tested 
and the electrophysiological effects that this hormone brought about were 
examined. The phosphorylation of endogenous proteins in the presence of insulin 
was also studied in an attempt to identify the signalling pathway involved. To 
explore the hypothesis that PPARγ agonists could alter Na+ absorption in the 
mpkCCDcl4 cell line, the effects of two of these drugs: pioglitazone and 
rosiglitazone; on basal and insulin-stimulated Na
+
 transport were examined. The 
activity of SGK1 was also monitored by measuring the phosphorylation of a 
downstream substrate NDRG1. 
 
3.2 Results 
3.2.1 Bioelectric properties of mpkCCDc14 cells 
Initial experiments were undertaken to investigate the bioelectric properties of 
mpkCCDc14 cells as they had not been previously characterised in our laboratory. 
The cells were seeded on snapwells and mounted in Ussing chambers to record Vt.  
Baseline Vt in hormone-deprived cells was -47.8 ± 0.8 mV (n = 302). When the 
current clamp pulse protocol was applied (Chapter 2), as can be seen in Figure 
3.1, Vt hyperpolarised.  Rt was calculated to be 2.5 ± 0.1 kΩ cm
2
 (n = 302) and Ieq 
was -20.4 ± 0.5 µA cm
-2
 (n = 302). These data demonstrate that mpkCCDc14 cells 
generate a large transepithelial voltage as well as a high resistance indicating these 
cells form a tight epithelial monolayer which give rise to a spontaneous current.  
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Figure 3.1 Bioelectric properties of mpkCCDc14 cells.  
(A) Example of continuous recording of Vt in mpkCCDc14 cells. The pulse protocol elicits 
baseline Vt and a -10 µA pulse produces a hyperpolarisation seen as a downward deflection. 
Addition of 10 µM amiloride to the apical bath is denoted by the arrow, Amil. (B-D) Pooled data 
(n = 8) showing control and amiloride treated Vt, Rt and Ieq. Data is shown as mean ± S.E.M. with 
asterisks denoting statistical significance (Student’s unpaired t-test), *** p  < 0.001. 
 
Amiloride, a potent inhibitor of the epithelial sodium channel (ENaC), was 
applied to the apical bath, arrow notes addition in Figure 3.1A. The effects of this 
ENaC inhibitor on Vt, Rt and Ieq can be seen in Figure 3.1B-D.  This drug 
significantly depolarised Vt from -43.8 ± 1.5 mV to -3.9 ± 0.4 mV (Figure 3.1B, n 
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= 8, p < 0.001).This was associated with a significant increase in Rt from 2.5 ± 0.2 
kΩ cm2 to 4.4 ± 0.4 kΩ cm2 (Figure 3.1B, n = 8, p < 0.001). Finally, Ieq was 
significantly reduced from -16.2 ± 1.7 µA cm
-2
 to -0.9 ± 0.1 µA cm
-2 
(Figure 
3.1D, n = 8, p < 0.001). Amiloride clearly inhibits the transepithelial voltage and 
the current that remains following the addition of the drug is negligible. These 
data clearly demonstrate that the majority of Ieq is carried by Na
+ 
ions moving via 
ENaC. 
 
To further characterize ENaC-mediated Ieq in these cells, experiments were 
carried out to define the dose-response relationship of amiloride as well as two 
other well-known inhibitors of ENaC: benzamil and 5-(N-Ethyl-N-isopropyl) 
amiloride (EIPA). Amiloride was added to the apical bath in increasing doses in a 
cumulative manner. Changes in Vt were recorded which allowed calculation of 
both Rt and Ieq (Figure 3.2, see Chapter 2). Increasing concentrations of amiloride 
were associated with a depolarisation of Vt, with the maximal dose (300µM) 
leaving a transepithelial voltage of -1.8 ± 0.4 mV (Figure 3.2A, n = 9). Rt 
increased in response to increasing concentrations of amiloride, peaking at 4.1 ± 
0.5 kΩ cm2 at a dose of 10 µM, then began to gradually fall over the final three 
doses, but remaining above that of control (Figure 3.2B, n = 9). Ieq was inhibited 
with increasing concentrations of amiloride with the maximum dose (300 µM). At 
this concentration Ieq was negligible, -0.6 ± 0.1 µA cm
-2
 (Figure 3.2C, n = 9). The 
concentration of amiloride need for half-maximal inhibition of Ieq (IC50) was 
calculated to be 0.77 ± 0.07 µM. 
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Figure 3.2 Dose response of amiloride - a potent ENaC inhibitor. 
The electrometric response to increasing concentrations of amiloride added to the apical bath in a 
cumulative manner: (a) Vt , (b) Rt  and (c) Ieq . Data is shown as mean ± S.E.M. (n = 9).  
 
Identical experiments were carried out to determine the dose-response 
relationships of two other known inhibitors of ENaC: benzamil and EIPA; Ieq was 
calculated for each drug (Figure 3.3 Dose response of benzamil, amiloride and 
EIPA. Sigmoid curves were fitted to the data using least squares regression 
(GraFit 5, Erithacus Software Limited) and the IC50 was calculated to determine 
the concentration of the drug that caused 50 % inhibition of Ieq. The IC50 of 
benzamil was calculated to be 22.6 ± 1.0 nM and this drug was therefore more 
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potent than amiloride. EIPA was the least potent and although the IC50 was 
calculated to be 90.0 ± 20.0 µM, the highest concentration tested (300 µM) caused 
only ~75% inhibition of Ieq making it difficult to accurately calculate the IC50. The 
rank order potencies amongst these compounds are therefore benzamil > 
amiloride > EIPA. These data confirm that mpkCCDcl4 cells spontaneously 
absorb Na
+
 from the apical bath via an ENaC-dependent mechanism (Bens et al., 
1999). 
 
 
 
Figure 3.3 Dose response of benzamil, amiloride and EIPA. 
The effects of increasing concentrations of three inhibitors of ENaC on basal Ieq. Data is shown as 
mean percentage inhibition of Ieq  ± S.E.M. (benzamil, n = 8, amiloride, n = 9, EIPA, n = 7). The 
sigmoid curves were fitted to these data by least squares regression (GraFit 5, Erithacus Software 
Limited). 
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3.2.2 The electrometric response to insulin 
To explore the effects of the hormone insulin on the basal current in the collecting 
duct cells, the electrical parameters of control and insulin-treated cells were 
compared. 20 nM insulin was chosen as a dose as this concentration had 
previously been shown to stimulate ENaC-mediated Na
+
 transport in the A6 cell 
line (Blazer-Yost et al., 1998). Other studies have found half-maximal 
concentrations of insulin required to stimulate Na
+
 transport in the low nM region 
(Blazer-Yost et al., 1989, Marunaka et al., 1992). Similarly, a more recent study 
demonstrated that in three cell lines: A6, M1 and mpkCCDcl4, the half-maximal 
dose required for stimulation of Na
+
 transport was 1-3 nM (Nofziger et al., 2005). 
Nofziger et al. showed that the concentration of insulin required to maximally 
stimulate Na
+
 transport in the mpkCCDcl4 cell line was 30 nM, therefore in the 
experiments carried out in the present study, 20 nM would be stimulating near-
maximal Na
+
 transport (Nofziger et al., 2005). 
 
Solvent vehicle or insulin (20 nM) were added to the basolateral bath after a 10 
min baseline recording. After a latency period of 5 min, the effects of this 
hormone became visible and after 60 min treatment Vt had become significantly 
hyperpolarised (Figure 3.4, n = 8, p < 0.001). This response was not seen in 
control cells which instead depolarized slightly over time (Figure 3.4, n = 8, p < 
0.01). This depolarization was observed in all Ussing chamber recordings in the 
present study and appears to be a slight run-down over time. In the presence of 
insulin, Rt significantly decreased (Figure 3.4, n = 8, p < 0.01) whereas control 
cells showed no change. With a hyperpolarisation of Vt and a decrease in Rt, a 
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significant increase in Ieq was observed (Figure 3.4, n = 8, p < 0.001). Under 
control conditions Ieq slightly decreased (Figure 3.4, n = 8, p < 0.001), which is 
consistent with a slight depolarisation of Vt and no change in Rt. The application 
of amiloride (10 µM) to the apical bath caused an inhibition of Ieq due to a 
depolarisation of Vt and an increase in Rt (Figure 3.4) as seen previously (Figure 
3.1). Therefore, acute addition of insulin stimulates an increase in ENaC-mediated 
Na
+
 absorption in this cell line. Interestingly in the presence of insulin following 
application of amiloride, Rt was significantly increased compared with control 
values (Figure 3.4, n = 8, p < 0.01) indicating that this hormone must be having 
another effect such as increasing paracellular resistance; these effects were not 
investigated further. Mean values for the electrical parameters measured at all 
compared time-points under control and insulin-stimulated conditions can be 
found in Table 3.1. 
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Figure 3.4 The electrometric response to acute application of insulin. 
Transepithelial voltage Vt recorded (top left trace) under control conditions or with addition of 
insulin (20nM), allowing calculation of Rt and Ieq (middle and bottom left traces).  Mean values 
from time points throughout the experiment were taken (a) prior to addition of vehicle / drug, (b) 
once the response to insulin was established and (c) after application of amiloride (10µM), shaded 
areas denote the sampling periods. Right hand panels show mean values for Vt (top), Rt (middle) 
and Ieq (bottom). Data is shown as mean ± S.E.M. (n = 8) and statistical significance (Student’s 
unpaired t-test) denoted by asterisks (* p < 0.05, ** p < 0.01, *** p < 0.001). 
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Table 3.1 Electrical parameters of control and insulin-treated cells. 
Mean data ± S.E.M. (n = 8) for Vt, Rt and Ieq recorded from vehicle- or insulin-treated cells. Time 
points are taken from a baseline recording, 60 min after vehicle / insulin and following 10 min 
exposure to amiloride. Asterisks denote statistically significant effects of insulin on Vt, Rt and Ieq 
compared to control cells (Student’s unpaired t-test), *, p < 0.05, **, p < 0.01, *** p < 0.001. 
 Vehicle-treated Insulin (20 nM) 
 Pre-
exposure 
60 min 
exposure 
Post-
amiloride 
Pre-
exposure 
60 min 
exposure 
Post-
amiloride 
Vt (mV) -47.0 ± 4.3 -39.8 ± 3.2 -3.0 ± 0.3 -47.9 ± 3.9 -58.8 ± 3.1*** -7.5 ± 0.8*** 
Rt (kΩ cm
2
) 2.4 ± 0.1 2.5 ± 0.2 4.1 ± 0.3 2.4 ± 0.1 2.1 ± 0.1* 4.9 ± 0.4** 
Ieq (µA cm
-2
) -20.4 ± 2.3 -16.7 ± 1.8 -1.6 ± 0.2 -20.5 ± 2.1 -28.6 ± 2.7** -0.9 ± 0.1* 
 
3.2.3 The effect of insulin on phosphorylation of endogenous 
proteins 
To investigate the signalling pathway underlying the insulin-mediated increase in 
amiloride-sensitive Na
+
 transport, the phosphorylation of endogenous proteins in 
response to insulin was monitored. Cells grown on transwells were maintained in 
serum-free media for 18-24 h, as described previously (Chapter 2), and cells were 
lysed (see Methods, 2.3.1) after 0-6 h exposure to insulin. This allowed 
construction of a time course showing the effects of insulin on the abundance of 
phosphorylated NDRG1-Thr
346/356/366
 and total protein. Within 15 min of 
application of insulin, the abundance of P-NDRG1-Thr
346/356/366
 was three-fold 
that of control (Figure 3.5B). This increased response peaked over the first hour of 
exposure to insulin, then fell slightly but remained elevated above that of control 
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for the following 5 hours (Figure 3.5B). These changes in abundance of 
phosphorlyated NDRG1-Thr
346/356/366
 occurred with no alteration to the abundance 
of total NDRG1 protein.  
 
Figure 3.5 Insulin-evoked phosphorylation of NDRG1-Thr
346/356/366
. 
Insulin (20nM) was applied to cells over a time course (0-6h), cells were then lysed and Western 
analysis was carried out. (A) Typical blot showing abundance of phospho-NDRG1-Thr
346/356/366
 
(top panel) and total NDRG1 (bottom panel). (B) Densitometric analysis showing levels of 
phospho-NDRG1-Thr
346/356/366
 and total NDRG1. Data is shown as a mean fraction of initial 
abundance ± S.E.M (n = 5). Statistical significance of insulin stimulation versus untreated cells is 
denoted by asterisks, ** p < 0.01, *** p < 0.001, calculated by one-way ANOVA with 
Bonferroni’s multiple comparison post test. 
 
Parallel experiments monitoring the abundance of phosphorylated Akt-Ser
473
 and 
total protein in response to a time course of insulin (20 nM, 0-6 h) were 
undertaken. Figure 3.6 shows the results of experiments that used this protocol to 
explore the effects of insulin upon the phosphorylation of Akt-Ser
473
. A four-fold 
increase in the abundance of P-Akt-Ser
473
 was observed within 15 min and this 
response peaked within the first hour (Figure 3.6B). Similar to the 
phosphorylation of NDRG1, the abundance of P-Akt-Ser
473
 declined over the next 
5 h but remained significantly stimulated over control (Figure 3.6B). Although 
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phosphorylation of Akt-Ser
473
 provides information about the status of this 
residue, phosphorylation of another residue, Thr
308
, is required for full activation 
of Akt. Since mTORC2 acts downstream of PI3-kinase to phosphorylate Akt at 
Ser
473
, this phosphorylation provides an excellent marker of PI3-kinase activity. 
Therefore these data show that exposing this cell line to insulin increases PI3-
kinase activity. To investigate the activity of Akt itself, the phosphorylation of a 
substrate of this kinase, PRAS40, was therefore monitored. 
 
Figure 3.6 Insulin evoked phosphorylation of Akt-Ser
473
. 
Insulin (20 nM) was applied to cells over a time course (0-6 h), cells were then lysed and Western 
analysis was carried out. (A) Typical blot showing abundance of phospho-Akt-Ser
473
 (top panel) 
and total Akt (bottom panel). (B) Densitometric analysis showing levels of phospho-Akt-Ser
473
 
and total Akt. Data is shown as mean fraction of initial abundance ± S.E.M (n = 5). Statistical 
significance of insulin stimulation versus untreated cells is denoted by asterisks, ** p < 0.01, *** 
p < 0.001, calculated by one-way ANOVA with Bonferroni’s multiple comparison post test. 
 
The abundance of phosphorylated PRAS40-Ser
246
 and total PRAS40 were 
measured under control and insulin stimulated conditions (20 nM, 30 min) to 
examine the effects of insulin upon Akt activity. After 30 min treatment with 
insulin, the level of phosphorylated PRAS40-Ser
246
 was double that of control 
(Figure 3.7B). However, a slight yet significant decrease in the abundance of total 
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protein was also observed (Figure 3.7B). Due to this change, the level of the 
phosphorylated form of PRAS40 may be underestimated so the abundance of 
phosphorylated-PRAS40-Ser
246
 was normalised to the overall abundance of 
PRAS40. Using this analysis, insulin induces nearly a 3-fold increase in 
phosphorylated PRAS40-Ser
246
 (Figure 3.7C). This format of calculating the level 
of phosphorylated PRAS40 has been employed in all subsequent studies of this 
protein. These data clearly show that 30 min exposure to insulin increases Akt 
activity in this cell line. 
 
Figure 3.7 Insulin evoked phosphorylation of PRAS40-Ser
246
. 
(A) Typical western blot showing the effects of insulin (20 nM) on the abundance of 
phosphorylated-PRAS40-Ser
246
 (upper panel) and total PRAS40 (lower panel). (B) Densitometric 
analysis showing levels of phospho-PRAS40-Ser
246
 and total PRAS40. (C) Further analysis of 
these data where the abundance of phosphorylated-PRAS40-Ser
246
 was normalised to the total 
abundance of this protein. Pooled data is shown as mean fraction of initial abundance ± S.E.M (n = 
28), asterisks denote statistical significance (*, p < 0.05, **, p < 0.01, ***, p < 0.001) determined 
by Student’s unpaired t-test. 
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3.2.4 The effect of PPARγ agonists on insulin-stimulated Na+ 
transport and SGK1 activity 
To investigate the role that PPARγ agonists play in basal and insulin-stimulated 
Na
+
 transport, two of these drugs: pioglitazone and rosiglitazone were used to 
examine the effect they exerted on both basal and insulin-stimulated ISC in 
mpkCCDc14 cells as well as their effect on SGK1 activity. Ussing chamber 
experiments were carried out in collaboration with Dr. Sarah Inglis, a postdoctoral 
research fellow in our laboratory.  
 
Under control conditions, insulin (20 nM) stimulated ISC (Figure 3.1) in a similar 
manner to recordings made under open circuit conditions (3.2.3). This response 
became apparent after 5 min and was inhibited with application of amiloride 
(10 µM). Preincubating cells with either pioglitazone (10 µM) or rosiglitazone 
(2 µM) for four hours did not alter the basal ISC, see Table 3.2. Furthermore, 
preincubation with either PPARγ agonist did not significantly alter the natriferic 
response to insulin (Figure 3.8). Thus neither pioglitazone or rosiglitazone alter 
ENaC activity in this murine collecting duct cell line. 
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Figure 3.8 The effects of PPARγ agonists on insulin-stimulated Ieq. 
PPARγ agonist-treated cells were preincubated (4hr) with either (A) pioglitazone (10µM) or (B) 
rosiglitazone (2µM), whilst control cells were preincubated with solvent vehicle alone. Insulin 
(20nM) was added basolaterally to the bath as indicated by the arrow and the short circuit current, 
ISC, recorded under each condition (mean ± S.E.M.) is shown as a fraction of the initial current 
recorded under unstimulated conditions at the onset of the experiment. 
 
Table 3.2 The effects of PPARγ agonists on basal ISC. 
Basal ISC recorded from either pioglitazone-treated cells (10µM, 4 h) or rosiglitazone-treated cells 
(2µM, 4 h) with their respective controls. Data is shown as mean ± S.E.M. (n = 9 for both pairs). 
 
 
 
Basal ISC
 
(µA cm
-2
) 
Control PPARγ agonist treated 
Rosiglitazone (2 µM, 4 h) 10.3 ± 1.3 10.6 ± 1.3 
Pioglitazone (10 µM, 4 h) 9.8 ± 1.3 10.0 ± 1.2 
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Since SGK1 activity has previously been reported to be stimulated with exposure 
to PPARγ-agonists, the effects that pioglitazone and rosiglitazone had on SGK1 
activity, by monitoring NDRG1-Thr
346/356/366
 phosphorylation, was investigated. 
Under control conditions, insulin (20 nM, 30 min) stimulated phosphorylation of 
NDRG1-Thr
346/356/366
 above basal levels (Figure 3.9). This is consistent with the 
results of the time course monitoring insulin stimulation of NDRG1-Thr
346/356/366
 
phosphorylation (Figure 3.5). Preincubation with pioglitazone (10 µM, 4 h) 
caused an inhibition of basal NDRG1-Thr
346/356/366
 phosphorylation (Figure 3.9A) 
and this was statistically significant. The addition of insulin increased 
phosphorylation of NDRG1-Thr
346/356/366 
to a level similar to control conditions 
(Figure 3.9A). Preincubation with rosiglitazone (2 µM, 4 h) did not alter either 
basal or insulin-stimulated NDRG1-Thr
346/356/366
 phosphorylation (Figure 3.9B). 
These changes in phosphorylation of NDRG1-Thr
346/356/366
 occurred without any 
alteration in the abundance of total NDRG1 (Figure 3.9). These data demonstrate 
that these drugs do not stimulate basal SGK1 activity in these cells and in the case 
of pioglitazone, actually suppress it. Furthermore, these PPARγ-agonists also do 
not alter insulin-stimulated SGK1 activity. 
 
 
 
 
78 
 
 
Figure 3.9 The effects of PPARγ agonists on SGK1 activity. 
Top panels: typical western blots showing the phosphorylation of  NDRG1-Thr
346/356/366
 under 
unstimulated or insulin-stimulated (20nM, 30 min) conditions in cells pretreated (4 hr) with either 
PPARγ agonists, (A) pioglitazone (10µM) or (B) rosiglitazone (2µM) or in control cells pretreated 
with solvent vehicle alone. Middle panels show the respective total protein blots for NDRG1. 
Lower panels show pooled data of phosphorylation of NDRG1-Thr
346/356/366
 (n = 6) and data is 
shown as mean ± S.E.M. Daggers denote statistical significance between unstimulated and insulin-
treated cells: ‡, p < 0.01. Asterisks denote statistically significant effects (One-way ANOVA 
Bonferroni post hoc test) of pioglitazone on basal phosphorylation of NDRG1-Thr
346/356/366
, *, p < 
0.05. 
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3.3 Discussion 
3.3.1 Bioelectric and pharmacological properties of unstimulated 
mpkCCDc14 cells 
Under hormone-deprived conditions mpkCCDcl4 cells display a spontaneous 
voltage with high resistance giving rise to a spontaneous current across the 
monolayer of -20.4 ± 0.5 µA cm
-2
 (n = 302). This finding accords well with other 
groups who have studied the electrical properties of these cells and found basal 
currents of 11.1 ± 0.1 µA / cm
2
 (Bens et al., 1999) and 10-15 µA / cm
2
 (Shane et 
al., 2006). It is important to note that these research groups used a convention in 
which ISC was described with positive values, the product of defining the 
movement of cations across a monolayer of cells as a positive movement of 
charge. The spontaneous current observed in this study occurs in the absence of 
any hormones which is unlike a bronchiolar cell line previously used in this 
laboratory that required the glucocorticoid dexamethasone to produce resistive 
monolayers with spontaneous currents (Ramminger et al., 2004).  
 
Ieq can be inhibited in a dose-dependent manner by amiloride, benzamil and EIPA, 
with the first two compounds known to be potent blockers of ENaC. The present 
data shows that the rank order potency of these drugs is benzamil > amiloride > 
EIPA. The EC50 values of amiloride and benzamil are similar to the values found 
by Bens et al. of 500 nM and 30 nM respectively (Bens et al., 1999). The basal 
current therefore can be attributed to the movement of Na
+
 ions passing through 
ENaCs in the apical membranes of these cells.  
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3.3.2 Bioelectric and pharmacological properties of insulin-
stimulated cells 
The addition of insulin (20nM) to the basolateral bath resulted in a significant 
hyperpolarisation of Vt and fall in Rt resulting in a significant increase in Ieq. 
Insulin produced a change in Ieq, ΔIeq, of -8.1 ± 0.6 µA cm
-2
. This finding accords 
well with those of Nofziger et al. who demonstrated that insulin (30nM) induced a 
change in short circuit current (ΔISC) of ~ 6 µA cm
-2
 in mpkCCDcl4 cells 
(Nofziger et al., 2005). Although the insulin response presented in this study has 
already been documented, the current clamp protocol employed here allows the 
quantification of Vt, Rt and Ieq. Furthermore, these data demonstrate that this 
method gives comparable results to direct short circuit measurements. The present 
data demonstrates a clear and significant natriferic response to insulin providing a 
model that allows exploration of the signalling pathway underpinning this 
response. 
 
A time course investigating the effect of treating cells with insulin (20 nM) 
revealed that within 15 min phosphorylation of both NDRG1-Thr
346/356/366
 and 
Akt-Ser
473
 had peaked to 3-fold or 4-fold that of control respectively. The peak 
response to insulin occurred within one hour and allowed identification of a time 
point (30 min) that produced a maximal response. This time point was therefore 
used in all subsequent experiments. As described previously (Chapter 2), 
NDRG1-Thr
346/356/366
 is a specific substrate of SGK1 but not of other closely 
related kinases such as Akt and therefore provides a method for monitoring SGK1 
activity. From these experiments it is clear that acute treatment with insulin 
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stimulates SGK1 activity as well as PI3-kinase activity. This finding is consistent 
with other studies that have reported an increase in phosphorylation of SGK1 in 
response to insulin in mpkCCDcl4 cells (Wang et al., 2008). Phosphorylation of 
PRAS40-Ser
246
 also increased with 30 min exposure to insulin indicating that Akt 
activity is also stimulated in response to insulin, this effect has also previously 
been demonstrated (Alessi et al., 1996). 
 
3.3.3 The effects of PPARγ agonists on ISC and SGK1 activity 
Preincubating cells with the PPARγ agonists pioglitazone or rosiglitazone did not 
alter basal or insulin-stimulated ISC indicating these drugs do not change ENaC 
activity in this cell line (Wilson et al., 2010). This finding is in accordance with a 
number of studies that have shown volume retention by PPARγ agonist treatment 
does not correlate with increased ENaC activity. Nofziger et al. demonstrated that 
in three different kidney-derived cells lines: A6, M1 and mpkCCDcl4; 
pioglitazone and GW7845, both PPARγ agonists did not enhance basal or insulin-
stimulated ENaC activity (Nofziger et al., 2005). Our laboratory has also 
demonstrated that both pioglitazone and rosiglitazone do not alter insulin-induced 
Na
+
 transport in another Na
+
 absorbing cell line, H441, derived from airway 
epithelia (Wilson et al., 2010). Vallon and colleages demonstrated that ENaC 
expression remained unaltered with rosiglitazone treatment and that this drug 
caused fluid retention in α-ENaC-/- mice. Furthermore, the authors demonstrated 
that in patch clamp studies of split-open cortical collecting ducts from wild-type 
mice neither rosiglitazone nor pioglitazone altered the open probability or the 
number of ENaC channels per patch (Vallon et al., 2009). Further evidence for 
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that lack of ENaC involvement came from a study that showed addition of 
amiloride did not prevent the increase in plasma volume brought about by 
farglitazar (Chen et al., 2005). Together with the present study, these findings do 
not support the theory that increased fluid retention due to PPARγ agonist 
treatment is brought about by alterations to ENaC activity in the distal nephron. 
 
These studies contrast with earlier work where it was demonstrated that fluid 
retention in mice brought about by treatment with either pioglitazone (Guan et al., 
2005) or rosiglitazone (Zhang et al., 2005) could be prevented by deletion of 
PPARγ in the collecting duct. Both of these studies also showed that TZDs could 
increase amiloride-sensitive Na
+
 transport, as shown by measuring transepithelial 
radiolabelled Na
+
 flux, in cultured collecting duct cells (Guan et al., 2005, Zhang 
et al., 2005). It is of note that the study carried out by Guan et al. showed an 
increase in Na
22
 flux but in the supplementary information give details of the 
electrical parameters recorded showing pioglitazone caused a depolarisation of Vt 
and a fall in Rt. Using Ohm’s law the transepithelial current can be calculated 
before and after pioglitazone treatment and there is no change in current; this is 
not consistent with an increase in ENaC-mediated Na
+
 absorption (Guan et al., 
2005). More recently, Pavlov et al. demonstrated that whilst PPARγ agonists did 
not alter short circuit current in mpkCCDcl4 cells, two PPARγ antagonists 
significantly decreased short circuit current. This study also showed that co-
expression of PPARγ with α-, β- and γ-ENaC in Chinese hamster ovary (CHO) 
cells could increase ENaC activity (Pavlov et al., 2009). Whilst Hong et al. 
demonstrated that TZD treatment increased expression of α-ENaC (Hong et al., 
83 
2003) other studies found no alteration to any subunits of ENaC but rather saw 
increased expression of the Na
+
 /  K
+
 ATPase in mice treated with farglitazar 
(Chen et al., 2005) as well as rosiglitazone (Song et al., 2004). Furthermore, the 
abundance of the water channel aquaporin 2 (AQP2) mRNA was found to be 
increased in mice treated with farglitazar (Chen et al., 2005). These studies 
provide alternative mechanisms for fluid retention that do not involve direct 
increases in ENaC activity. It is also interesting to note that Vallon et al. discuss 
the possibility that TZD treatment can lead to activation of a non-selective cation 
channel in mouse inner medullary collecting duct (IMCD) cells. This channel is 
sensitive to amiloride at concentrations used in the study by Guan et al. and could 
account for the amiloride-sensitive current they measured in primary collecting 
duct cells (Guan et al., 2005, Vallon et al., 2009). 
 
The present study demonstrated that whilst pioglitazone decreased basal SGK1 
activity, insulin stimulated activity similar to control conditions. Rosiglitazone 
had no apparent effect on basal or insulin-stimulated SGK1 activity. These data 
do not indicate a role for SGK1 in response to PPARγ activation. This is in 
contrast with studies that have found exposing human CCD cells (Hong et al., 
2003) or proximal tubule cells (Saad et al., 2009) to PPARγ agonists increased 
both SGK1 mRNA and protein expression. It is important to note that the study 
carried out by Hong et al. immunoprecipitated SGK1 out of human CCD cells and 
then used a generic peptide sequence as a substrate to measure SGK1 activity 
(Hong et al., 2003). This peptide can be recognised by various AGC kinases and 
therefore the results absolutely depend on the accurate immunoprecipitation of 
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SGK1, as any other similar kinases could equally phosphorylate the substrate. 
Artunc and colleagues studied SGK1
-/-
 mice and discovered that SGK1
-/-
 mice still 
retained fluid in response to pioglitazone, albeit to a lesser extent than in wild-
type mice (Artunc et al., 2008). This finding indicates that SGK1 contributes in 
mediating PPARγ-induced fluid retention, but it does not fully account for it. The 
findings of the present study do not support a role for increased SGK1 activity in 
response to PPARγ agonist treatment in mpkCCDcl4 cells and this is consistent 
with Nofziger et al. who did not observe any alteration to SGK1 expression in 
response to PPARγ agonist exposure (Nofziger et al., 2005). 
 
Together our findings conclude that the PPARγ agonists pioglitazone and 
rosiglitazone do not alter basal or insulin-stimulated ENaC activity in the 
mpkCCDcl4 cell line and do not stimulate SGK1 activity. The present data also 
confirm that mpkCCDcl4 cells generate spontaneous Na
+ 
absorption mediated via 
ENaC. Insulin can stimulate this response and also increase activity of PI3-kinase, 
Akt and SGK1. To further investigate the role that these kinases play in mediating 
the natriferic effect of insulin in the collecting duct, specific small molecule 
inhibitors were used. The first of these inhibitor experiments investigated the role 
of PI3-kinase in mediating basal and insulin-stimulated Na
+
 transport. 
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Chapter 4 - The role of PI3-kinase in 
basal and insulin-stimulated Na
+
 
transport 
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4.1 Introduction 
Having identified a model of insulin-stimulated Na
+
 transport in the collecting 
duct (see Chapter 3), the next aim in this thesis was to investigate the signalling 
pathway involved in this stimulation.  
 
When insulin binds its receptor in the basolateral membrane of epithelial cells the 
receptor undergoes autophosphorylation at several tyrosine residues (White et al., 
1985). These phosphorylated residues are recognised by phosphotyrosine-binding 
(PTB) domains of insulin receptor substrates (IRS) which are recruited to the 
plasma membrane (Sun et al., 1991). The phosphorylated insulin receptor 
subsequently phosphorylates the IRS at various residues, some of which are 
recognised by the p85 regulatory subunit of PI3-kinase, in turn recruiting it to the 
plasma membrane. The catalytic subunit of PI3-kinase, p110, phosphorylates 
phosphatidylinositol (4,5) bisphosphate (PIP2) to produce phosphatidylinositol 
(3,4,5) triphosphate (PIP3). PIP3 binds to pleckstrin homology (PH) domains on 
effector proteins including 3-phosphoinositide-dependent protein kinase 1 (PDK1) 
which is thought to play a role in insulin signalling by phosphorylating the 
activation loop of AGC kinases including Akt, SGK1 and S6K (Park et al., 1999). 
PDK1 has been shown to be PI3-kinase-dependent as studies where, in the 
presence of excess PIP3, phosphorylation of Akt-Thr
308
 was greatly increased 
(Komander et al., 2004). Inhibition of PI3-kinase in mammary tumour cells with 
wortmannin (100nM) or LY294002 (50µM) resulted in a novel dephosphorylation 
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of SGK1 (Park et al., 1999). Taken together these studies suggest that PDK1 acts 
downstream of PI3-kinase in the insulin signalling pathway. 
 
PI3-kinase also activates the mammalian target of rapamycin complex 2, 
mTORC2, by an unknown mechanism. mTORC2 is also thought to play a role in 
insulin signalling by phosphorylating the hydrophobic motif of AGC kinases 
including Akt-Ser
473
 and SGK1-Ser
422
. Studies where PI3-kinase was inhibited 
with PI103 (1µM, 30 min) resulted in dephosphorylation of both Akt-Ser
473
 and 
SGK1-Ser
422 
(García-Martínez and Alessi, 2008) indicating mTORC2 lies 
downstream of PI3-kinase. 
 
Furthermore, insulin-stimulated Na
+
 transport has also been shown to be 
dependent on PI3-kinase. Treatment of the A6 kidney cell line with an insulin 
tyrosine receptor kinase inhibitor, HNMPA, inhibited the insulin-stimulated short 
circuit current by ~50% (Record et al., 1998). Two PI3-kinase inhibitors: 
wortmannin and LY294002 also inhibited the insulin-stimulated short circuit 
current. These findings demonstrate that the natriferic effect of insulin is 
dependent on PI3-kinase. A study involving the mpkCCDcl4 cell line showed that 
an analogous stimulation of Na
+
 absorption using insulin-like growth factor (IGF) 
could be inhibited using LY294002 (Staruschenko et al., 2007). Furthermore, 
another study using this cell line where the p110α subunit of PI3-kinase was 
inhibited using compounds that specifically target this subunit: PI103 and PIK90, 
revealed that p110α was required for the stimulation of Na+ transport by insulin 
(Wang et al., 2008). Both of these studies show that insulin stimulates Na
+
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transport in mpkCCDcl4 cells and that PI3-kinase activity is critical for this 
response. Interestingly in the H441 airway epithelial cell line, application of 
insulin alone cannot evoke an ENaC-mediated Na
+
 current (Brown et al., 2008). 
Similarly expression of constitutively active PI3-kinase mimics this effect, also 
with no stimulation of ENaC-mediated transport. Therefore activation of PI3-
kinase does not always equate to an increase in ENaC activity in absorptive 
epithelia. Wang et al. also showed that inhibition of the Na
+
 current in 
mpkCCDcl4 cells with PI103 and PIK90 is accompanied by inhibition of the 
phosphorylation of downstream kinases including SGK1 and Akt. This further 
suggests that these proteins are involved in the signalling pathway linking insulin 
binding its receptor to increased Na
+
 reabsorption.  
 
The majority of these studies have demonstrated an involvement of PI3-kinase in 
the insulin signalling pathway. To confirm a role of PI3-kinase in our model of 
insulin signalling, we investigated the effects of three PI3-kinase inhibitors: 
wortmannin, PI103 and the more novel GDC0941. The effects of these 
compounds on basal and insulin-stimulated Na
+
 transport were examined in 
addition to measuring the activity of the endogenous proteins PI3-kinase, SGK1 
and Akt. Both PI103 (Raynaud et al., 2007) and wortmannin (Brunn et al., 1996) 
have previously been shown to inhibit the mammalian target of rapamycin 
complex 1 (mTORC1) in addition to inhibiting PI3-kinase. Therefore the effects 
of a specific inhibitor of mTORC1, rapamycin, on unstimulated and insulin-
stimulated current as well as the phosphorylation of endogenous proteins were 
also investigated. 
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4.2 Results 
4.2.1 The effects of PI3-kinase inhibtors on Ieq  
Wortmannin (100 nM) or solvent vehicle were added bilaterally to Ussing 
chambers for 30 min followed with basolateral application of insulin (20 nM) for 
a further 60 min. Figure 4.1 shows that wortmannin rapidly and significantly 
inhibited the basal current by 48.8 ± 2.4% (n = 5, p < 0.01). This decrease in Ieq 
occurred with a concomitant decrease in Vt and little effect on Rt, full details of 
the effects on electrical parameters can be found in Table 4.1. Control cells 
showed a slight decrease in Ieq over the same 30 min period but this was not 
statistically significant. Therefore wortmannin is inhibiting basal Na
+
 absorption 
and suggests PI3-kinase plays an important role in this transport. 
 
The addition of insulin (20nM) to the basolateral bath in control cells produced a 
stimulation of Ieq, (Figure 4.1) however due to the baseline drift in Vt this 
stimulation is difficult to quantify. In the presence of wortmannin however, the 
addition of insulin does not stimulate Ieq, instead it decreases slightly over 60 min 
(Figure 4.1). This decrease in Ieq is accompanied by a statistically significant fall 
in Rt over the 60 min period (Table 4.1, n = 5, p < 0.001). The resistance in 
control cells remained unchanged with the addition of insulin as seen previously. 
Wortmannin is preventing stimulation of Na
+
 transport indicating a role for PI3-
kinase in this signalling pathway. However, the alteration to Rt suggests that this 
drug is affecting epithelial integrity therefore further investigation into the role of 
PI3-kinase was studied using two other inhibitors. 
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Figure 4.1 Effects of wortmannin on insulin-stimulated Ieq. 
Ieq of control and wortmannin (100 nM) treated cells. Vehicle / drug were added bilaterally for 
30min, arrow indicates addition. Insulin (20nM) was added basolaterally for 60 min, grey shading 
indicates treatment. Amiloride (10µM) was added for 10min at the end of the experiment, arrow 
and Amil. indicates addition. Mean data is shown as fraction of the initial current ± S.E.M. (n = 5).  
 
Table 4.1 Electrical parameters of control and wortmannin-treated cells. 
Mean data ± S.E.M. (n = 5) for Vt, Rt and Ieq from vehicle- or wortmannin-treated cells. Values are 
from baseline, 30 min exposure to vehicle / drug and 60 min after exposure to insulin. Asterisks 
denote statistically significant effects of vehicle / wortmannin on Vt, Rt and Ieq calculated using a 
Student’s unpaired t-test, *, p < 0.05, **, p < 0.01, *** p < 0.001. 
 Vehicle-treated Wortmannin (100 nM) 
 Baseline 30 min 
vehicle 
60 min 
insulin 
Baseline 30 min wort. 60 min 
insulin 
Vt (mV) -57.0 ± 3.4 -50.2 ± 2.1 -54.4 ± 5.3 -52.6 ± 4.9 -21.8 ± 2.4*** -3.6 ± 1.9*** 
Rt (kΩ cm
2
) 2.1 ± 0.2 2.2 ± 0.2 2.2 ± 0.1 2.2 ± 0.2 2.0 ± 0.2 0.5± 0.2*** 
Ieq (µA cm
-2
) -27.5 ± 2.7 -23.1 ± 1.1 -24.9 ± 1.9 -25.4 ± 3.6 -9.0 ± 2.0** -7.3 ± 0.7* 
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The role of PI3-kinase in mediating both basal and insulin-stimulated Na
+
 
absorption was further investigated using PI103. Experiments identical to that 
used to explore the effects of wortmannin were carried out. Figure 4.2 and Table 
4.2 show that PI103 (1 µM, 30 min) caused no significant alteration to basal Ieq. 
Control values also showed a decay in Ieq over 30 min treatment with solvent 
vehicle. Both changes in Ieq in control and PI103 treated cells were accompanied 
by a depolarisation of Vt but no change in Rt, all mean values of electrical 
parameters for this experiment can be found in Table 4.2. The addition of 20nM 
insulin to the basolateral bath in control cells produced a significant increase in Ieq 
(Figure 4.2, n = 6, p < 0.01). In PI103-treated cells, the response to insulin was 
almost completely abolished. Therefore similar to wortmannin, PI103 is 
preventing the natriferic effect of insulin but unlike wortmannin, PI103 is not 
inhibiting the basal current. 
 
Table 4.2 Electrical parameters of control and PI103-treated cells. 
Mean data ± S.E.M. (n = 6) for Vt, Rt and Ieq recorded from vehicle-treated or PI103-treated cells. 
Values are from baseline, 30 min exposure to vehicle / PI103 and then 60 min after exposure to 
insulin. Asterisks denote statistically significant changes in Vt, Rt and Ieq in vehicle- and PI103-
treated cells calculated using a Student’s unpaired t-test, **, p < 0.01. 
 Vehicle-treated PI103 (1µM) 
 Baseline 30 min 
vehicle 
60 min 
insulin 
Baseline 30 min 
PI103 
60 min 
insulin 
Vt (mV) -50.7 ± 6.2 -46.8 ± 5.3 -57.0 ± 7.0* -53.1 ± 7.2 -45.7 ± 6.4 -43.6 ± 5.3 
Rt (kΩ cm
2
) 2.1 ± 0.2 2.1 ± 0.2 2.0 ± 0.1 2.1 ± 0.4 2.1 ± 0.4 2.3 ± 0.4 
Ieq (µA cm
-2
) -26.1 ± 5.0 -24.0 ± 4.2 -29.1 ± 3.6** -30.0 ± 6.5 -22.4 ± 6.1 -23.5 ± 5.0 
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Figure 4.2 Effects of PI103 on insulin-stimulated Ieq. 
 Ieq of cells treated with either solvent vehicle or PI103 (1µM) for 30 min, arrow indicates the 
addition of solvent / drug. Insulin (20nM) was added basolaterally for 60 min, followed by the 
addition of amiloride (10µM, 10 min) indicated by the arrow, Amil. Mean data is represented as a 
fraction of the basal current at the beginning of the experiment ± S.E.M (n = 6).  
 
The final PI3-kinase inhibitor tested was a relatively new compound, GDC0941 
(Folkes et al., 2008). The effects of this compound were tested in a slightly 
different manner; the duration of insulin stimulation was reduced to 30 min. This 
was due to parallel studies monitoring phosphorylation of endogenous proteins 
with exposure to insulin which revealed maximal stimulation occurred within 30 
min (3.2.3). Figure 4.3 shows that bilateral application of 1µM GDC0941 did not 
significantly alter basal Ieq, Vt or Rt (Table 4.3). Similarly there was no change to 
control cells (Figure 4.3). GDC0941 is having no effect on the basal current and 
this suggests that PI3-kinase activity is not required for the maintenance of 
spontaneous Na
+
 absorption in this cell line. 
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Figure 4.3 shows that the addition of insulin normally produced an increase in Ieq 
and this effect was significant (Table 4.3). This change in Ieq was accompanied by 
a hyperpolarisaton of Vt and a small decrease in Rt (Table 4.3). The application of 
insulin to GDC0941-treated cells produced only a small stimulation of Ieq. This 
change in Ieq occurred with no significant change in either Vt or Rt (Table 4.3). 
Therefore similar to both wortmannin and PI103, GDC0941 almost completely 
abolishes the insulin-stimulated Ieq, providing further evidence that this response 
is dependent on PI3-kinase activity. 
 
Table 4.3 Electrical parameters of control and GDC0941-treated cells. 
Mean data ± S.E.M. (n = 5) for Vt, Rt and Ieq from vehicle- or GDC0941-treated cells. Values are 
from baseline, 30 min exposure to vehicle / GDC0941 and then 30 min after exposure to insulin. 
Asterisks denote statistically significant changes in Vt, Rt and Ieq in vehicle- and GDC0941-treated 
cells calculated using a Student’s unpaired t-test, *, p < 0.05. 
 
 Vehicle-treated GDC0941 (1 µM) 
 Baseline 30 min 
vehicle 
30 min 
insulin 
Baseline 30 min 
GDC0941 
30 min 
insulin 
Vt (mV) -46.5 ± 6.8 -46.3 ± 6.5 -55.8 ± 5.0 53.7 ± 3.6 -43.0 ± 5.6 -39.2 ± 4.9 
Rt (kΩ cm
2
) 2.2 ± 0.2 2.3 ± 0.2 2.2 ± 0.2 2.7 ± 0.2 2.4 ± 0.2 2.1 ± 0.2 
Ieq (µA cm
-2
) -20.7 ± 1.3 -19.5 ± 1.3 -25.5 ± 1.4* -20.9 ± 3.3 -18.9 ± 4.1 -19.5 ± 4.4 
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Figure 4.3 Effects of GDC0941 on insulin-stimulated Ieq. 
Ieq of cells treated with either solvent vehicle or GDC0941 (1µM) for 30 min, arrow indicates the 
addition of solvent / drug. Insulin (20nM) was added basolaterally for 30 min, followed by the 
addition of amiloride (10µM, 10 min) indicated by the arrow, Amil. Mean data is represented as a 
fraction of the basal current at the beginning of the experiment ± S.E.M (n = 5).  
 
Wortmannin and PI103 are also known to inhibit the mammalian target of 
rapamycin complex 1, mTORC1 (Fan et al., 2006, Bain et al., 2007). To 
investigate the role that this protein complex plays in insulin-stimulated Na
+
 
transport in the collecting duct, a highly selective inhibitor of this complex, 
rapamycin (Bain et al., 2007), was studied. An identical experimental approach to 
the PI3-kinase inhibitors was employed. Figure 4.4 shows that rapamycin had no 
effect upon the current recorded from unstimulated cells and also failed to modify 
the electrometric response to insulin. These data suggest that mTORC1 does not 
contribute to the mechanism allowing spontaneous Na
+
 absorption or the 
signalling pathway by which insulin stimulates Na
+
 transport. All mean values of 
the electrical parameters recorded can be found in Table 4.4. 
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Figure 4.4 Effects of rapamycin on insulin-stimulated Ieq. 
Ieq of cells treated with either solvent vehicle or rapamycin (100nM) for 30 min, arrow indicates 
the addition of solvent / drug. Insulin (20nM) was added basolaterally for 60 min, followed by the 
addition of amiloride (10µM, 10 min) indicated by the arrow, Amil. Mean data is represented as a 
fraction of the basal current at the beginning of the experiment ± S.E.M (n = 5).  
 
 
Table 4.4 Electrical parameters of control and rapamycin-treated cells. 
Mean data ± S.E.M. (n = 5) for Vt, Rt and Ieq from vehicle- or rapamycin-treated cells. Values are 
from baseline, 30 min exposure to vehicle / rapamycin and then 60 min after exposure to insulin. 
Asterisks denote statistically significant changes in Vt, Rt and Ieq in vehicle- and rapamycin-treated 
cells calculated using a Student’s unpaired t-test, *, p < 0.05. 
 Vehicle-treated Rapamycin (100nM) 
 Baseline 30 min 
vehicle 
60 min 
insulin 
Baseline 30 min 
rapamycin 
60 min 
insulin 
Vt (mV) -63.0 ± 2.3 -59.9 ± 2.8 -65.9 ± 1.5* -49.3 ± 9.7 -47.9 ± 9.2 -54.0 ± 8.0 
Rt (kΩ cm
2
) 2.4 ± 0.2 2.3 ± 0.2 2.0 ± 0.2 2.1 ± 0.3 2.1 ± 0.3 2.0 ± 0.4 
Ieq (µA cm
-2
) -27.8 ± 3.4 -27.3 ± 3.7 -34.2 ± 3.0* -23.3 ± 4.1 -23.8 ± 4.5 -28.7 ± 5.3* 
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4.2.2 The effects of PI3-kinase inhibitors on phosphorylation of 
endogenous proteins 
The effects that three PI3-kinase inhibitors exerted on the activity of PI3 kinase, 
SGK1 and Akt were investigated by measuring the phosphorylation of their 
respective substrates: Akt-Ser
473
, NDRG-Thr
346/356/366
 and PRAS40-Ser
246
 (see 
Chapter 3). Under control conditions, insulin (20 nM, 30 min) normally increased 
phosphorylation of Akt-Ser
473
 (Figure 4.5A), NDRG-Thr
346/356/366
 (Figure 4.5B) 
and PRAS40-Ser
246
 (Figure 4.5C), above basal levels confirming previous 
findings. Wortmannin (100nM, 30 min) caused a complete loss of 
phosphorylated-Akt-Ser
473
 (Figure 4.5A) and NDRG-Thr
346/356/366 
(Figure 4.5B) 
under control and insulin-stimulated conditions. Phosphorylation of PRAS40-
Ser
246
 in wortmannin-treated cells was also greatly reduced under control and 
insulin-stimulated conditions (Figure 4.5C). The changes in phosphorylation of 
Akt and NDRG1 occured without any change to the abundance of their respective 
total protein. As described previously, the abundance of total PRAS40 does 
appear to alter slightly in the presence of insulin therefore the pooled data of P-
PRAS40-Ser
246
 has been adjusted to accommodate these changes. These data 
indicate that wortmannin is inhibiting PI3-kinase activity, as shown by a loss of 
phosphorylation of mTORC2. Furthermore these data demonstrate that both 
SGK1 and Akt lie downstream of PI3-kinase as phosphorylation of their 
respective substrates has been abolished or greatly reduced. 
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Figure 4.5 Effects of wortmannin on the phosphorylation of endogenous proteins. 
Top panels: typical western blots showing the phosphorylation of (A) Akt-Ser
473
, (B) NDRG1-
Thr
346/356/366
 and (C) PRAS40-Ser
246
 under unstimulated or insulin-treated (20nM, 30 min) 
conditions in vehicle treated, left hand pair, or wortmannin treated (100nM, 30 min) cells, right 
hand pair. Middle panels show the respective total protein blots for (A) Akt, (B) NDRG1 and (C) 
PRAS40. Lower panels: pooled data of phosphorylation of (A) Akt-Ser
473
, n = 5, (B) NDRG1-
Thr
346/356/366
, n = 7, and (C) PRAS40-Ser
246
, n = 4. Data is shown as mean ± S.E.M. and asterisks 
denote statistical significance (One-way ANOVA Bonferroni post hoc test) between control and 
wortmannin-treated cells: *, p < 0.05, **, p < 0.01, whilst daggers denote statistical significance 
between basal and insulin-treated cells under control conditions: †, p < 0.05, ‡, p < 0.01.  
 
The control data in Figure 4.6 confirm that insulin normally evokes increased 
phosphorylation of Akt-Ser
473
 (Figure 4.6A), NDRG-Thr
346/356/366
 (Figure 4.6B) 
and PRAS40-Ser
246
 (Figure 4.6C). PI103 (1 µM, 30 min) abolished mTORC2 
activity, as shown by a complete loss of phosphorylated Akt-Ser
473
, under both 
control and insulin-stimulated conditions (Figure 4.6A). SGK1 activity was 
inhibited in the presence of PI103, as seen by a complete loss of NDRG1-
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Thr
346/356/366
 phosphorylation (Figure 4.6B). Similarly Akt activity was inhibited 
as seen by reduced phosphorylation of PRAS40-Ser
246
 (Figure 4.6C). These data 
show that PI103 can inhibit PI3-kinase activity as seen with a loss of downstream 
phosphorylation and these findings are consistent with those examining the effects 
of wortmannin. 
  
 
Figure 4.6 Effects of PI103 on the phosphorylation of endogenous proteins. 
Top panels: typical western blots showing the phosphorylation of (A) Akt-Ser
473
, (B) NDRG1-
Thr
346/356/366
 and (C) PRAS40-Ser
246
 under unstimulated or insulin-treated (20nM, 30 min) 
conditions in vehicle treated, left hand pair, or PI103 treated (1µM, 30 min) cells, right hand pair. 
Middle panels show the respective total protein blots for (A) Akt, (B) NDRG1 and (C) PRAS40. 
Lower panels show pooled data of phosphorylation of (A) Akt-Ser
473
, n = 5, (B) NDRG1-
Thr
346/356/366
, n = 6, and (C) PRAS40-Ser
246
, n = 5. Data is shown as mean ± S.E.M. and asterisks 
denote statistical significance (One-way ANOVA Bonferroni post hoc test) between control and 
PI103-treated cells: *, p < 0.05, **, p < 0.01, *** P < 0.001, whilst daggers denote statistical 
significance between basal and insulin-treated cells under control conditions: †, p < 0.05, ‡, p < 
0.01. 
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Figure 4.7 shows again that insulin greatly increases phosphorylation of Akt-
Ser
473
 (Figure 4.7A), NDRG1-Thr
346/356/366
 (Figure 4.7B) and PRAS40-Ser
246
 
(Figure 4.7C). GDC0941 (1 µM, 30 min) completely abolished Akt-Ser
473
 and 
NDRG1-Thr
346/356/366
 phosphorylation under control and insulin-stimulated 
conditions (Figure 4.7A, B). Phosphorylation of PRAS40-Ser
246
 was also 
markedly reduced (Figure 4.7C). These data indicate that GDC0941 inhibits PI3-
kinase as shown by loss of phosphorylation of downstream substrates. 
 
 
Figure 4.7 Effects of GDC0941 on the phosphorylation of endogenous proteins. 
Top panels: typical western blots showing phosphorylation of (A) Akt-Ser
473
, (B) NDRG1-
Thr
346/356/366
 and (C) PRAS40-Ser
246
 under unstimulated or insulin-treated (20nM, 30 min) 
conditions in vehicle treated, left hand pair, or GDC0941 treated (1µM, 30 min) cells, right hand 
pair. Middle panels: respective total protein blots for (A) Akt, (B) NDRG1 and (C) PRAS40. 
Lower panels: pooled data of phosphorylation of (A) Akt-Ser
473
, n = 6, (B) NDRG1-Thr
346/356/366
, n 
= 6, and (C) PRAS40-Ser
246
, n = 6. Data is shown as mean ± S.E.M. and asterisks denote statistical 
significance (One-way ANOVA Bonferroni post hoc test) between control and GDC0941-treated 
cells: *, p < 0.05, **, p < 0.01, *** p < 0.001, whilst daggers denote statistical significance 
between basal and insulin-treated cells under control conditions: †, p < 0.05, ‡, p < 0.01. 
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The effects rapamycin exerted on the phosphorylation of endogenous proteins was 
examined to investigate the role of mTORC1. Figure 4.8 shows under control 
conditions acute addition of insulin increased phosphorylation of Akt-Ser
-473
 
(Figure 4.8A), NDRG1-Thr
346/356/366
 (Figure 4.8B) and PRAS40-Ser
246
 (Figure 
4.8C). Rapamycin (100 nM, 30 min) did not alter phosphorylation of any of the 
three substrates examined, under both unstimulated and insulin-stimulated 
conditions (Figure 4.8). These data indicate that mTORC1 is not involved in basal 
or insulin-stimulated mTORC2, SGK1 or Akt activity. 
 
 
Figure 4.8 Effects of rapamycin on the phosphorylation of endogenous proteins. 
Top panels: typical western blots showing the phosphorylation of (A) Akt-Ser
473
, (B) NDRG1-
Thr
346/356/366
 and (C) PRAS40-Ser
246
 under unstimulated or insulin-treated (20nM, 30 min) 
conditions in vehicle treated, left hand pair, or rapamycin treated (100nM, 30 min) cells, right hand 
pair. Middle panels show the respective total protein blots for (A) Akt, (B) NDRG1 and (C) 
PRAS40. Lower panels show pooled data of phosphorylation of (A) Akt-Ser
473
, n = 5, (B) 
NDRG1-Thr
346/356/366
, n = 7, and (C) PRAS40-Ser
246
, n = 5. Data is shown as mean ± S.E.M. and 
daggers denote statistical significance (One-way ANOVA Bonferroni post hoc test)  between basal 
and insulin-treated cells under control conditions: †, p < 0.05, ‡, p < 0.01. 
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To confirm that rapamycin inhibited mTORC1, the same lysates were subject to 
western analysis using antibodies against a physiological substrate of mTORC1: 
the 70kDa ribosomal S6 kinase (P70-S6K) by measuring phosphorylation of the 
Thr
389
 residue as well as the abundance of total S6K. Under control conditions 
insulin increased phosphorylation of P70-S6K-Thr
389
 (Figure 4.9, n = 4, p < 0.01). 
Rapamycin (100nM, 30 min) completely abolished phosphorylation of P70-S6K-
Thr
389
. This finding demonstrates that insulin can stimulate mTORC1 activity and 
that rapamycin specifically inhibits mTORC1 in these cells. 
 
Figure 4.9 Effects of rapamycin on the phosphorylation of P70-S6kinase-Thr
389
. 
Top panel: typical western blots showing the phosphorylation of P70-S6K-Thr
389
 under 
unstimulated or insulin-treated (20nM, 30 min) conditions in vehicle treated, left hand pair, or 
rapamycin treated (100nM, 30 min) cells, right hand pair. Middle panel shows the respective total 
protein blots for S6K. Lower panel shows the pooled data of phosphorylation of P70-S6K-Thr
389
 
n = 4. Data is shown as mean ± S.E.M. and asterisks denote statistical significance (One-way 
ANOVA Bonferroni post hoc test) between control and rapamycin-treated cells: **, p < 0.01, ***, 
p < 0.001, whilst daggers denote statistical significance between basal and insulin-treated cells 
under control conditions: ‡, p < 0.01. 
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4.3 Discussion 
4.3.1 The role of PI3-kinase in basal and insulin-stimulated Na+ 
transport 
Bilateral addition of wortmannin to cells mounted in Ussing chambers produced a 
rapid inhibition of basal Ieq suggesting that spontaneous transport of Na
+
 across 
these epithelial cells is dependent on PI3-kinase. Wortmannin is a well-used 
inhibitor of PI3-kinase and inhibits signalling by covalently binding a lysine 
residue within the catalytic p110α subunit (Wymann et al., 1996). The present 
finding is in accordance with a study showing inhibition of basal sodium current 
in A6 cells (Record et al., 1998) by treatment with wortmannin (100 nM). Further 
studies demonstrating the  importance of PI3-kinase in maintaining the basal 
current have come from using the inhibitor LY-294002 in A6 cells (Păunescu et 
al., 2000, Record et al., 1998, Wang et al., 2001) and mpkCCDcl4 cells 
(Staruschenko et al., 2007). However, two other compounds used in the present 
study: PI103 and GDC0941; had only modest effects on the basal current. Both 
PI103 and GDC0941 are relatively recent additions to the growing number of PI3-
kinase inhibitors and GDC0941 in particular has been reported to be highly 
selective (Garcia-Echeverria and Sellers, 2008). All three compounds tested in the 
present study caused complete loss of mTORC2 activity and since this kinase lies 
downstream of PI3-kinase indicates these drugs abolish PI3-kinase activity. It 
therefore seems likely that wortmannin is producing its effects on the basal 
current through inhibition of other targets. Wortmannin has been reported to 
inhibit both polo-like kinase (PLK) and smooth-muscle myosin light-chain kinase 
103 
(SmMLCK) (Bain et al., 2007). These kinases have not previously been reported 
to play a role in Na
+
 transport but could explain why this compound, but not the 
other two, had significant effects on the basal current. It is also interesting to note 
that LY-294002 has been reported to have several off-target effects including 
mTORC1, PLK1 (polo like kinase 1), PIMK1 (provirus integration site for 
Moloney murine leukaemia virus kinase 1), HIPK (homeodomain-interacting 
protein kinase), GSK3 (glycogen synthase kinase 3) and CK2 (casein kinase 2) 
(Davies et al., 2000, Bain et al., 2007). It is of note that CK2 is inhibited by 
LY294002 since this kinase has been linked to modulation of ENaC activity 
(Bachhuber et al., 2008). Therefore both wortmannin and LY-294002 do not 
inhibit PI3-kinase selectively and it seems prudent that the use of either of these 
compounds to study ENaC-mediated Na
+
 transport is discontinued and replaced 
with more novel selective inhibitors. The present data provide novel evidence that 
spontaneous Na
+
 absorption can occur in the complete absence of PI3-kinase 
activity. 
 
Furthermore, since both PI103 and GDC0941 caused a complete loss of 
phosphorylated NDRG1-Thr
346/356/366
 under basal conditions yet exerted only 
modest effects on the basal current, this suggests that spontaneous Na
+
 absorption 
can also occur in the absence of SGK1 activity. This is in sharp contrast to 
previous studies where overexpression of a kinase-dead form of SGK1 in A6 and 
M1 cells completely abolished amiloride-sensitive currents (Faletti et al., 2002, 
Helms et al., 2003, Náray-Fejes-Tóth et al., 2004a). Similar findings were also 
observed in a study where isolated rabbit cortical collecting duct cells transfected 
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with antisense nucleotides targeting SGK1 displayed minimal amiloride-sensitive 
currents (Náray-Fejes-Tóth et al., 2004a). Whilst these studies clearly indicate 
that SGK1 is required for basal Na
+
 absorption the results from the present study 
are not consistent with this. Whilst the above data have been obtained from 
overexpression studies which may not reflect physiological conditions, our work 
has been carried out in a mammalian collecting duct cell line under physiological 
conditions. This highlights the benefits of using these novel small molecule 
inhibitors in a native cell line. The present study also demonstrates that both 
PI103 and GDC0941 significantly reduced Akt activity and also suggests that Akt 
does not play a major role in the maintenance of the basal current. 
 
Insulin-stimulated Ieq was significantly inhibited by all three compounds tested 
and this finding is consistent with several other studies that have shown inhibitors 
of PI3-kinase: LY-294002 and wortmannin (Record et al., 1998) and PI103 
(Wang et al., 2008) abolish the natriferic response to insulin. Under insulin-
stimulated conditions all three PI3-kinase inhibitors tested in the present study 
abolished the activity of mTORC2 indicating inhibition of PI3-kinase. This is 
consistent with a study that showed inhibition of insulin-induced phosphorylation 
of Akt-Ser
473
 using PI103 in the same cell line (Wang et al., 2008). Furthermore 
all three inhibitors used in the present study caused a complete loss of 
phosphorylated NDRG1-Thr
346/356/366
 indicating insulin can stimulate SGK1 
activity downstream of PI3-kinase. This result accords well with a study that 
showed that both LY294002 and wortmannin inhibited serum-induced 
phosphorylation of SGK1 in mammary tumour cells (Park et al., 1999). Another 
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study carried out in the mpkCCDcl4 cell line also revealed both LY294002 and 
PI103 prevented the insulin-induced phosphorylation of SGK1 by insulin (100 
nM, 1hr) (Wang et al., 2008). Similarly the insulin-stimulated phosphorylation of 
the Akt substrate PRAS40-Ser
246
 was significantly reduced in the presence of all 
three compounds tested. This demonstrates that like SGK1, Akt activity is largely 
dependent on PI3-kinase. This finding is in accordance with a study that showed 
that the phosphorylation of two residues on Akt is required for full activity:  Ser
473
 
and Thr
308
; and activity was abolished by the inhibitors LY294002 and PI103 
(Wang et al., 2008). Together these data provide novel evidence that PI3-kinase as 
well as mTORC2 and SGK1 are not required for spontaneous Na
+
 absorption in 
the collecting duct. PI3-kinase however, appears to be absolutely crucial for 
insulin-stimulated Na
+ 
transport. 
 
4.3.2 The role of mTORC1 in basal and insulin-stimulated Na+ 
transport 
The present data confirmed rapamycin is a specific inhibitor of mTORC1 (Proud, 
2007) as shown with loss of phosphorylation of a downstream substrate but with 
no effects on downstream substrates of mTORC2, SGK1 or Akt. This confirms 
that the PI3-kinase inhibitors employed in this study were not exerting additional 
effects on Na
+
 transport via off-target inhibition of mTORC1 as previously 
reported (Fan et al., 2006, Bain et al., 2007). Furthermore with the lack of effect 
on SGK1 activity, the present data provide evidence that mTORC1 does not 
phosphorylate and activate SGK1. This is in sharp contrast to a recent paper that 
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reported mTORC1 was the elusive “PDK2” due to the finding that rapamycin 
could inhibit SGK1-Ser
422
 phosphorylation (Hong et al., 2008). Another study 
however demonstrated rapamycin did not alter SGK1-Ser
422
 in three different cell 
lines expressing full length SGK1 (García-Martínez and Alessi, 2008). The 
authors concluded that the results seen by Hong et al. were due to a commercial 
SGK1 antibody recognising phosphorylated bands of S6K since these two kinases 
share similar hydrophobic motifs (García-Martínez and Alessi, 2008). Therefore 
the present data is in accordance with García-Martínez and Alessi and indicates 
that mTORC1 does not lie upstream of SGK1. 
 
Rapamycin did not alter either basal or insulin-stimulated Ieq indicating that this 
complex is not involved in either maintaining basal Na
+
 transport or mediating the 
natriferic response to insulin. This data is in contrast to a study examining the 
effects of rapamycin in the A6 cell line (Rokaw et al., 1996a). The authors 
reported that acute addition of rapamycin stimulated amiloride-sensitive Na
+
 
transport and this response was additive to insulin-stimulated Na
+
 transport. This 
suggests that mTORC1 can modulate ENaC-mediated Na
+
 transport and the 
authors attribute this effect to the inhibition of protein kinase C (Rokaw et al., 
1996a). Interestingly, in complete contrast, a study from fetal airway cells 
reported rapamycin as having an inhibitory effect on basal amiloride-sensitive 
currents (Otulakowski et al., 2007). The authors concluded that this was due to an 
inhibition of α-ENaC translation. The results from the present study in a 
mammalian collecting duct cell line do not report either an inhibitory or 
stimulatory effect of rapamycin, indicating a lack of a role of mTORC1 in basal or 
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insulin-stimulated Na
+
 transport. These contrasting data could be due to the 
different cell lines utilised. However ongoing research in our laboratory has found 
that rapamycin also does not alter amiloride-sensitive Na
+
 currents recorded from 
groups of H441 airway epithelial cells (unpublished data), providing further 
evidence that mTORC1 is not involved in basal Na
+
 transport in absorptive 
epithelia. 
 
The experiments in this chapter provide novel evidence that the mpkCCDcl4 cell 
line can spontaneously absorb Na
+
 via ENaC in the absence of PI3-kinase activity. 
In contrast, these data highlight that PI3-kinase activity is absolutely crucial in 
mediating the stimulation of Na
+
 absorption by insulin. Furthermore, these 
findings also indicate that mTORC1 plays no role in either the basal or insulin-
stimulated current. 
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Chapter 5 – The role of Akt and SGK1 in 
basal and insulin-stimulated Na
+
 
transport 
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5.1 Introduction 
The serum and glucocorticoid regulated kinase (SGK1), a downstream target of 
PI3-kinase, has previously been implicated in mediating ENaC activity (Chen et 
al., 1999, Náray-Fejes-Tóth et al., 1999, Debonneville et al., 2001). SGK1 was 
discovered in a rat mammary tumour cell line by Webster and colleagues and was 
the first example of protein kinase transcription being regulated by 
glucocorticoids (Webster et al., 1993b). This study observed that both serum and 
the glucocorticoid dexamethasone could induce SGK1 mRNA expression within 
30 min, with the latter having greater effect. SGK1 was found to contain a 
glucocorticoid response element (GRE) in its promoter region that allowed 
dexamethasone to bind and mediate transcription (Webster et al., 1993b, Itani et 
al., 2002). This increase in SGK1 mRNA levels in response to dexamethasone 
was subsequently found to be induced by aldosterone as well and this was 
demonstrated in the amphibian A6 kidney cell line (Chen et al., 1999), in primary 
cortical collecting duct cells from rabbit (Náray-Fejes-Tóth et al., 1999) and also 
in rat colon (Shigaev et al., 2000). Oocyte expression studies revealed that co-
expression of α-, β- and γ- ENaC subunits with SGK1 increased amiloride-
sensitive currents (Chen et al., 1999, Shigaev et al., 2000), indicating that SGK1 
could enhance ENaC activity. However, the mechanism by which it did so 
remained unclear. 
 
These studies revealed SGK1 involvement in mineralocorticoid / glucocorticoid 
stimulation of Na
+
 transport. SGK1 was subsequently shown to play a role in 
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insulin-stimulated Na
+
 transport (Faletti et al., 2002). As discussed previously 
(Chapter 3), insulin has been shown to increase ENaC activity in the kidney 
(Handler et al., 1981a, Fidelman et al., 1982). A6 cells overexpressing full-length 
wild-type SGK1 have been shown to display increased ENaC activity (Faletti et 
al., 2002). This increased activity could not be potentiated further by stimulation 
with insulin but matched the response of untransfected parent cells to insulin. 
Overexpression of a kinase dead SGK1 mutant in this cell line not only prevented 
the natriferic response to insulin but also inhibited basal levels of Na
+
 transport 
(Faletti et al., 2002). Another study using a tetracycline-inducible system in A6 
cells showed that expression of a constitutively active SGK1 increased basal Na
+
 
transport but addition of insulin could not stimulate the short circuit current 
further as seen in control cells (Alvarez De La Rosa and Canessa, 2003). These 
data together indicate a role for SGK1 in insulin-mediated stimulation of ENaC. 
 
Insulin is thought to act via a signalling cascade dependent on PI3-kinase resulting 
in an increase in SGK1 activity (Park et al., 1999, Kobayashi and Cohen, 1999) 
rather than increasing the expression of this kinase like corticosteroids. SGK1 
activity requires phosphorylation at two residues: Thr
256
 in the activation loop and 
Ser
422
 in the catalytic domain. PDK1 was shown to be the kinase responsible for 
phosphorylation of Thr
256
 in vitro (Kobayashi and Cohen, 1999) and in vivo (Park 
et al., 1999). More recently, the elusive kinase that phosphorylates the Ser
422
 
residue, previously termed PDK2, was found to be the mammalian target of 
rapamycin complex 2 (mTORC2) (García-Martínez and Alessi, 2008). Without 
phosphorylation at the hydrophobic motif by mTORC2, SGK1 cannot be 
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phosphorylated by PDK1 on the activation loop, therefore phosphorylation of 
Ser
422
 is critical for SGK1 activity (García-Martínez and Alessi, 2008). 
 
It has been proposed that active SGK1 mediates its effects on Na
+
 transport by 
phosphorylating the ubiquitin ligase Nedd4-2. Phosphorylation of Nedd4-2 
prevents it from interacting with PY motifs on ENaC, normally tagging the 
channel for degradation. Therefore with less internalisation and more Na
+
 
channels in the membrane there would be an increase in Na
+
 transport (Snyder et 
al., 2002). SGK1 has also been shown to directly interact with ENaC itself 
(Diakov and Korbmacher, 2004) although whether this happens under 
physiological conditions remains unclear. 
 
The role of SGK1 in mediating hormone-stimulated Na
+
 transport in the kidney 
has been well-documented (for review see Pearce and Kleyman, 2007), therefore 
it came as a surprise that SGK1 knockout mice displayed no overt phenotype 
(Wulff et al., 2002). Only when mice were fed a low-sodium diet did they show 
an impaired ability to upregulate Na
+
 reabsorption. Another study demonstrated 
that Na
+
 absorption in the colon, which can be regulated in a similar manner to the 
collecting duct with corticosteroids, was actually enhanced in SGK1
-/-
 mice 
(Rexhepaj et al., 2006). Work carried out in our laboratory has shown that in 
H441 airway epithelial cells, expression of a constitutively active SGK1 can 
increase amiloride-sensitive Na
+
 currents (Brown et al., 2008) but the expression 
of an inactive SGK1 mutant did not suppress glucocorticoid-induced currents 
(Inglis et al., 2007). These findings suggest that mediators other than SGK1 can 
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regulate Na
+
 absorption, possibly other isoforms of SGK including SGK2 and 
SGK3 or other protein kinases that share a similar homology to SGK1 such as 
protein kinase B (Akt). 
 
The role of Akt in mediating hormonal stimulation of ENaC activity was 
investigated in a study that used a tetracycline inducible system expressing either 
constitutively active or inactive Akt in A6 cells (Arteaga and Canessa, 2005). This 
study demonstrated that expression of constitutively active or inactive Akt did not 
alter levels of ENaC activity measured as amiloride sensitive short circuit current. 
The application of insulin produced a stimulation of ENaC activity but this was 
not different to control cells indicating that expression of active or inactive Akt 
did not alter the insulin-mediated increase in Na
+
 transport. In sharp contrast, a 
study carried out by Lee et al. (2007) observed that overexpression of Akt or 
SGK1 in fisher rat thyroid cells expressing ENaC greatly increased amiloride-
sensitive short circuit currents. Inhibition of both Akt and SGK1 expression using 
siRNA reduced ENaC activity below basal levels and also prevented the increase 
in current in response to insulin treatment. Furthermore in M1 cells, silencing 
expression of Akt prevented insulin stimulation of ENaC activity (Lee et al., 
2008). This study suggests that both Akt and SGK1 are involved in mediating 
increases in Na
+
 transport via ENaC in response to insulin. Clearly the role that 
Akt plays in mediating either basal or homone-stimulated Na
+
 absorption remains 
unclear and both of the above studies utilised expression systems which do not 
always depict physiological conditions. 
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The creation of novel small molecule inhibitors of Akt and SGK1, Akti-1/2 
(Barnett et al., 2005) and GSK650394A (Sherk et al., 2008) respectively, allowed 
a method by which to inhibit either kinase and examine their effects in a native 
system. The following experiments investigated the effects these drugs exerted on 
both basal and insulin-stimulated Na
+
 transport in the mpkCCDc14 collecting duct 
cell line. By monitoring the phosphorylation of endogenous proteins we could 
also confirm that the inhibitors were selective and identify the doses required for 
effective inhibition of kinase activity. 
 
Due to the difficulty that a drifting baseline in Ussing chamber experiments 
caused when trying to draw comparisons from data collected, identified in the 
PI3-kinase inhibitor studies, the experimental design was subsequently improved. 
Double paired experiments were setup where four cultures of cells from identical 
passage were grown on snapwells, mounted in Ussing chambers and recorded 
from. The first pair allowed recording of a control response to insulin with 
unstimulated and insulin-stimulated conditions. The second pair allowed 
recording of the effects of a test substance under unstimulated and insulin-
stimulated conditions. This allowed accurate measurement of the effects a drug 
exerted on unstimulated current and allowed calculation of the change in current, 
ΔIeq.  
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5.2 Results 
5.2.1 Effects of Akti-1/2 on basal and insulin-stimulated Na+ 
transport 
The effects that three doses of Akti-1/2 (1, 3, 10 µM) had on basal levels of Na
+
 
transport were examined. Figure 5.1 and Table 5.1 show that bilateral addition of 
both 1 µM and 3 µM Akti-1/2 for 30 min did not alter the basal current 
significantly. At 10µM Akti-1/2 the basal current was significantly inhibited by 
17.8 ± 7.0% (Table 5.1). Despite this inhibition, more than 80 % of the 
spontaneous current remained suggesting that Akti-1/2 is not inhibiting the 
mechanism allowing spontaneous Na
+
 absorption. All mean values of Ieq are 
presented in Table 5.1. 
 
 
 
Figure 5.1 Effects of Akti-1/2 on basal Ieq. 
Ieq of cells treated with solvent vehicle or Akti-1/2 (1-10 µM) for 30 min, arrow indicates addition. 
Data is shown as mean current, calculated as a fraction of the initial current, ± S.E.M. (n = 5). 
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Table 5.1 Ieq of control and Akti-1/2-treated cells. 
Mean data ± S.E.M. (n = 5) for Ieq recorded from cells treated with vehicle or Akti-1/2 (1-10 µM). 
Values are from baseline and after 30 min exposure to vehicle / Akti-1/2. Statistical significance 
was calculated using unpaired Student’s t-test, * p < 0.05. 
 
 
Treatment 
Ieq (µA cm
-2
) 
Baseline 30 min exposure 
1µM Akti-1/2 Control -24.2 ± 2.0 -23.6 ± 2.1 
Experimental -20.3 ± 2.4 -18.7 ± 2.4 
3µM Akti-1/2 Control -14.5 ± 1.3 -13.6 ± 1.1 
Experimental -15.8 ± 1.0 -14.5 ± 0.9 
10µM Akti-1/2 Control -14.9 ± 3.2 -14.0 ± 3.1 
Experimental -15.1 ± 2.7 -11.1 ± 1.2* 
 
The effects of Akti-1/2 on insulin-stimulated Na
+
 transport were subsequently 
investigated and for each dose tested, a separate control response to insulin was 
measured. Due to the nature of the double-paired experiments the change in Ieq, 
ΔIeq, brought about by insulin stimulation could be calculated. Figure 5.2A-C 
shows that in control experiments, insulin (20 nM, 30 min) consistently produced 
a significant increase in ΔIeq: 1µM control: -7.1 ± 1.8 µA cm
-2
 (n = 5, p < 0.01); 
3µM control: -5.4 ± 0.7 µA cm
-2
 (n = 5, p < 0.001); 10µM control: -5.2 ± 0.8 µA 
cm
-2
 (n = 5, p < 0.001). Statistical significance was calculated by comparing the 
mean ΔIeq after 30 min in both control and Akti-1/2-treated cells using an 
unpaired Student’s t-test. These insulin-induced increases in Ieq were associated 
with a hyperpolarisation of Vt and a slight fall in Rt; all mean values of electrical 
parameters measured can be found in the appendix (Chapter 9). 
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Figure 5.2D-F show increasing concentrations of Akti-1/2 caused a dose-
dependent inhibition of the insulin-stimulated Ieq. 1µM Akti-1/2 inhibited the 
response to insulin by 43.4 ± 4.6% with a ΔIeq of -3.5 ± 1.6 µA cm
-2
 (n = 5, p < 
0.05). 3µM Akti-1/2 inhibited the insulin-evoked Ieq by 31.3 ± 12.5% with a ΔIeq 
of -3.6 ± 0.8 µA cm
-2
 (n = 5, p < 0.05). Finally 10µM Akti-1/2 inhibited the 
response to insulin by 80.8 ± 7.3% with a ΔIeq of 0.8 ± 0.3µA cm
-2
 (n = 5, p < 
0.01). Together these results indicate that Akti-1/2 is inhibiting the natriferic 
response to insulin. 
 
5.2.2 Effects of Akti-1/2 on phosphorylation of endogenous 
proteins 
As previously observed (see Chapter 3), insulin (20 nM) normally increased the 
phosphorylation of Akt-Ser
473
 indicating an increase in mTORC2 activity, this can 
be seen in Figure 5.3. At all concentrations tested, Akti-1/2 significantly reduced 
both basal and insulin-stimulated phosphorylation of Akt-Ser
473
. This data 
indicates that Akti-1/2 is preventing the mTORC2-mediated phosphorylation of 
Akt-Ser
473
.  Figure 5.4 shows that under unstimulated conditions, the addition of 
insulin (20 nM) also significantly increased the phosphorylation of PRAS40-
Ser
246
, indicating an increase in Akt activity. Akti-1/2 significantly reduced basal 
phosphorylation of PRAS40-Ser
246
 at 3µM and 10µM and inhibited insulin-
stimulated phosphorylation of PRAS40-Ser
246
 at all concentrations (Figure 5.4). 
These data demonstrate that in this cell line Akti-1/2 is inhibiting Akt activity. 
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The data in Figure 5.5 show that control cells show a significant increase in the 
phosphorylation of NDRG-Thr
346/356/366
 with the addition of insulin, 
demonstrating again that insulin stimulates SGK1 activity. A surprising find was 
that at all doses of Akti-1/2, phosphorylated NDRG-Thr
346/356/366 
was significantly 
inhibited under unstimulated and insulin-stimulated conditions.  
 
These data provide evidence that whilst Akti-1/2 inhibits Akt activity, this drug is 
also inhibiting SGK1 activity and is therefore not selective. Akti-1/2 inhibits Akt 
by direct interactions with the PH domain (Barnett et al., 2005) so it is surprising 
that it inhibits SGK1 which does not have a PH domain. The inhibition of 
mTORC2 phosphorylation of Akt-Ser
473
 provides a common pathway for 
inhibition of SGK1 since SGK1 absolutely requires mTORC2 activity, so perhaps 
Akti-1/2 is inhibiting this kinase off-target. The data from the Ussing chamber 
experiments can therefore not be attributed to specifically targeting Akt and these 
results highlight the importance of checking specificity of inhibitors within 
particular cell lines. 
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Figure 5.3 Effects of Akti-1/2 on the phosphorylation of Akt-Ser
473
. 
Cells were exposed to solvent vehicle (Cont.) or to Akti-1/2 (1, 3 or 10µM, 30 min preincubation) 
and then maintained under hormone-free conditions (Ins. -) or exposed to 20nM insulin (Ins. +) for 
a further 30 min before being lysed. (A) Typical western blot showing phosphorylation of Akt-
Ser
473
. (B) Typical western blot showing total Akt protein. (C) Pooled data from phospho-Akt-
Ser
473
 blots, n = 6, data is presented at mean ± S.E.M. Daggers denote statistically significant 
effects of insulin on the phosphorylation of Akt-Ser
473: †, p < 0.05, ‡, p < 0.01. Asterisks denote 
statistically significant effects (Two-way ANOVA Bonferroni post hoc test ) of Akti-1/2 on either 
basal or insulin-stimulated phosphorylation of Akt-Ser
473
: *, p < 0.05, **, p < 0.01, p < 0.001.  
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Figure 5.4 Effects of Akti-1/2 on the phosphorylation of PRAS40-Ser
246
. 
Cells were exposed to solvent vehicle (Cont.) or to Akti-1/2 (1, 3 or 10µM, 30 min preincubation) 
and then maintained under hormone-free conditions (Ins. -) or exposed to 20nM insulin (Ins. +) for 
a further 30 min before being lysed. (A) Typical western blot showing phosphorylation of 
PRAS40-Ser
246
. (B) Typical western blot showing total PRAS40 protein. (C) Pooled data from 
phospho-PRAS40-Ser
246
 blots, n = 5, data is presented at mean ± S.E.M. Daggers denote 
statistically significant effects of insulin on the phosphorylation of PRAS40-Ser
246: †, p < 0.05, ‡, 
p < 0.01. Asterisks denote statistically significant effects (Two-way ANOVA Bonferroni post hoc 
test) of Akti-1/2 on either basal or insulin-stimulated phosphorylation of PRAS40-Ser
246
: *, p < 
0.05, **, p < 0.01, p < 0.001.  
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Figure 5.5 Effects of Akti-1/2 on the phosphorylation of NDRG1-Thr
346/356/366
. 
Cells were exposed to solvent vehicle (Cont.) or to Akti-1/2 (1, 3 or 10µM, 30 min preincubation) 
and then maintained under hormone-free conditions (Ins. -) or exposed to 20nM insulin (Ins. +) for 
a further 30 min before being lysed. (A) Typical western blot showing phosphorylation of 
NDRG1-Thr
346/356/366
. (B) Typical western blot showing total NDRG1 protein. (C) Pooled data 
from phospho-NDRG1-Thr
346/356/366
 blots, n = 6, data is presented at mean ± S.E.M. Daggers 
denote statistically significant effects of insulin on the phosphorylation of NDRG-Thr
346/356/366: †, p 
< 0.05, ‡, p < 0.01. Asterisks denote statistically significant effects (Two-way ANOVA Bonferroni 
post hoc test) of Akti-1/2 on either basal or insulin-stimulated phosphorylation of NDRG1-
Thr
346/356/366
: *, p < 0.05, **, p < 0.01, p < 0.001.  
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5.2.3 Effects of GSK650394A on basal and insulin-stimulated Na+ 
transport 
Identical experiments to those carried out with Akti-1/2 were used to investigate 
the effects of three doses of the SGK1 inhibitor, GSK650394A (1, 3, 10µM) on 
basal Ieq. Figure 5.6 shows that similar to Akti-1/2, lower doses of GSK650394A 
do not alter basal Ieq significantly. 10µM GSK650394A significantly inhibited the 
basal current by 21.4 ± 10.6% (Table 5.2). Again, similar to the results with Akti-
1/2, ~ 80 % of the current remains, therefore GSK650394A cannot be inhibiting 
the major mechanism allowing spontaneous Na
+
 absorption. All basal values of Ieq 
before and after treatment with vehicle / drug can be found in Table 5.2. 
 
 
 
Figure 5.6 Effects of GSK650394A on basal Ieq. 
Ieq of cells treated with solvent vehicle or GSK650394A (1-10µM) for 30 min, arrow indicates 
addition. Data is shown as mean Ieq, calculated as a fraction of the initial current, ± S.E.M. (n = 5). 
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Table 5.2 Ieq of control and GSK650394A-treated cells. 
Mean data ± S.E.M. (n = 5) for Ieq recorded from cells treated with vehicle or GSK650394A (1-10 
µM). Values are from baseline and after 30 min exposure to vehicle / GSK650394A. Statistical 
significance was calculated using an unpaired Student’s t-test, * p < 0.05. 
 
Treatment Ieq (µA cm
-2
) 
Baseline 30 min exposure 
1µM GSK650394A Control -12.8 ± 2.2 -12.0 ± 2.1 
Experimental -12.6 ± 2.1 -13.0 ± 2.6 
3µM GSK650394A Control -17.6 ± 2.5 -16.5 ± 2.8 
Experimental -20.0 ± 3.4 -20.9 ±3.9 
10µM GSK650394A Control -18.7 ± 4.0 -16.4 ± 3.1 
Experimental -21.9 ± 3.9 -15.4 ± 3.9* 
 
The effects of GSK650394A on insulin-stimulated Na
+
 transport were 
subsequently examined. Similar to the experiments carried out with Akti-1/2, a 
separate control response to insulin was carried out for each dose of 
GSK650394A tested. Figure 5.7A-C shows the control experiments where insulin 
(20 nM, 30 min) consistently produced a significant increase in ΔIeq: 1µM control: 
-5.8 ± 0.5 µA cm
-2
 (n = 5, p < 0.001); 3µM control: -5.8 ± 0.2 µA cm
-2
 (n = 5, p < 
0.001); 10µM control: -8.3 ± 2.2 µA cm
-2
 (n = 5, p < 0.01). Statistical significance 
was determined by comparing the mean ΔIeq after 30 min in both control and 
GSK650394A-treated cells using an unpaired Student’s t-test. Again, insulin-
induced changes in Ieq were associated with a depolarisation of Vt and small fall in 
Rt and these values can be found in the appendix. The effects of increasing doses 
of GSK650394A on insulin-induced Ieq can be seen in Figure 5.7D-F. 
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This compound causes a dose-dependent inhibition of insulin-stimulated Ieq. 1µM 
GSK650394A inhibited the response to insulin by 44.5 ± 7.6% with a ΔIeq of -3.3 
± 0.6 µA cm
-2
 (n = 5, p < 0.05). 3µM GSK650394A inhibited the insulin-evoked 
Ieq by 54.8 ± 1.5% with a ΔIeq of -2.6 ± 0.1 µA cm
-2
 (n = 5, p < 0.001). Finally 
10µM GSK650394A essentially abolished the response to insulin with an 
inhibition of 96.9 ± 5.6% and a ΔIeq of 0.5 ± 0.4µA cm
-2
 (n = 5, p < 0.01). This 
data clearly demonstrates that GSK650394A can effectively block the natriferic 
response to insulin. The phosphorylation of endogenous proteins was 
subsequently examined to determine the specificity of this inhibitor. 
 
5.2.4 Effects of GSK650394A on phosphorylation of endogenous 
proteins 
Insulin (20 nM) increased SGK1 activity under control conditions as shown by 
significantly increased phosphorylation of NDRG1-Thr
346/356/366
 (Figure 5.8). The 
addition of GSK650394A to cells significantly reduced basal phosphorylation of 
NDRG1-Thr
346/356/366
 at 3µM and 10µM. Insulin-stimulated phosphorylation of 
NDRG1-Thr
346/356/366
 was significantly reduced by all concentrations of 
GSK650394A (Figure 5.8). These data are consistent with GSK650394A 
inhibiting SGK1 activity. 
 
Figure 5.9 again shows that the addition of insulin significantly increased the 
phosphorylation of Akt-Ser
473
 indicating an increase in mTORC2 activity. The 
addition of GSK650394A did not significantly alter basal phosphorylation of Akt-
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Ser
473
 at any of the concentrations tested. Insulin-stimulated phosphorylation of 
Akt-Ser
473
 remained unaltered at 1µM GSK650394A, however at increased 
concentrations of the drug, insulin-stimulated phosphorylation of Akt-Ser
473
 was 
significantly reduced (Figure 5.9). These findings suggest that at higher doses of 
GSK650394A, mTORC2 activity or PI3-kinase activity become inhibited. 
 
The effects of this drug on Akt activity were subsequently examined. Under 
control conditions, insulin significantly increased the phosphorylation of 
PRAS40-Ser
246
, see Figure 5.10. The addition of GSK650394A did not 
significantly alter basal phosphorylation of PRAS40-Ser
246
 at any of the 
concentrations tested and similarly, insulin-stimulated phosphorylation of 
PRAS40-Ser
246
 also remained unaltered at all concentrations of GSK650394A 
tested (Figure 5.10). These data indicate that Akt activity remains unaltered in the 
presence of this compound. The inhibition of insulin-stimulated Ieq does appear to 
occur with an inhibition of SGK1 activity and not Akt activity but this compound 
may be inhibiting further upstream of SGK1 as well as shown by a decrease in 
mTORC2 activity. 
 
127 
 
Figure 5.8 Effects of GSK650394A on the phosphorylation of NDRG1-Thr
346/356/366
. 
Cells were exposed to solvent vehicle (Cont.) or to GSK650394A (1-10µM, 30 min preincubation) 
and then maintained under hormone-free conditions (Ins. -) or exposed to 20nM insulin (Ins. +) for 
a further 30 min before being lysed. (A) Typical western blot showing phosphorylation of 
NDRG1-Thr
346/356/366
. (B) Typical western blot showing total NDRG1 protein. (C) Pooled data 
from P-NDRG1-Thr
346/356/366
 blots, n = 6, data is presented as mean ± S.E.M. Daggers denote 
statistically significant effects of insulin on the phosphorylation of NDRG-Thr
346/356/366: ‡, p < 
0.01. Asterisks denote statistically significant effects (Two-way ANOVA Bonferroni post hoc test) 
of GSK650394A on either basal or insulin-stimulated phosphorylation of NDRG1-Thr
346/356/366
: *, 
p < 0.05, **, p < 0.01, ***, p < 0.001.  
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Figure 5.9 Effects of GSK650394A on the phosphorylation of Akt-Ser
473
. 
Cells were exposed to solvent vehicle (Cont.) or to GSK650394A (1, 3 or 10µM, 30 min 
preincubation) and then maintained under hormone-free conditions (Ins. -) or exposed to 20nM 
insulin (Ins. +) for a further 30 min before being lysed. (A) Typical western blot showing 
phosphorylation of Akt-Ser
473
. (B) Typical western blot showing total Akt protein. (C) Pooled data 
from phospho-Akt-Ser
473
 blots, n = 6, data is presented as mean ± S.E.M. Daggers denote 
statistically significant effects of insulin on the phosphorylation of Akt-Ser
473: †, p < 0.05, ‡, p < 
0.01. Asterisks denote statistically significant effects (Two-way ANOVA Bonferroni post hoc test) 
of GSK650394A on either basal or insulin-stimulated phosphorylation of Akt-Ser
473
: **, p < 0.01.  
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Figure 5.10 Effects of GSK650394A on the phosphorylation of PRAS40-Ser
246
. 
Cells were exposed to solvent vehicle (Cont.) or to GSK650394A (1-10µM, 30 min preincubation) 
and then maintained under hormone-free conditions (Ins. -) or exposed to 20nM insulin (Ins. +) for 
a further 30 min before being lysed. (A) Typical western blot showing phosphorylation of 
PRAS40-Ser
246
. (B) Typical western blot showing total PRAS40 protein. (C) Pooled data from 
phospho-PRAS40-Ser
246
 blots, n = 6, data is presented as mean ± S.E.M. Daggers denote 
statistically significant effects (Two-way ANOVA Bonferroni post hoc test) of insulin on the 
phosphorylation of PRAS40-Ser
246: †, p < 0.05, ‡, p < 0.01.  
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5.3 Discussion 
5.3.1 Effects of Akti-1/2 on basal and insulin-stimulated Na+ 
transport 
Initial experiments carried out investigated the effects of Akti-1/2 on the basal Ieq. 
Of the three concentrations tested only 10 µM Akti-1/2 caused a significant 
inhibition of the basal current. However, this effect was modest with ~ 80% of the 
current remaining implying that this compound does not inhibit the major 
mechanism allowing the apparently spontaneous absorption of Na
+
. The effect 
that Akti-1/2 exerted on the insulin-induced Ieq was subsequently tested. As seen 
previously (Chapter 2), insulin evoked an increase in Ieq in all control recordings 
with a hyperpolarisation of Vt and reduction in Rt. At increasing doses, Akti-1/2 
inhibited the insulin-induced Na
+
 current, with the response essentially abolished 
at 10µM.  
 
To determine the effectiveness of Akti-1/2 and examine the specificity of this 
compound, phosphorylation of endogenous proteins were monitored. Akti-1/2 
inhibited the phosphorylation of both Akt-Ser
473
 and PRAS40-Ser
246
 in a dose-
dependent manner. This data confirms that the inhibitor is significantly reducing 
Akt activity. The original study that characterized the effects of Akti-1/2 found 
that this compound had an IC50 of 4.6 µM and 21.0 µM for Akt1 and Akt2 
respectively (Barnett et al., 2005). In the present study 10 µM Akti-1/2 was 
required to fully inhibit Akt activity shown with loss of PRAS40-Ser
246
 
phosphorylation. Another study investigating the effects of Akti-1/2 on Akt 
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activity in the presence of insulin in liver cells revealed that 1µM Akti-1/2 
inhibited insulin-stimulated Akt1 and Akt2 activity (Logie et al., 2007). The 
authors found that insulin (10 nM) increased the activity of PKBα by over 10-fold 
and that treatment with Akti-1/2 (0.1-10 µM) significantly reduced this activity. 
Phosphorylation of Akt-Ser
473
 and Akt-Thr
308
 were both abolished at 0.5 µM and 
PRAS40-Ser
246
 phosphorylation was greatly reduced. In the present study, much 
higher doses of Akti-1/2 were required to abolish Akt-Ser
473
 phosphorylation 
(10 µM) and this could be due to differing levels of PKB activity in the kidney 
versus the liver (Logie et al., 2007).  
 
To establish the selectivity of Akti1/2 for Akt / SGK1, the activity of the closely 
related kinase SGK1 was monitored. Interestingly, at all doses tested, both basal 
and insulin-stimulated levels of phosphorylation of NDRG-Thr
346/356/366
 were 
significantly reduced and at 10µM Akti-1/2, SGK1 activity was essentially 
abolished. In vitro kinase assays of Akti-1/2 assayed against other protein kinases 
revealed that at low doses of Akti-1/2 (0.1µM, 1µM), SGK1 activity was 
modestly reduced but at 10 µM SGK1 activity was only 15% of the control value 
(Logie et al., 2007), which is in accordance with the present data. In mpkCCDcl4 
cells, 10µM Akti-1/2 was required to fully inhibit the insulin-induced increase in 
Ieq. However, at this concentration, the activity of both Akt and SGK1 has been 
abolished as demonstrated by loss of phosphorylated-NDRG1-Thr
346/356/366
 and 
Akt-Ser
473
, as well as a significant reduction in PRAS40-Ser
246
 phosphorylation. 
These findings therefore demonstrate that inhibition of the insulin-induced Ieq 
cannot solely be attributed to inhibition of Akt alone since SGK1 activity is 
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abolished as well. This highlights the difference in effective doses between cell 
lines and that using larger doses can result in loss of specificity. Thus, the role that 
Akt plays in both basal and insulin-mediated Na
+
 transport across the collecting 
duct cannot be excluded and clearly warrants further investigation. 
 
5.3.2 Effects of GSK650394A on basal and insulin-stimulated Na+ 
transport 
Experiments examining the effect of the SGK1 inhibitor GSK650394A on the 
basal Ieq revealed that, similar to Akti-1/2, at low concentrations there were no 
significant alterations to the current but at 10 µM the current was inhibited by 
~ 20%. The effects of GSK650394A on the insulin-induced increase in Na
+
 
transport were also investigated. All three doses of this drug tested significantly 
inhibited the insulin-evoked Ieq but at 10 µM the response was essentially 
abolished.  SGK1 activity, as monitored by phosphorylation of NDRG1-
Thr
346/356/366
, was dose-dependently inhibited by GSK650394A and was absent at 
10 µM. These data accord well with the group that first described this drug who 
showed a dose-dependent inhibition of SGK1 activity, as monitored using an in 
vitro activity-based scintillation proximity assay, by GSK650394A and observed 
an IC50 for SGK1 of 62 nmol / L (Sherk et al., 2008). This concentration is a lot 
lower than the doses tested in the present study and suggests larger basal activity 
in the collecting duct compared to the level found in the prostate cancer cell line 
utilised by Sherk et al. in their study. It seems unusual that 3 µM GSK650394A 
results in ~ 55% inhibition of insulin-stimulated Ieq but the activity of SGK1 as 
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monitored by NDRG1-Thr
346/356/366
 phosphorylation was almost abolished. This 
could suggest that low levels of SGK1 have enough capacity to mediate the 
insulin-stimulated response but when SGK1 activity is completely abolished at 
10 µM there is no natriferic effect of insulin. 
 
In the present study, GSK650394A did not alter phosphorylation of the Akt 
substrate PRAS40-Ser
246
 at any of the concentrations tested which suggests that 
Akt activity remains unaltered. This finding is in agreement with in vitro kinase 
assay studies that showed GSK650394A had > 30 fold selectivity for SGK1 over 
Akt 1, 2 and 3 (Sherk et al., 2008). However, in the present study it was also 
observed that insulin-stimulated phosphorylation of Akt-Ser
473
 was inhibited by 
3µM and 10µM GSK650394A. This could suggest that at high concentrations 
GSK650394A can inhibit mTORC2 since this kinase specifically phosphorylates 
Akt-Ser
473
 although no other studies have reported this. Equally this compound 
could be inhibiting PI3-kinase which would decrease both PDK1 and mTORC2 
activity which would be expected to lower Akt activity. The present data show no 
alteration to the phosphorylation of an Akt substrate indicating Akt activity is 
unaffected. However phosphorylation of downstream subtrates of Akt have been 
shown to persist at low levels of Akt activity (Logie et al., 2007) therefore the 
effects of GSK650394A on mTORC2 or PI3-kinase remain uncertain.  
 
These findings suggest that GSK650394A is inhibiting SGK1 but may be acting 
upstream at mTORC2 or PI3-kinase, further work could investigate off-target 
inhibition. Despite this, Akt activity remains unaltered and therefore the inhibition 
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of the current by GSK650394A can be attributed to inhibition of the SGK1 
signalling pathway. These results firstly indicate that SGK1 is not involved in 
mediating basal Ieq since ~ 80% of the current remains and this is consistent with 
the data found in the previous chapter (Chapter 4). These findings are modest 
compared with those seen in a study where Fisher rat thyroid cells expressing α, β 
and γ ENaC subunits were co-transfected with siRNA against SGK1 and the 
activity of ENaC measured as amiloride-sensitive short circuit current was 
reduced by 50 % compared to control cells (Lee et al., 2007). Furthermore a 
dominant negative form of SGK1 expressed in A6 cells inhibited all natriferic 
activity which would suggest that SGK1 plays an essential role in mediating basal 
Na
+
 transport (Faletti et al., 2002). However, expression of an inactive form of 
SGK1 in A6 cells in which Ser
422
 was mutated to an alanine, caused no significant 
alteration to the short circuit current compared to either a parental cell line or cells 
expressing an empty vector (Faletti et al., 2002). In agreement with the present 
study, this would suggest that SGK1 does not play a vital role in maintaining 
basal levels of Na
+
 transport.  
 
The present data also indicate that SGK1 is a key mediator of the natriferic effect 
of insulin in the collecting duct since the response is fully abolished at 10 µM 
GSK650394A. This finding supports previous studies who showed that either 
stable expression of wild-type SGK1 (Faletti et al., 2002) or tetracycline-induced 
expression of constitutively active SGK1 (Alvarez De La Rosa and Canessa, 
2003, Arteaga and Canessa, 2005) in A6 cells induced an increase in ENaC 
activity that could not be potentiated any further with insulin stimulation, 
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indicating insulin acts via SGK1. Futhermore, silencing the expression of SGK1 
in fisher rat thyroid cells that express α, β and γ ENaC subunits prevents increases 
in amiloride-sensitive current by application of insulin (Lee et al., 2007). Our 
laboratory has also demonstrated that insulin can stimulate glucocorticoid-induced 
currents in H441 airway epithelial cells and this occurs with an increase in SGK1 
activity, suggesting a role for SGK1 in hormone-regulated Na
+
 transport (Inglis et 
al., 2009). Thus, the findings of the present study and previous work indicate a 
crucial role for SGK1 in the insulin-mediated increase in Na
+
 transport. 
 
Altogether the findings in this chapter demonstrate that in this cell line Akti-1/2 
inhibits SGK1 activity and therefore highlights the importance of verifying the 
effects of an inhibitor in a specific cell line. The role that Akt plays in mediating 
Na
+
 transport consequently remains unresolved. The present results also indicate 
GSK650394A can inhibit SGK1 activity without affecting Akt activity but at 
higher concentrations impinges on mTORC2 activity suggesting that this 
compound may begin to target either mTORC2 or PI3-kinase at greater doses. 
However, SGK1 signalling appears to be blocked without altering Akt activity 
and these findings demonstrate that the majority of the basal Ieq in these cells is 
independent of SGK1 activity but conversely insulin-stimulated Ieq is absolutely 
dependent on it.  
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Chapter 6 - The role of mTORC2 in 
hormonal stimulation of Na
+
 transport 
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6.1 Introduction 
mTOR can form two complexes; mTORC1 and mTORC2, both of which lie 
downstream of PI3-kinase and can phosphorylate various AGC kinases including 
Akt, S6 kinase and SGK1. mTORC2 comprises six subunits: mTOR, rictor 
(rapamycin-insensitive companion of mTOR), mSin1, mLST8, PROTOR and 
DEPTOR (Guertin and Sabatini, 2007) and phosphorylates the Ser
422 
residue of 
SGK1 (García-Martínez and Alessi, 2008). This event allows PDK1 to 
phosphorylate the Thr
256
 residue and activate SGK1 (5.1). mTORC2 therefore 
forms a link between PI3-kinase and SGK1 in the insulin signalling pathway. 
Previous studies have demonstrated the involvement of PI3-kinase (Record et al., 
1998), SGK1 (Faletti et al., 2002) and Nedd4-2 (Kamynina and Staub, 2002) in 
the stimulation of Na
+
 transport by insulin but the role of mTORC2 is unknown. 
Having identified a role for both PI3-kinase and SGK1 in mediating the natriferic 
effect of insulin in the mpkCCDcl4 collecting duct cell line we sought to 
determine the role of mTORC2 in this pathway. The recent creation of two novel 
small molecule inhibitors of mTOR: PP242 (Feldman et al., 2009) and TORIN1 
(Thoreen et al., 2009) allowed a method of targeting mTORC2 by using them in 
conjunction with the selective inhibitor of mTORC1, rapamycin. The present 
study has demonstrated that mTORC1 plays no role in mediating the stimulation 
of Na
+
 transport by insulin (4.2.2) so any effect of TORIN1 and PP242 can be 
attributed to an inhibition of mTORC2 activity. This methodology allows a novel 
means by which to test the role of mTORC2 in mediating a physiological 
response in a collecting duct cell line. 
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As well as insulin mediating ENaC activity in the collecting duct, other hormones 
can stimulate Na
+
 transport via this channel including aldosterone (Lee et al., 
2008) and vasopressin (Bugaj et al., 2009). We therefore used our novel approach 
of targeting mTORC2 activity in a native system to determine the role this kinase 
plays in mediating the actions of aldosterone and vasopressin. The 
mineralocorticoid aldosterone is a steroid hormone secreted by the adrenal gland 
and stimulates Na
+
 absorption, K
+
 secretion and H2O absorption in the 
aldosterone-sensitive distal nephron (ASDN), which includes the connecting 
tubule, cortical and medullary collecting ducts. This hormone, similar to the 
glucocorticoid dexamethasone, is thought to increase Na
+
 absorption firstly by 
increasing expression of SGK1 followed by expression of ENaC and Na
+
 / K
+ 
ATPase subunits (Loffing and Korbmacher, 2009). Whilst aldosterone has been 
shown to increase transcription of SGK1, it has also been implicated in activating 
a PI3-kinase signalling pathway that would activate SGK1 (Blazer-Yost et al., 
1999, Faletti et al., 2002, Tong et al., 2004b, Păunescu et al., 2000). This 
activation would require mTORC2 activity, therefore to investigate this 
hypothesis, two mTOR inhibitors TORIN1 and PP242, as well as the mTORC1 
inhibitor rapamycin were utilised and their effects on Na
+
 transport examined. 
 
Abnormal glucocorticoid or mineralocorcticoid receptor activation can similarly 
stimulate ENaC-mediated Na
+
 transport and this is seen in certain forms of 
hypertension (Ulick et al., 1979). These clinical conditions can be due to 
abnormal aldosterone secretion or lack of 11-β-hydroxysteroid dehydrogenase 
activity metabolizing cortisol to cortisone (Lifton et al., 2001). In the case of 
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apparent mineralocorticoid syndrome, the MR is abnormally activated by cortisol 
which cannot be converted to the inactive cortisone due to the lack of 11-βHSD2 
activity (Mune et al., 1995). It would also lead to increased GR activation due to 
increased concentrations of glucocorticoids. Together this would give rise to an 
abnormal stimulation of ENaC and a resulting hypertensive condition (New et al., 
1977). It has been proposed that the effects of excess glucocorticoids occurs due 
to increased transcription of SGK1 (Wang et al., 2001) in an analogous manner to 
aldosterone.  
 
Vasopressin (AVP), also known as anti-diuretic hormone (ADH) is a peptide 
hormone released from the hypothalamus and alters water and salt reabsorption in 
the kidney. AVP exerts its effects by binding V2 receptors in the basolateral 
membrane of epithelia lining the ASDN, activating adenylate cyclase which 
produces the second messenger cAMP (Morel, 1981). Membrane permeable 
analogues of cAMP as well as activators of the downstream protein kinase A 
(PKA) have previously been shown to activate Na
+
 transport via ENaC in M1 
cells (Nakhoul et al., 1998), perfused rat cortical collecting duct cells (Schafer and 
Troutman, 1990) as well as mpkCCDcl4 cells (Butterworth et al., 2005). cAMP is 
thought to act via protein kinase A (PKA) to increase ENaC-mediated Na
+
 
transport by increasing insertion of ENaCs into the membrane from a recycling 
channel pool (Morris and Schafer, 2002, Butterworth et al., 2005). As well as 
increasing the number of ENaCs in the apical membrane, cAMP is also thought to 
increase the basolateral surface expression of the Na
+
 / K
+
 ATPase pumps (Gonin 
et al., 2001). SGK1 has been implicated in mediating the effects of AVP 
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downstream of cAMP as Perrotti and colleagues showed that SGK1 activity was 
increased with the addition of cAMP in COS-7 cells expressing SGK1 (Perrotti et 
al., 2001). Furthermore, mTORC2 was implicated as a mutated Ser
422
 on SGK1 
prevented cAMP stimulation of activity. The authors concluded that SGK1 
contains PKA phosphorylation site and that PKA could phosphorylate SGK1 and 
stimulate ENaC-mediated Na
+
 transport (Perrotti et al., 2001). cAMP has been 
shown to stimulate benzamil-sensitive ISC in H441 airway epithelial cells (Thomas 
et al., 2004). SGK1 phoshorylation was also stimulated with cAMP but this 
occurred after the increase in ISC. Similarly in a submandibular gland cell line 
cAMP was found to stimulate amiloride-sensitive ISC and this was attributed to an 
increase in SGK1 and α-ENaC expression (Vasquez et al., 2008). To investigate 
the role of mTOR and SGK1 in the signalling pathway linking vasopressin with 
increased ENaC-mediated Na
+
 transport in the mpkCCDcl4 cell line, the 
inhibitors TORIN1 and PP242 were used. 
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6.2 Results 
6.2.1 The effects of TORIN1 on basal and insulin-stimulated Na+ 
transport 
As TORIN1 had not been used in this laboratory or in this cell line before, a dose-
response study was carried out to determine an effective dose of this drug that 
would inhibit mTORC2 activity. The phosphorylation of Akt-Ser
473
 and NDRG1-
Thr
346/356/366
 were therefore monitored as markers of mTORC2 activity and SGK1 
activity; Akt activity was also monitored. Increasing concentrations of TORIN1 
(0.01 µM-1 µM) were added to cells for 30 min and exposed to either 
unstimulated or insulin-stimulated conditions (20 nM) for a further 30 min. Cells 
were then lysed and western analysis carried out probing for phosphorylation of 
Akt-Ser
473
, NDRG1-Thr
346/356/366
 or PRAS40-Ser
246
 as well as the respective total 
protein. 
 
Figure 6.1 shows that under control conditions, insulin significantly stimulated 
phosphorylation of Akt-Ser
473
. All concentrations tested of TORIN1 significantly 
reduced both basal and stimulated phosphorylation of Akt-Ser
473
 but at 
concentrations at 100 nM or greater there was a complete loss of phosphorlyation. 
Therefore this drug appears to be very effective at inhibiting mTORC2 activity. 
Figure 6.2 shows that insulin also significantly stimulated phosphorylation of 
NDRG1-Thr
346/356/366
 indicating increased SGK1 activity. Increasing 
concentrations of TORIN1 reduced basal phosphorylation of NDRG1-
Thr
346/356/366
. All concentrations of TORIN1 tested significantly reduced the 
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insulin-stimulated phosphorylation of NDRG1-Thr
346/356/366
 (Figure 6.2). This data 
is consistent with SGK1 activity being dependent on mTORC2. Akt activity was 
significantly stimulated by application of insulin to cells as seen with increased 
phosphorylation of PRAS40-Ser
246
 in Figure 6.3. Whilst increasing doses did not 
inhibit basal phosphorylation significantly there was a clear trend showing a 
reduction in the phosphorylation of this kinase. At all concentrations of TORIN1 
tested, insulin-stimulated phosphorylation of PRAS40-Ser
246
 was significantly 
reduced (Figure 6.3) indicating an inhibition of Akt activity. From these finding a 
dose of 100 nM was chosen as mTORC2 and SGK1 activity were abolished.  
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Figure 6.1 The effects of TORIN1 on the phosphorylation of Akt-Ser
473
. 
(A) Typical western blot showing phosphorylated Akt-Ser
473
 under unstimulated or insulin-
stimulated (20 nM, 30 min) conditions and exposed to increasing concentrations of TORIN1 
(30 min). (B) Typical western blot showing total Akt protein. (C) Pooled data of Akt-Ser
473 
phosphorylation (n = 5). Data is shown as mean ± S.E.M. and daggers denote statistical 
significance between basal and insulin-treated cells under control conditions: †, p < 0.05, ‡, p < 
0.01. Asterisks denote statistically significant effects (Two-way ANOVA Bonferroni post hoc test) 
of TORIN1 on either basal or insulin-stimulated phosphorylation of Akt-Ser
473
: *, p < 0.05, **, p < 
0.01, ***, p < 0.001. 
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Figure 6.2 The effects of TORIN1 on the phosphorylation of NDRG1-Thr
346/356/366
. 
(A) Typical western blot showing phosphorylation NDRG1-Thr
346/356/366
 under unstimulated or 
insulin-stimulated (20 nM, 30 min) conditions and exposed to increasing concentrations of 
TORIN1 (30 min). (B) Typical western blot showing total NDRG1 protein. (C) Pooled data of 
NDRG1-Thr
346/356/366
 phosphorylation (n = 5). Data is shown as mean ± S.E.M. and daggers denote 
statistical significance between basal and insulin-treated cells under control conditions: †, p < 0.05, 
‡, p < 0.01. Asterisks denote statistically significant effects (Two-way ANOVA Bonferroni post 
hoc test ) of TORIN1 on either basal or insulin-stimulated phosphorylation of NDRG1-
Thr
346/356/366
: ***, p < 0.001. 
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Figure 6.3 The effects of TORIN1 on the phosphorylation of PRAS40-Ser
246
. 
(A) Typical western blot showing phosphorylation PRAS40-Ser
246 
under unstimulated or insulin-
stimulated (20 nM, 30 min) conditions and exposed to increasing concentrations of TORIN1 (30 
min). (B) Typical western blot showing total PRAS40 protein. (C) Pooled data of PRAS40-Ser
246
 
phosphorylation (n = 5). Data is shown as mean ± S.E.M. and daggers denote statistical 
significance between basal and insulin-treated cells under control conditions: †, p < 0.05, ‡, p < 
0.01. Asterisks denote statistically significant effects (Two-way ANOVA Bonferroni post hoc test) 
of TORIN1 on either basal or insulin-stimulated phosphorylation of PRAS40-Ser
246
: **, p < 0.01, 
***, p < 0.001 
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With an effective dose of TORIN1 established the effects that this compound 
exerted on basal Ieq were investigated. Figure 6.4 shows that TORIN1 (100 nM, 
60 min) modestly but significantly inhibited basal Ieq by 10.8 ± 3.1% (n = 14, p < 
0.05). Table 6.1 shows the mean values of Ieq recorded and values of Vt and Rt can 
be found in the appendix (Chapter 9). 
 
 
Figure 6.5A shows that insulin (20 nM, 30 min) significantly stimulated Ieq with a 
ΔIeq of -6.2 ± 0.9 µA cm
-2
 (n = 5, p < 0.001). Statistical significance was 
calculated by comparing the mean ΔIeq after 30 min in both control and TORIN1-
treated cells using an unpaired Student’s t-test. TORIN1 significantly inhibited the 
insulin-stimulated increase in Ieq by 73.3 ± 3.6% (Figure 6.5C, n = 5, p < 0.01). 
The addition of insulin in the presence of TORIN1 produced a small but 
significant increase in Ieq of -1.6 ± 0.4 µA cm
-2
, (Figure 6.5B, n = 5, p < 0.05). All 
values of Vt and Rt can be found in the appendix. These results clearly 
demonstrate that TORIN1 is inhibiting insulin-stimulated Na
+
 transport indicating 
that mTORC2 must play an important role in this action. 
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Figure 6.4 The effects of TORIN1 on basal Ieq. 
Ieq of cells treated with solvent vehicle or TORIN1 (100nM) for 60 min, arrow indicates addition. 
Data is shown as mean current, presented as a fraction of the initial current, ± S.E.M. (n = 14). 
 
 
 
Table 6.1 Ieq of control and TORIN1-treated cells. 
Mean data ± S.E.M. (n = 14) for Ieq recorded from cells treated with vehicle or TORIN1 (100 nM, 
60 min). Values are from baseline and after 60 min exposure to vehicle / TORIN1. Statistical 
significance was calculated using an unpaired Student’s t-test, * p < 0.05. 
 
Treatment Ieq (µA cm
-2
) 
Baseline 60 min exposure 
Vehicle -18.3 ± 1.3 -15.8 ± 1.1 
100 nM TORIN1 -16.8 ± 1.1 -12.9 ± 0.8* 
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Figure 6.5 The effects of TORIN1 on insulin-stimulated Ieq. 
Ieq of cells pre-treated for 30 min with either (A) solvent vehicle or (B) TORIN (100nM) then 
exposed to either unstimulated or insulin-stimulated (20nM) conditions for a further 30 min, arrow 
indicates addition of vehicle / insulin. Data is presented as mean ΔIeq, calculated as a fraction of 
the current 5 min before insulin was added, ± S.E.M (n = 5).  (C) Pooled data from the peak 
response, ΔIeq, to insulin under control and TORIN1 treated cells. Data is presented as mean ± 
S.E.M. (n = 5) and statistical significance (Student’s unpaired t-test) is denoted by asterisks, **, 
p < 0.01. 
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6.2.2 The effects of PP242 on basal and insulin-stimulated Na+ 
transport 
The role of mTORC2 was further investigated using another mTOR inhibitor 
PP242. The effect that this compound had on phosphorylation of endogenous 
proteins was again confirmed first. Figure 6.6 shows that under control conditions 
insulin significantly increased the phosphorylation of Akt-Ser
473
, NDRG-
Thr
346/356/366
 and PRAS40-Ser
246
 again demonstrating that this hormone stimulates 
mTORC2, SGK1 and Akt activity respectively.   
 
PP242 caused a complete loss of phosphorylated-Akt-Ser
473
 under control and 
insulin-stimulated conditions indicating mTORC2 activity was abolished, see 
Figure 6.6A. Similarly, SGK1 activity was inhibited by PP242 as seen by a loss of 
NDRG-Thr
346/356/366
 phosphorylation (Figure 6.6B). The activity of Akt was 
significantly inhibited in response to PP242 as phosphorylation of PRAS40-Ser
246
 
in PP242-treated cells was greatly reduced (Figure 6.6C). The changes in 
phosphorylation of Akt and NDRG1 occurred without any change to the 
abundance of total protein. These findings demonstrate that PP242 at 1 µM 
abolishes mTORC2 activity which inhibits SGK1 activity and reduces Akt 
activity. 
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Figure 6.6 The effects of PP242 on the phosphorylation of endogenous proteins. 
Top panels: typical western blots showing the phosphorylation of (A) Akt-Ser
473
, (B) NDRG1-
Thr
346/356/366
 and (C) PRAS40-Ser
246
 under unstimulated or insulin-stimulated (20nM, 30 min) 
conditions in vehicle treated, left hand pair, or PP242 treated (1µM, 30 min) cells, right hand pair. 
Middle panels show the respective total protein blots for (A) Akt, (B) NDRG1 and (C) PRAS40. 
Lower panels show pooled data of phosphorylation of (A) Akt-Ser
473
, n = 5, (B) NDRG1-
Thr
346/356/366
, n =5, and (C) PRAS40-Ser
246
, n = 5. Data is shown as mean ± S.E.M. and daggers 
denote statistical significance between basal and insulin-treated cells under control conditions: †, 
p < 0.05, ‡, p < 0.01. Asterisks denote statistically significant effects (One-way ANOVA 
Bonferroni post hoc test) of TORIN1 on either basal or insulin-stimulated phosphorylation of 
NDRG1-Thr
346/356/366
, Akt-Ser
473
 or PRAS40-Ser
246
: *, p < 0.05, **, p < 0.01, ***, p < 0.001. 
 
 
 
 
151 
Since PP242 was shown to clearly inhibit mTORC2, the effects this compound 
exerted upon basal Ieq were subsequently investigated. Figure 6.7 shows that 
PP242 (1 µM, 60 min) inhibited basal Ieq by 24.3 ± 2.1%, a statistically significant 
effect (Table 6.2). All values of Ieq from control and PP242-treated cells before 
and after treatment can be seen in Table 6.2, values of Vt and Rt can be found in 
the appendix. This data suggests that mTORC2 is not playing the dominant role in 
the mechanism allowing spontaneous Na
+
 absorption in this cell line. This is 
consistent with the data found with TORIN1 and also SGK1 (Chapter 5) and PI3-
kinase inhibition (Chapter 4). 
 
 
Figure 6.8A shows that insulin (20 nM, 30 min) stimulated Ieq by -6.7 ± 0.5 
µA cm
-2
 (n = 5, p < 0.001). This increase in current under control conditions 
occurred with a significant hyperpolarisation of Vt and a decrease in Rt (see 
appendix for values). PP242 significantly inhibited the natriferic response by 83.7 
± 6.7% (Figure 6.8C, n = 5, p < 0.001). The addition of insulin produced a small 
increase in Ieq of -1.1 ± 0.4 µA cm
-2
 and this response was significant (Figure 
6.8B, n = 5, p < 0.05). Therefore, similar to TORIN1, PP242 is inhibiting insulin-
stimulated Na
+
 transport indicating that mTORC2 plays an important role in this 
response. These findings provide further evidence for insulin signalling via a PI3-
kinase / mTORC2 / SGK1 pathway to stimulate ENaC activity. 
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Figure 6.7 The effects of PP242 on basal Ieq. 
Ieq of cells treated with solvent vehicle or PP242 (1µM) for 60 min, arrow indicates addition. Data 
is shown as mean current, calculated as a fraction of the initial current, ± S.E.M. (n = 15). 
 
 
Table 6.2 Ieq of control and PP242-treated cells. 
Mean data ± S.E.M. (n = 15) for Ieq recorded from cells treated with vehicle or PP242 (1 µM, 
60 min). Values are from baseline and after 60 min exposure to vehicle / PP242. Statistical 
significance was calculated using an unpaired Student’s t-test, ** p < 0.01. 
 
Treatment Ieq (µA cm
-2
) 
Baseline 60 min exposure 
Vehicle -24.0 ± 1.6 -19.9 ± 1.3 
1 µM PP242 -23.4 ± 2.0 -14.3 ± 1.0** 
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Figure 6.8 The effects of PP242 on insulin-stimulated Ieq. 
 Ieq of cells pre-treated for 30 min with either (A) solvent vehicle or (B) PP242 (1µM) then 
exposed to either unstimulated or insulin-stimulated (20nM) conditions for a further 30 min, arrow 
indicates addition of vehicle / insulin. Data is presented as mean ΔIeq, calculated as a fraction of 
the current 5 min before insulin was added, ± S.E.M (n = 5).  (C) Pooled data from the peak 
response, ΔIeq, to insulin under control and PP242 treated cells. Data is presented as mean ± 
S.E.M. (n = 5) and statistical significance (Student’s unpaired t-test) is denoted by asterisks, ***, 
p < 0.001. 
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6.2.3 The role of mTORC2 in aldosterone-mediated stimulation of 
Na
+
 transport 
Preliminary experiments of the present study examined the stimulatory effects of 
aldosterone on Ieq at two different concentrations (500 nM, 5 µM). Each recording 
had a separate control and Table 6.3 shows that in unstimulated cells, Ieq runs 
down over 3 h. With the addition of 500 nM aldosterone, there was no stimulation 
above initial baseline Ieq but this hormone prevented the run-down seen in control 
cells. Only at 5 µM did aldosterone produce a significant stimulation of Ieq (Table 
6.3). However at this supraphysiological dose of aldosterone it is likely that these 
effects are being mediated by GR-activation rather than MR-activation and is not 
representative of the physiological action of aldosterone (Gaeggeler et al., 2005). 
 
Table 6.3 Ieq of control and aldosterone-treated cells. 
Mean data ± S.E.M. (n = 7) for Ieq recorded from paired experiments looking at two concentrations 
of aldosterone (500 nM, 5 µM) added bilaterally. Each experiment has its own control recording. 
Values are from baseline and after 3 h exposure to vehicle / aldosterone. Statistical significance 
was calculated using an unpaired Student’s t-test, * p < 0.05. 
 
Treatment Ieq (µA cm
-2
) 
Baseline 3 h exposure 
Vehicle -18.8 ± 2.1 -13.3 ± 2.0 
500 nM aldosterone -19.1 ± 2.4 -17.7 ± 3.2 
Vehicle -23.7 ± 1.3 -17.7 ± 2.0 
5 µM aldosterone -20.7 ± 1.3 -26.7 ± 1.7* 
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6.2.4 The role of mTORC2 in dexamethasone-mediated 
stimulation of Na
+
 transport 
Since the mpkCCDc14 cell line appeared to display GR-mediated Na
+
 transport 
the effects of a synthetic GR agonist, dexamethasone, on Na
+
 transport were 
investigated. Furthermore, the role that mTORC2 / SGK1 played in this response 
was investigated using TORIN1 and PP242. 
 
The electrometric response to dexamethasone was examined in a similar manner 
to insulin. Dexamethasone was added bilaterally to the Ussing chambers at a 
physiological dose (200 nM) after a 10 min baseline recording. The recording 
time was increased to 2.5 h since this hormone is thought to exert it effects by 
increasing transcription of the downstream effector SGK1 (Wang et al., 2001). 
Similar to the experiments studying the electrometric response to insulin, time 
points were taken from: the initial baseline recording; the peak response to the 
drug; and following treatment with amiloride; allowing a comparison with the 
responses seen in control and dexamethasone-treated cells (Figure 6.9, shaded 
areas A, B and C). Figure 6.9 shows that after 2.5 h dexamethasone had produced 
a significant stimulation of Na
+
 transport with a ΔIeq of -15.1 ± 1.3 µA cm
-2
. This 
increase in current occurred with a concomittant hyperpolarisation of Vt and a 
small but significant decrease in Rt (Figure 6.9). This is in contrast with control 
cells where Ieq decreased over time, Vt depolarized slightly and there was a small 
but significant increase in Rt (Figure 6.9). All mean values of the electrical 
parameters recorded can be seen in Table 6.4.  
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The apical addition of amiloride (10 µM) caused nearly complete inhibition of Ieq 
in control cells. In dexamethasone-treated cells Ieq was also inhibited but the 
current remaining was significantly greater than control (Figure 6.9). Amiloride 
depolarised Vt in both control and hormone-treated cells but Vt in control cells was 
significantly smaller than dexamethasone-treated cells. Rt increased following 
treatment with amiloride in both control and dexamethasone-treated cells, but in 
control cells Rt was significantly larger than in hormone-treated cells (Figure 6.9). 
These data demonstrate that dexamethasone is stimulating ENaC-mediated Na
+
 
transport. 
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Figure 6.9 The electrometric response to acute application of dexamethasone. 
Transepithelial voltage Vt was recorded (top left trace) under control conditions or with application 
of dexamethasone (200 nM), allowing calculation of Rt and Ieq (middle and bottom left traces).  
Mean values from different time points throughout the experiment were taken (a) prior to addition 
of vehicle / drug, (b) once the response to dexamethasone was established and (c) after application 
of amiloride (10 µM), shaded areas denote the sampling periods. The right hand panels show the 
mean values for Vt (top), Rt (middle) and Ieq (bottom). Data is shown as mean ± S.E.M. (n = 13) 
and statistical significance (Student’s unpaired t-test) is denoted by asterisks (**, p < 0.01, ***, 
p < 0.001).  
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Table 6.4 Electrical parameters of control and dexamethasone-treated cells. 
Mean data ± S.E.M. (n = 13) for Vt, Rt and Ieq recorded from vehicle-treated or dexamethasone-
treated cells. Time points are taken from a baseline recording, 2.5 h after vehicle / dexamethasone 
and following 10 min exposure to amiloride. Asterisks denote statistically significant effects of 
dexamethasone on Vt, Rt and Ieq compared to control cells calculated using a Student’s unpaired t-
test, **, p < 0.01, ***, p < 0.001. 
 Vehicle-treated Dexamethasone (200 nM) 
 Pre-
exposure 
2.5 h 
exposure 
Post-
amiloride 
Pre-
exposure 
2.5 h 
exposure 
Post-
amiloride 
Vt (mV) -52.2 ± 2.5 -50.8 ± 1.1 -5.2 ± 0.4 -46.9 ± 4.0 -62.8 ± 3.6** -9.5 ± 1.1** 
Rt (kΩ cm
2
) 2.6 ± 0.1 3.1 ± 0.1 6.1 ± 0.2 2.2 ± 0.2 2.0 ± 0.1*** 4.8 ± 0.4** 
Ieq (µA cm
-2
) -20.4 ± 0.8 -16.4 ± 0.7 -0.9 ± 0.1 -20.9 ± 1.2 -32.2 ± 1.9*** -1.9 ± 0.2*** 
 
6.2.4.1 The effects of TORIN1 on  dexamethasone-stimulated Na+ 
transport 
Experiments similar to those carried out looking at the effects of TORIN1 on the 
insulin-induced current were carried out using dexamethasone. Figure 6.10 shows 
that under control conditions dexamethasone (200 nM, 2.5 h) produced a 
significant stimulation of Ieq with a ΔIeq of -13.8 ± 3.1 µA cm
-2
 (n = 5, p < 0.001). 
This was accompanied by a hyperpolarisation of Vt and decrease in Rt (see 
Appendix). Following pre-treatment with TORIN1 (100 nM, 30 min), the 
response to dexamethasone was significantly inhibited by 87.3 ± 3.7 % (Figure 
6.10C, n = 5, p < 0.01) with a ΔIeq of -1.7 ± 0.5 µA cm
-2
 which was not a 
significant response. TORIN1 is inhibiting dexamethasone-stimulated Ieq 
indicating a role for mTORC1/2. 
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Figure 6.10 The effects of TORIN1 on dexamethasone-stimulated Ieq. 
Ieq of cells pre-treated for 30 min with either (A) solvent vehicle or (B) TORIN1 (100nM) then 
exposed to either unstimulated or dexamethosone-stimulated (200nM) conditions for a further 2.5 
h, arrow indicates addition of vehicle / dexamethasone. Data is presented as mean ΔIeq, calculated 
as a fraction of the current 5 min before dexamethasone was added, ± S.E.M (n = 5).  (C) Pooled 
data from the peak response, ΔIeq, to dexamethasone under control and TORIN1 treated cells. Data 
is presented as mean ± S.E.M. (n = 5) and statistical significance (Student’s unpaired t-test) is 
denoted by asterisks, ** p < 0.01. 
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The effects of dexamethasone on both mTORC2 and SGK1 activity were 
subsequently examined by monitoring the phosphorylation of endogenous 
proteins. The effects of TORIN1 on the activity of these kinases were also 
investigated.  Figure 6.11 shows that as seen previously under control conditions, 
basal levels of phosphorylation of both Akt-Ser
473
 and NDRG1-Thr
346/356/366 
persist under control conditions. Exposure of cells to dexamethasone (200 nM) for 
2.5 h did not alter the level of phosphorylation of Akt-Ser
473
 (Figure 6.11A). 
However, there was a substantial increase in the phosphorylation of NDRG1-
Thr
346/356/366
, nearly a 10-fold increase above basal levels, (Figure 6.11B). These 
data indicate that SGK1 activity but not mTORC2 activity is stimulated with 
exposure to dexamethasone.  
 
In cells pre-treated with TORIN1, phosphorylation of Akt-Ser
473
 was essentially 
abolished under both unstimulated and dexamethasone-stimulated conditions 
(Figure 6.11A). Similarly, the phosphorylation of NDRG1-Thr
346/356/366
 was 
abolished under hormone-free conditions and was significantly reduced in 
dexamethasone-treated cells (Figure 6.11B), however some phosphorylation 
remained. This is consistent with TORIN1 inhibiting the already active mTORC2, 
preventing SGK1 activation and therefore phosphorylation of downstream 
NDRG1-Thr
346/356/366
. Changes in Akt-Ser
473
 phosphorylation occurred without 
alteration to the overall expression of Akt. It is interesting to note that under 
control conditions with dexamethasone-treatment (2
nd
 lane), expression of total 
NDRG1 was reduced, as well as the appearance of a second, slower migrating 
band (Figure 6.11B).  
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Figure 6.11 The effects of TORIN1 on the phosphorylation of endogenous proteins in 
response to treatment with dexamethasone. 
Top panels: typical western blots showing the phosphorylation of (A) Akt-Ser
473
 and (B) NDRG1-
Thr
346/356/366
 under unstimulated or dexamethasone-stimulated (200nM, 2.5 hr) conditions in 
vehicle treated, left hand pair, or TORIN1 treated (100nM, 30 min) cells, right hand pair. Middle 
panels show the respective total protein blots for (A) Akt and (B) NDRG1. Lower panels show 
pooled data of phosphorylation of (A) Akt-Ser
473
, n = 6, and (B) NDRG1-Thr
346/356/366
, n = 6. Data 
is shown as mean ± S.E.M. and daggers denote statistical significance between basal and 
dexamethasone-treated cells under control conditions: ‡, p < 0.01. Asterisks denote statistically 
significant effects (One-way ANOVA Bonferroni post hoc test) of TORIN1 on either basal or 
dexamethasone-stimulated phosphorylation of Akt-Ser
473 
or NDRG1-Thr
346/356/366
: **, p < 0.01, 
***, p < 0.001. 
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6.2.4.2  The effects of PP242 on dexamethasone-stimulated Na+ 
transport 
Identical experiments to those carried out looking at the effects of TORIN1 were 
carried out to investigate the effects of PP242 on the dexamethasone stimulation 
of Na
+
 transport. Figure 6.12A shows that under control conditions 
dexamethasone produced a significant stimulation of ΔIeq of -16.0 ± 1.4 µA cm
-2
 
(n = 5, p < 0.001). This increase in amiloride-sensitive Ieq was accompanied by a 
significant hyperpolarisation of Vt and decrease in Rt (see Appendix for values). 
Pre-treating cells with 1 µM PP242 significantly inhibited the response to 
dexamethasone by 92.1 ± 3.9 % (Figure 6.12B), with a ΔIeq of -1.7 ± 0.5 µA cm
-2
 
which was significantly smaller than the control response (Figure 6.12C, n = 5, 
p < 0.001). PP242 is therefore also clearly inhibiting dexamethasone-stimulated 
Na
+
 transport, similar to TORIN1 and this indicates that mTORC1/2 is involved in 
this action.  
 
The effects that PP242 exerted on the phosphorylation of endogenous proteins 
under unstimulated and dexamethasone-stimulated conditions were subsequently 
investigated. Figure 6.13 shows that under hormone-free conditions, cells exhibit 
basal levels of phosphorylation of both Akt-Ser
473
 (Figure 6.13A) and NDRG1-
Thr
346/356/366
 (Figure 6.13B). Exposing cells to dexamethasone did not alter 
Akt-Ser
473
 phosphorylation as seen in the TORIN1 experiments (Figure 6.13A), 
but again NDRG1-Thr
346/356/366
 was significantly increased, nearly 10-fold that  
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Figure 6.12 The effects of PP242 on dexamethasone-stimulated Ieq. 
Ieq of cells pre-treated for 30 min with either (A) solvent vehicle or (B) PP242 (1μM) then exposed 
to either unstimulated or dexamethosone-stimulated (200nM) conditions for a further 2.5 h, arrow 
indicates addition of vehicle / dexamethasone. Data is presented as mean ΔIeq, calculated as a 
fraction of the current 5 min before dexamethasone was added, ± S.E.M (n = 5).  (C) Pooled data 
from the peak response, ΔIeq, to dexamethasone under control and PP242 treated cells. Data is 
presented as mean ± S.E.M. (n = 5) and statistical significance (Student’s unpaired t-test) is 
denoted by asterisks, *** p < 0.001. 
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above basal levels (Figure 6.13) This again indicates that dexamethasone is 
increasing SGK1 but not mTORC2 activity. 
 
Application of PP242 significantly reduced phosphorylation of Akt-Ser
473
 under 
both unstimulated and dexamethasone-treated conditions (Figure 6.13A). 
Similarly, PP242 essentially abolished phosphorylated NDRG1-Thr
346/356/366
 under 
hormone-free and dexamethasone-stimulated conditions (Figure 6.13B). This 
confirms that PP242 is inhibiting basal mTORC2 activity and that SGK1 activity 
is clearly dependent on mTORC2 activity. Changes to Akt-Ser
473
 phosphorylation 
occurred without any alteration to total Akt expression, but again total NDRG1 
was reduced under control conditions in the presence of dexamethasone (Figure 
6.13B, 2
nd
 lane) and a faint band shift was also observed. These findings suggest 
that the inhibition of Ieq with PP242 can be attributed to an inhibition of mTORC2 
resulting in SGK1 not being activated shown as with abolished phosphorylation of 
NDRG1-Thr
346/356/366
. Furthermore these data are consistent with the results 
examining the effects of TORIN1. 
 
6.2.4.3 The effects of rapamycin on dexamethasone-stimulated 
Na
+
 transport 
Since TORIN1 and PP242 inhibit both mTORC1 and mTORC2, a selective 
inhibitor of mTORC1, rapamycin, was used to investigate the role of mTORC1 in 
the dexamethasone-mediated stimulation of Na
+
 transport. Experiments identical 
to those carried out examining the effects of TORIN1 and PP242 were carried out  
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Figure 6.13 The effects of PP242 on the phosphorylation of endogenous proteins in response 
to treatment with dexamethasone. 
Top panels: typical western blots showing the phosphorylation of (A) Akt-Ser
473
 and (B) NDRG1-
Thr
346/356/366
 under unstimulated or dexamethasone-stimulated (200nM, 2.5 hr) conditions in 
vehicle treated, left hand pair, or PP242 treated (1µM, 30 min) cells, right hand pair. Middle 
panels show the respective total protein blots for (A) Akt and (B) NDRG1. Lower panels show 
pooled data of phosphorylation of (A) Akt-Ser
473
, n = 4, and (B) NDRG1-Thr
346/356/366
, n = 4. Data 
is shown as mean ± S.E.M. and daggers denote statistical significance between basal and 
dexamethasone-treated cells under control conditions: ‡, p < 0.01. Asterisks denote statistically 
significant effects (One-way ANOVA Bonferroni post hoc test) of PP242 on either basal or 
dexamethasone-stimulated phosphorylation of Akt-Ser
473
 or NDRG1-Thr
346/356/366
: *, p < 0.05, **, 
p < 0.01. 
 
to investigate the effects of rapamycin on Ieq. Figure 6.9 shows that 
dexamethasone stimulated sodium transport under control conditions with a ΔIeq 
of -15.8 ± 2.0 µA cm
-2
 (n = 3, p < 0.01). This increase in Ieq occurred with a 
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concomitant hyperpolarisation of Vt and a slight decrease in Rt (for values see 
Appendix). 
 
Rapamycin had no effect on basal current, as seen previously in Chapter 4. 
However, unlike in the insulin-stimulated cells, rapamycin caused an 84.2 ± 3.4 % 
inhibition of the response to dexamethasone (Figure 6.14B, n = 3, p < 0.01). In the 
presence of rapamycin, ΔIeq was reduced to -2.6 ± 0.9 µA cm
-2
 and this was 
significantly smaller than the control response (Figure 6.14C). This data indicates 
that mTORC1 is playing an important role in mediating the dexamethasone 
stimulation of Na
+
 transport.  
 
The effects that rapamycin had on phosphorylation of endogenous protein was 
examined. Cells were lysed and western analysis carried out examining 
phosphorylation of Akt-Ser
473
, NDRG1-Thr
346/356/366
 as well as for the mTORC1 
substrate P70-S6K-Thr
389
. Figure 6.15 shows basal levels of phosphorylation were 
observed for Akt-Ser
473
 (Figure 6.15A), NDRG-Thr
346/356/366
 (Figure 6.15B) and 
P70-S6K-Thr
389
 (Figure 6.15C). Application of dexamethasone did not alter levels 
of phosphorylation compared to control conditions in either Akt-Ser
473
 (Figure 
6.15A) or P70-S6K-Thr
389
 (Figure 6.15C). As previously seen (Figure 6.13), 
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Figure 6.14 The effects of rapamycin on dexamethasone-stimulated Ieq. 
Ieq of cells pre-treated for 30 min with either (A) solvent vehicle or (B) rapamycin (100nM) then 
exposed to either unstimulated or dexamethosone-stimulated (200nM) conditions for a further 2.5 
h, arrow indicates addition of vehicle / dexamethasone. Data is presented as mean ΔIeq, calculated 
as a fraction of the current 5 min before dexamethasone was added, ± S.E.M (n = 5).  (C) Pooled 
data from the peak response, ΔIeq, to dexamethasone under control and rapamycin treated cells. 
Data is presented as mean ± S.E.M. (n = 5) and statistical significance (Student’s unpaired t-test) is 
denoted by asterisks, **, p < 0.01. 
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exposure of cells to dexamethasone produced a considerable increase in 
phosphorylation of NDRG1-Thr
346/356/366
 (Figure 6.15B) again indicating that this 
hormone is stimulating SGK1 activity but not mTORC1 or mTORC2 activity.  
 
In the presence of rapamycin, phosphorylation of Akt-Ser
473
 remained unaltered 
in control conditions under hormone-free and hormone-treated cells (Figure 
6.15A). Similarly, phosphorylation of NDRG1-Thr
346/356/366 
was unaffected by 
rapamycin with basal levels of phosphorylation and a very large increase in 
phosphorylation following 2.5 h exposure to dexamethasone (Figure 6.15B).
 
However, phosphorylation of P70-S6K-Thr
389
 was essentially abolished in the 
presence of rapamycin under both unstimulated and dexamethasone-stimulated 
conditions (Figure 6.15C). Changes in phosphorylation of Akt-Ser
473
 occurred 
without any alteration to overall expression of Akt. As seen previously (Figure 
6.13), expression of total NDRG1 was altered with a lighter band and a darker 
band that migrated more slowly (Figure 6.15B). In the presence of rapamycin, 
total S6K was slightly reduced under both unstimulated and dexamethasone-
treated conditions (Figure 6.15C) and also appeared to migrate slightly quicker 
than in control conditions. These data indicate that whilst rapamycin inhibits 
mTORC1 activity it exerts no effect on either SGK1 or mTORC2 activity. 
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Figure 6.15 The effects of rapamycin on the phosphorylation of endogenous proteins in 
response to treatment with dexamethasone. 
Top panels: typical western blots showing the phosphorylation of (A) Akt-Ser
473
, (B) NDRG1-
Thr
346/356/366
 and (C) P70-S6K-Thr
389
 under unstimulated or dexamethasone-stimulated (200nM, 
2.5 hr) conditions in vehicle treated, left hand pair, or rapamycin treated (100nM, 30 min) cells, 
right hand pair. Middle panels show the respective total protein blots for (A) Akt , (B) NDRG1 
and (C) S6K. Lower panels show pooled data of phosphorylation of (A) Akt-Ser
473
, n = 4, (B) 
NDRG1-Thr
346/356/366
, n = 4, and (C) P70-S6K-Thr
389
, n = 4. Data is shown as mean ± S.E.M. and 
daggers denote statistical significance between basal and dexamethasone-treated cells under 
control conditions: ‡, p < 0.01. Asterisks denote statistically significant effects (One-way ANOVA 
Bonferroni post hoc test) of rapamycin on either basal or dexamethasone-stimulated 
phosphorylation of Akt-Ser
473
, NDRG1-Thr
346/356/366
 or P70-S6K-Thr
389
: **, p < 0.01, *** p < 
0.001. 
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6.2.5 The role of mTORC2 in AVP-mediated stimulation of Na+ 
transport 
The effect that the peptide hormone arginine vasopressin (AVP) exerted on the 
biophysical properties of the collecting duct cells was investigated in a similar 
manner to insulin and dexamethasone. Figure 6.16 shows that basolateral addition 
of AVP (10 nM, 30 min) produced a rapid and significant stimulation of Na
+
 
transport with a ΔIeq of -16.3 ± 1.7 µA cm
-2
. This stimulation of Ieq occurred with 
a depolarisation of Vt and a marked decrease in Rt (Figure 6.18). This response is 
in sharp contrast to both insulin and dexamethasone that stimulated Ieq by 
hyperpolarising Vt and causing only a slight fall in Rt. All values of electrical 
parameters recorded can be found in Table 6.5. 
 
The addition of amiloride (10 µM, 10 min) in both control and AVP-treated cells 
significantly inhibited Ieq (Figure 6.16). Vt was also significantly reduced in both 
untreated and AVP-treated cells and the Vt remaining following amiloride-
treatment in AVP-treated cells was consistently and significantly smaller than that 
found in control cells (Figure 6.18). Under control conditions the addition of 
amiloride caused a significant increase in Rt but in AVP-treated cells however, Rt 
did not alter with the addition of amiloride (Figure 6.18). This is an unusual 
finding since amiloride has consistenly increased Rt in control experiments. 
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Figure 6.16 The electrometric response to acute application of vasopressin. 
Transepithelial voltage Vt was recorded (top left trace) under control conditions or with application 
of arginine vasopressin (AVP, 10nM), allowing calculation of Rt and Ieq (middle and bottom left 
traces).  Mean values from different time points throughout the experiment were taken (a) prior to 
addition of vehicle / drug, (b) once the response to AVP was established and (c) after application 
of amiloride (10µM), shaded areas denote the sampling periods. The right hand panels show the 
mean values for Vt (top), Rt (middle) and Ieq (bottom). Data is shown as mean ± S.E.M. (n = 9) and 
statistical significance (Student’s unpaired t-test) is denoted by asterisks (**, p < 0.01, ***, 
p < 0.001). 
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Table 6.5 Electrical parameters of control and AVP-treated cells. 
Mean data ± S.E.M. (n = 9) for Vt, Rt and Ieq recorded from vehicle-treated or AVP-treated cells. 
Time points are taken from a baseline recording, 30 min after vehicle / dexamethasone and 
following 10 min exposure to amiloride. Asterisks denote statistically significant effects of AVP 
on Vt, Rt and Ieq compared to control cells calculated using a Student’s unpaired t-test, *** 
p < 0.001. 
 
 Vehicle-treated AVP (10 nM) 
 Pre-
exposure 
30 min 
exposure 
Post-
amiloride 
Pre-
exposure 
30 min 
exposure 
Post-
amiloride 
Vt (mV) -47.5 ± 3.6 -44.9 ± 3.9 -4.6 ± 0.5 -43.8 ± 4.5 -26.6 ± 4.2** -1.4 ± 0.4*** 
Rt (kΩ cm
2
) 2.2 ± 0.1 2.3 ± 0.1 4.1 ± 0.2 2.1 ± 0.1 0.7 ± 0.1*** 0.7 ± 0.1*** 
Ieq (µA cm
-2
) -22.4 ± 2.6 -20.2 ± 2.1 -1.1 ± 0.1 -22.7 ± 3.1 -36.4 ± 4.3** -2.2 ± 0.5 
 
 
Vasopressin is known to mediate its effects via a cAMP- and PKA-dependent 
pathway. To confirm this in our cell line the phosphorylation of CREB-Ser
133
, a 
substrate of PKA, was monitored. Figure 6.17 shows that AVP evoked a 
significant increase in the abundance of phosphorylated-CREB-Ser
133
 without 
altering overall expression of this protein, therefore AVP is activating a cAMP / 
PKA-dependent pathway. 
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Figure 6.17 The effects of AVP on the phosphorylation of CREB-Ser
133
. 
(A) Typical western blots showing phosphorylated-CREB-Ser
133
 (upper) or total CREB (lower) 
under unstimulated or AVP-stimulated (10 nM, 30 min) conditions. (B) Pooled data of 
phosphorylated-CREB-Ser
133
 or total CREB (n = 14). Data is shown as mean ± S.E.M. and 
asterisks denote statistical significance (Student’s unpaired t-test) between basal and AVP-treated 
cells: *, p < 0.05. 
 
6.2.5.1 The effects of TORIN1 on AVP-stimulated Na+ transport 
The effects of TORIN1 on the AVP-induced Na
+
 current were investigated 
employing experiments identical to those examining the effects of this compound 
on the insulin-induced Na
+
 current. Figure 6.18A shows that acute addition of 
AVP produced a marked stimulation of Ieq with a ΔIeq of -11.9 ± 1.1 µA cm
-2
. 
This was accompanied by a significant depolarisation of Vt as well as a significant 
decrease in Rt (see Appendix). In the presence of TORIN1, AVP produced a 
significant stimulation of Ieq with a ΔIeq of -10.7 ± 1.3 µA cm
-2
 in a similar 
manner to control cells (Figure 6.18B) and this was not significantly different 
from the response seen in vehicle-treated cells (Figure 6.18C). These findings 
demonstrate that TORIN1 is not inhibiting AVP-stimulated Na
+
 transport and 
therefore neither mTORC1/2 appear to be involved in this response. 
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Figure 6.18 The effects of TORIN1 on AVP-stimulated Ieq. 
Ieq of cells pre-treated for 30 min with either (A) solvent vehicle or (B) TORIN1 (100nM) then 
exposed to either unstimulated or AVP-stimulated (10nM) conditions for a further 30 min, arrow 
indicates addition of vehicle / AVP. Data is presented as mean ΔIeq, calculated as a fraction of the 
current 5 min before AVP was added, ± S.E.M (n = 5).  (C) Pooled data from the peak response, 
ΔIeq, to AVP under control and TORIN1 treated cells. Data is presented as mean ± S.E.M. (n = 5).  
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The phosphorylation of NDRG1-Thr
346/356/366
 in response to AVP and in the 
presence of TORIN1 was monitored to investigate the role of SGK1 in the AVP 
response. Under control conditions, basal levels of phosphorylation were observed 
for NDRG1-Thr
346/356/366
 (Figure 6.19B). Application of AVP significantly 
suppressed phosphorylation of NDRG1-Thr
346/356/366 
(Figure 6.19B). This data 
indicates that AVP is inhibiting SGK1 activity.  
 
Phosphorylation of NDRG1-Thr
346/356/366
 in the presence of TORIN1 was 
essentially abolished under both unstimulated and AVP-stimulated conditions 
(Figure 6.19B). This is consistent with SGK1 lying downstream of mTORC2. 
Changes in phosphorylation of NDRG1-Thr
346/356/366
 occurred without any 
alteration to the overall expression of the total protein (Figure 6.19). 
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Figure 6.19 The effects of TORIN1 on the phosphorylation of NDRG1-Thr
346/356/366
 under 
control and AVP-stimulated conditions. 
Top panel: typical western blots showing the phosphorylation of NDRG1-Thr
346/356/366
 under 
unstimulated or AVP-stimulated (10 nM, 30 min) conditions in vehicle treated, left hand pair, or 
TORIN1 treated (100nM, 30 min) cells, right hand pair. Middle panel shows the respective total 
protein blot for NDRG1. Lower panel shows pooled data of phosphorylated-NDRG1-Thr
346/356/366
, 
n = 4. Data is shown as mean ± S.E.M. and daggers denote statistical significance between basal 
and AVP-treated cells under control conditions: †, p < 0.05. Asterisks denote statistically 
significant effects (One-way ANOVA Bonferroni post hoc test) of TORIN1 on basal or AVP-
stimulated phosphorylation of NDRG1-Thr
346/356/366
: *, p < 0.05. 
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6.2.5.2 The effects of PP242 on AVP-stimulated Na+ transport  
Identical experiments to those looking at the effects of TORIN1 on AVP-
stimulated Ieq were carried out investigating the effects of PP242. Acute addition 
of AVP produced a marked stimulation of Ieq with a ΔIeq of -19.8 ± 1.8 µA cm
-2 
(Figure 6.20A). This increase in current occurred with a concomitant 
depolarisation of Vt as well as a significant decrease in Rt (for values see 
Appendix). Again AVP is clearly stimulating ENaC-mediated Na
+
 transport. In 
PP242-treated cells, AVP also produced a significant stimulation of Ieq with a ΔIeq 
of -21.2 ± 3.3 µA cm
-2
 (Figure 6.20B) and this response was not significantly 
different to that seen in vehicle-treated cells (Figure 6.20C). This increase in Ieq 
occurred in an identical manner to the control cell with a depolarisation of Vt and 
large fall in Rt. These findings indicate that similar to TORIN1, PP242 is exerting 
no effect on AVP-stimulated Na
+
 transport and therefore mTORC1/2 is not 
involved in this response. 
 
 
Under control conditions, basal levels of phosphorylation were observed for 
NDRG1-Thr
346/356/366
 (Figure 6.21B) indicating SGK1 is active under control 
conditions. Phosphorylation of NDRG1-Thr
346/356/366 
in the presence of AVP was 
significantly suppressed (Figure 6.21B). This data again suggests that AVP is 
inhibiting SGK1 activity. In the presence of PP242, phosphorylation of NDRG1-
Thr
346/356/366
 was essentially abolished under both unstimulated and AVP-
stimulated conditions (Figure 6.21B). These data indicate that PP242 inhibits 
SGK1 activity. 
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Figure 6.20 The effects of PP242 on AVP-stimulated Ieq. 
Ieq of cells pre-treated for 30 min with either (A) solvent vehicle or (B) PP242 (1μM) then exposed 
to either unstimulated or AVP-stimulated (10nM) conditions for a further 30 min, arrow indicates 
addition of vehicle / AVP. Data is presented as mean ΔIeq, calculated as a fraction of the current 5 
min before AVP was added, ± S.E.M (n = 5).  (C) Pooled data from the peak response, ΔIeq, to 
AVP under control and PP242 treated cells. Data is presented as mean ± S.E.M. (n = 5).  
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Figure 6.21 The effects of PP242 on the phosphorylation of NDRG1-Thr
346/356/366
 under 
control and AVP-stimulated conditions. 
Top panels: typical western blot showing the phosphorylation of NDRG1-Thr
346/356/366
 under 
unstimulated or AVP-stimulated (10 nM, 30 min) conditions in vehicle treated, left hand pair, or 
PP242 treated (100nM, 30 min) cells, right hand pair. Middle panel shows the respective total 
protein blots for NDRG1. Lower panel shows the pooled data of phosphorylated-NDRG1-
Thr
346/356/366
, n = 6. Data is shown as mean ± S.E.M. and daggers denote statistical significance 
between basal and AVP-treated cells under control conditions: ‡, p < 0.01. Asterisks denote 
statistically significant effects (One-way ANOVA Bonferroni post hoc test) of TORIN1 on either 
basal or AVP-stimulated phosphorylation of NDRG1-Thr
346/356/366
: **, p < 0.01. 
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6.3 Discussion 
6.3.1 The role of mTORC2 in basal and insulin-stimulated Na+ 
transport 
Since the selective blocker of mTORC1 rapamycin did not alter basal Na
+
 
transport, any effects with the mTOR inhibitors PP242 and TORIN1 could be 
attributed to inhibition of mTORC2. Both PP242 and TORIN1 modestly inhibited 
the basal Ieq with PP242 showing a greater inhibition of the current than TORIN1. 
Since mTORC2 acts downstream of PI3-kinase, these modest effects on basal 
current are in accordance with our findings that inhibition of PI3-kinase with both 
PI103 and GDC0941 did not greatly inhibit basal Ieq. It is interesting to note 
however, that whilst PI103 and GDC0941 did not significantly alter basal Ieq, both 
TORIN1 and PP242 did so. With mTORC2 acting downstream of PI3-kinase this 
suggests that another factor may play a role in mTORC2 activation and 
elucidation of the mechanism of mTORC2 activation would be of great interest in 
this regard. These findings provide further evidence that the mechanism 
maintaining spontaneous Na
+
 absorption in this cell line is largely independent of 
PI3-kinase, mTORC2 and SGK1 contrary to previous findings (Record et al., 
1998, Wang et al., 2001, Faletti et al., 2002). The difference with the findings 
from the present study compared to previous investigations could be due to the 
use of more selective inhibitors rather than using less specific inhibitors 
(Păunescu et al., 2000) or overexpression systems (Alvarez De La Rosa and 
Canessa, 2003) to target the signalling pathway. The present study have also 
utilised novel drugs to target mTORC2 and examine the effect on basal Na
+ 
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absorption which has not been studied previously. The use of these drugs is a 
novel method of preventing activation of SGK1, shown by the loss of downstream 
signalling, and provides convincing evidence that neither mTORC2 nor SGK1 
play a dominant role in the maintenance of spontaneous ENaC-mediated Na
+
 
absorption. 
 
The effects of both PP242 and TORIN1 on the insulin-induced Ieq were examined. 
As seen previously (Chapter 2), insulin evokes a stimulation of Ieq that reflects a 
hyperpolarisation of Vt and fall in Rt. Both inhibitors significantly reduced the 
insulin-induced current but they did not abolish it fully, a small response to insulin 
could still be seen. Therefore mTORC2 appears to play a major role in mediating 
the natriferic response to insulin, although other factors must play a minor role in 
this response. The residual response that has been seen with PI3-kinase, mTORC2 
and SGK1 inhibition could be due to the effects of phospholipids. PIP2 and PIP3 
are present at low levels under unstimulated conditions and it has been proposed 
that these lipids themselves can modulate ENaC activity (Blazer-Yost and 
Nofziger, 2005). ENaC has been shown to contain a PIP2 binding site and 
mutation of this domain lowers basal ENaC activity (Kunzelmann et al., 2005). 
PIP2 has been proposed to alter both open probability and number of channels in 
the membrane (Pochynyuk et al., 2006). PIP3 appears to play a more regulatory 
role as levels of this phosphoinositol are dependent on PI3-kinase activity (Blazer-
Yost and Nofziger, 2005). It has been proposed that PIP2 however could maintain 
basal levels of ENaC and therefore be responsible or at least play a role in 
maintaining spontaneous Na
+
 absorption (Pochynyuk et al., 2008). 
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To identify the role of mTORC2 in the insulin signalling cascade leading to 
increased Na
+
 absorption, the phosphorylation of endogenous proteins was 
monitored. mTORC2 has been shown to directly phosphorylate Akt at Ser
473 
on its 
hydrophobic motif (Sarbassov et al., 2005) therefore the phosphorylation of this 
residue was monitored as a marker of mTORC2 activity. The activity of two 
downstream targets of mTORC2: SGK1 (García-Martínez and Alessi, 2008) and 
Akt (Sarbassov et al., 2005) were also examined by measuring the 
phosphorylation of their substrates NDRG1-Thr
346/356/366
 and PRAS40-Ser
246 
respectively. The phosphorylation of all three of these proteins was significantly 
increased by treatment with insulin, as seen previously (Chapter 3). TORIN1 
inhibited the phosphorylation of Akt-Ser
473
 at 100nM under unstimulated and 
insulin-stimulated conditions and this phosphorylation was completely abolished 
at higher concentrations. PP242 completely abolished basal and insulin-stimulated 
phosphorylation of Akt-Ser
473
 at 1µM. SGK1 activity was abolished at 100nM 
TORIN1 and 1µM PP242 and Akt activity was reduced with both compounds but 
not completely abolished. This data is in accordance with studies that show 
mTORC2 is required for activation of SGK1 by phosphorylating the hydrophobic 
domain Ser
422
 which allows PDK1 to bind and phosphorylate the Thr
256
 residue 
(Biondi et al., 2001), activating the kinase. In contrast, Akt activation does not 
require phosphorylation at its hydrophobic motif by mTORC2, therefore Akt can 
still be active without phosphorylation at Akt-Ser
473
 (Alessi et al., 1996) which 
would explain PRAS40-Ser
246
 phosphorylation. 
 
183 
These results highlight the role of mTORC2 in mediating insulin-induced Na
+ 
transport. However, there is a high degree of homology in the catalytic domains of 
PI3-kinase, mTORC1 and mTORC2 (Bain et al., 2007) which raises the 
possibility that these inhibitors could be acting on PI3-kinase. This kinase is a 
critical effector in the signalling pathway, inhibition of it abolishes the natriferic 
response to insulin as seen previously (Chapter 4). This issue was addressed in the 
study in which TORIN1 was first described (Thoreen et al., 2009). The authors 
used cells in which a key component of both TOR complexes, mLST8, had been 
deleted rendering Akt-Ser
473
 constitutively dephosphorylated. They then 
monitored the phosphorylation of Akt-Thr
308
, a process that requires two key 
steps: recruitment to the plasma membrane by PIP3 and phosphorylation by the 3-
phosphoinositide-dependent protein kinase-1 PDK1, both of which are 
downstream of PI3-kinase. This process can be modified in response to 
phosphorylation of the hydrophobic motif Akt-Ser
473
 (Frödin et al., 2002) but 
since this was constitutively dephosphorylated, any phosphorylation of Akt-Thr
308
 
would reflect PI3-kinase activity. The phosphorylation of this residue was only 
reduced by TORIN1 at high concentrations, > 1 µM (Thoreen et al., 2009). 
Therefore, our results with TORIN1 can be attributed to an inhibition of mTOR 
and not PI3-kinase. Similarly, parallel studies in our laboratory using H441 
airway epithelial cells have revealed that TORIN1 exerts only a small effect on 
Akt-Thr
308
 phosphorylation whilst abolishing Akt-Ser
473
 phosphorylation 
(unpublished data), providing further evidence that TORIN1 is not affecting PI3-
kinase activity. 
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Although similar experiments were not carried out in the study that first described 
PP242 (Feldman et al., 2009), the authors showed that only at high doses of this 
drug (2.5 µM) was there a loss of Akt-Thr
308
 phosphorylation. Moreover this loss 
of phosphorylation was removed in cells that were transfected with an inactive 
mutant Akt-Ser
473
 and treated with increasing doses of PP242. This suggests that a 
loss of interaction of Akt-Ser
473
 with Akt-Thr
308
 rather than a loss of PI3-kinase 
activity was responsible for the decrease in Akt-Thr
308
 phosphorylation (Feldman 
et al., 2009). Therefore PP242 appears to be a selective inhibitor of mTOR rather 
than PI3-kinase, similar to TORIN1. Therefore the results found with both 
TORIN1 and PP242 can be attributed to inhibition of mTOR and not PI3-kinase. 
Since rapamycin does not alter basal or insulin-induced Na
+
 transport excluding a 
role for mTORC1, these effects can also be attributed to inhibition of mTORC2. 
 
 
6.3.2 The role of mTORC2 in dexamethasone-stimulated Na+ 
transport 
With supraphysiological doses of aldosterone required to elicit a response in this 
cell line it is clear that GR-activation rather than MR-activation of Na
+
 transport is 
occurring. It is interesting to note that the original paper that described these cells 
use concentrations of 0.5 µM aldosterone in the bulk of the experiments and 
conclude that the responses seen are likewise mediated via GR-activation (Bens et 
al., 1999). Whilst this cell line cannot be used to study the physiological response 
of aldosterone, since GR-mediated Na
+
 transport was clearly present we studied 
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the effects of a synthetic GR agonist dexamethasone. This stimulation of Na
+ 
transport is of physiological relevance since certain forms of hypertension are 
caused either by increased concentrations of aldosterone or cortisol abnormally 
stimulating Na
+
 transport by activating both the MR and GR. This is true in 
apparent mineralocorticoid excess (AME) syndrome where excess aldosterone is 
produced or in cases where 11-βHSDH activity is lost and cortisol cannot be 
metabolized into cortisone thereby activating MR as well as GR (Lifton et al., 
2001).  
 
Dexamethasone stimulated Na
+
 transport in the mpkCCDcl4 cell line by 
hyperpolarising Vt and reducing Rt, a similar electrometric response to insulin 
(Chapter 3), albeit at a slower rate. Ieq was abolished with application of the ENaC 
inhibitor amiloride, confirming that the current observed is carried by Na
+
 ions via 
ENaC. The changes in electrical properties across the monolayer are comparable 
to those observed in A6 cells where treatment with 100 nM dexamethasone 
produced a hyperpolarisation of Vt and a decrease in Rt therefore giving an 
increase in Ieq (Wang et al., 2001). This study revealed that the dexamethasone-
induced increase in Na
+
 transport was maximal at 8 hours and fell slightly after 24 
hours, indicating that this glucocorticoid induces a substantial and long-lasting 
increase in ENaC-mediated Na
+
 transport. This stimulation of Na
+
 reabsorption 
occurs much later than that seen with insulin and this is consistent with the theory 
that whilst insulin stimulates a signalling pathway that activates SGK1, 
dexamethasone increases expression of SGK1 followed by increasing expression 
of ENaC subunits (Wang et al., 2001). Here the increase in Na
+
 transport after 
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2.5 h exposure to dexamethasone was greater than that observed with a 30 min 
exposure to insulin, with ΔIeq of -15.1 ± 1.3 µA cm
-2
 and -11.7 ± 1.4 µA cm
-2
 
respectively. These data demonstrate that dexamethasone also stimulates ENaC-
mediated Na
+
 transport in mpkCCDc14 cells. 
 
The role of mTOR in the stimulation of Na
+
 transport by dexamethasone was 
examined using inhibitors of mTOR: PP242 and TORIN1; and mTORC1 with 
rapamycin. The dexamethasone-induced stimulation of Na
+
 transport was 
essentially abolished in the presence of both TORIN1 and PP242. To determine 
whether this result was solely due to mTORC2 activity the effects of rapamycin 
on the natriferic effect of dexamethasone were examined. Interestingly, rapamycin 
substantially inhibited the dexamethasone-induced Ieq although not as fully as with 
TORIN1 and PP242. These data suggest that mTORC1 plays a major role in 
mediating this response with perhaps a small role for mTORC2 to account for the 
difference in inhibition. This is in sharp contrast with the insulin-induced Ieq 
where mTORC1 played no role. This finding is consistent with a previous study 
that has demonstrated that aldosterone-stimulated amiloride-sensitive currents in 
A6 cells can be inhibited by rapamycin (Rokaw et al., 1996b). The mechanism by 
which this occurred was investigated in a later study, using dexamethasone in this 
case, and the authors concluded that rapamycin inhibited translocation of the 
activated-GR into the nucleus (Edinger et al., 2002). This finding provides a 
mechanism by which rapamycin inhibits Ieq, however this effect was only seen in 
cells pretreated for 8 h with rapamycin. The results from the present study were 
drawn from experiments where rapamycin was added acutely and this prevented 
187 
the onset of dexamethasone-stimulated Na
+
 transport. Interestingly a very recent 
study shows that Na
+
 transport in mpkCCDcl4 cells pre-stimulated with insulin 
and aldosterone was not inhibited with acute treatment of rapamycin indicating a  
lack of a role of mTORC1 in this natriferic response (Lu et al., 2010). Clearly 
further work into the role of mTORC1 in corticosteroid-mediated Na
+
 absorption 
is warranted. 
 
To elucidate the signalling mechanism involved in the dexamethasone-induced 
increase in Na
+
 transport, phosphorylation of endogenous proteins in the presence 
of these inhibitors were examined. Under control conditions dexamethasone 
produced a hyperphosphorylation of NDRG1-Thr
346/356/366
 indicating a large 
increase in SGK1 activity. This is in agreement with previous studies that 
observed a substantial increase in SGK1 phosphorylation in response to 
dexamethasone treatment (Chen et al., 1999, Wang et al., 2001). In contrast, Akt-
Ser
473
 phosphorylation remained unaltered in response to dexamethasone. The 
lack of alteration to Akt-Ser
473
 phosphorylation indicates that mTORC2 activity is 
unchanged since this kinase specifically phosphorylates this site (Sarbassov et al., 
2005). It is therefore unusual that SGK1 activity is so greatly increased, as SGK1 
activity relies on mTORC2 phosphorylation (García-Martínez and Alessi, 2008). 
One possible explanation for this is that instead of dexamethasone increasing 
SGK1 activity but instead increasing the abundance of this kinase, basal levels of 
PI3-kinase activity and therefore mTORC2 and PDK1 activity could be activating 
the increased number of SGK1 molecules. This could explain why SGK1 activity 
increases without an increase in mTORC2 activity. Further experiments 
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measuring expression of SGK1 at the mRNA and protein level would confirm 
this. These findings indicate that dexamethasone instead of stimulating a PI3-
kinase and mTORC2 signalling pathway, increases the abundance of SGK1 that 
can feed into an already active pathway. This is at odds with previous studies that 
have proposed that aldosterone / dexamethasone stimulate the PI3-kinase / SGK1 
signalling cascade that increase SGK1 activity and therefore ENaC activity 
(Blazer-Yost et al., 1999, Faletti et al., 2002, Păunescu et al., 2000, Wang et al., 
2001, Tong et al., 2004a). In A6 cells, levels of PIP3 were increased following 
exposure to aldosterone indicating an increase in PI3-kinase activity (Blazer-Yost 
et al., 1999). Several groups have shown that inhibiting PI3-kinase with LY-
294002 prevent aldosterone / dexamethasone induced ENaC-mediated Na
+
 
transport in A6 cells (Wang et al., 2001, Păunescu et al., 2000). Similarly A6 cells 
expressing a mutant SGK1 which cannot be activated abolishes the stimulation of 
current seen in A6 cells expressing wild-type SGK1, highlighting the importance 
of active SGK1 in mediating increased Na
+
 transport (Faletti et al., 2002). 
However, whilst these latter studies highlight the importance of PI3-kinase and 
SGK1 activity in mediating hormonal transport they do not directly demonstrate 
increased activation of these kinases in response to mineralocorticoids. The 
present data do not support dexamethasone stimulating PI3-kinase activity and 
this suggests that an already active pathway can mediate an increase in Na
+
 
transport. 
 
PP242 and TORIN1 substantially reduce Akt-Ser
473
 and NDRG1-Thr
346/356/366
 
phosphorylation under control and dexamethasone-treated conditions, indicating 
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inhibition of mTORC2 and SGK1 activity respectively. However, in the presence 
of rapamycin, the phosphorylation of Akt-Ser
473
 and NDRG1-Thr
346/356/366
 remain 
unaltered under control and dexamethasone-treated conditions. These data suggest 
that mTORC1 does not phosphorylate Akt-Ser
473
 and this is in accordance with a 
study that showed that mTORC2 and not mTORC1 phosphorylates this residue 
(Sarbassov et al., 2005). Furthermore, mTORC1 is not involved in SGK1 activity 
as NDRG1-Thr
346/356/366
 remains hyperphosphorylated in response to 
dexamethasone. This is in contrast with a study that showed that rapamycin could 
inhibit SGK1-Ser
422
 phosphorylation and that this complex was the elusive 
“PDK2” (Hong et al., 2008). However a more recent study has demonstrated that 
rapamycin had no effect on SGK1-Ser
422
 phosphorylation (García-Martínez and 
Alessi, 2008). Furthermore these authors conclude that the results from Hong et 
al. were due to a commerical SGK1 antibody recognising phosphorylated bands 
of S6K since these two kinases share similar hydrophobic motifs (García-
Martínez and Alessi, 2008, Lu et al., 2010). Therefore the data from the present 
study demonstrate that rapamycin does not inhibit SGK1 activity and mTORC1 is 
not the kinase responsible for hydrophobic domain phosphorylation in SGK1, 
confirming the work of García-Martínez and Alessi. Rapamycin did however 
inhibit mTORC1 activity as shown by complete loss of phosphorylated P70-S6K-
Thr
389
, a downstream substrate of mTORC1 and this is consistent with previous 
findings that rapamycin is a selective inhibitor of this complex (García-Martínez 
and Alessi, 2008, Lu et al., 2010). 
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Altogether, these data provide a somewhat confusing result. Whilst the natriferic 
response to insulin is dependent on mTORC2 and not mTORC1, the natriferc 
response to dexamethasone appears to be dependent on mTORC1, since mTOR 
and mTORC1 inhibition substantially reduces dexamethasone-induced Ieq. A role 
for mTORC2 cannot be completely ruled out and perhaps both complexes are 
required for the full response to dexamethasone. Since mTORC2 activity does not 
appear to be increased in response to dexamethasone, with no alteration seen in 
Akt-Ser
473
 phosphorylation, it does not seem likely that this kinase is involved in a 
pathway leading to increased Na
+
 transport. With perhaps an increase in the 
abundance of SGK1 explaining the increase in SGK1 activity, the 
dexamethasone-mediated stimulation of Na
+
 transport appears to be occurring 
outwith the signalling model used to explain the natriferic effect of insulin. 
Furthermore, the inhibition of the current with rapamycin suggests a role for S6 
kinase in mediating this response although this kinase has not previously been 
linked with ENaC activity. Edinger and colleagues demonstrated that rapamycin 
prevented the activated-GR translocating into the nucleus (Edinger et al., 2002). 
Studies of fetal distal lung epithelial FDLE cells revealed that basal amiloride-
sensitive currents were sensitive to rapamycin (Otulakowski et al., 2007). The 
authors postulated that the decreased currents were due to an inhibition of mTOR-
dependent pathways leading to protein synthesis of transport proteins. These 
studies indicate that mTORC1-dependent protein synthesis is important in 
hormonally regulated Na
+
 transport. Investigation into other signalling molecules 
upregulated by corticosteroids such as GILZ or KiRas2A which have been linked 
to ENaC activity would be of great interest to examine this hypothesis further.  
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6.3.3 The role of mTORC2 in AVP-stimulated Na+ transport 
The basolateral addition of AVP rapidly depolarised Vt but also significantly 
reduced Rt. Therefore an overall increase in Ieq was observed and this response 
was quite different to that elicited by either insulin (3.2.3) or dexamethasone 
(6.2.4). The addition of amiloride abolished Vt but had no significant effect on Rt 
giving an overall inhibition of Ieq. Since amiloride inhibits Ieq at the end of the 
experiment this suggests that there is a stimulation of ENaC-mediated Na
+
 
transport. The initial fall in Rt which is associated with depolarisation of Vt could 
suggest that there is an increase in Cl
-
 absorption but since there is no current left 
in the presence of amiloride and Rt remains unaltered, this seems unlikely. 
Previous studies have found in contrast with our findings, that AVP 
hyperpolarises Vt in isolated perfused rat cortical collecting ducts (Schafer and 
Troutman, 1990) and in the M1 collecting duct cell line (Nakhoul et al., 1998) 
which is consistent with an increase in Na
+
 absorption. In A6 cells application of 
vasotocin, analogous to mammalian vasopressin, produced a hyperpolarisation of 
Vt (Verrey, 1994). However when cells were pre-treated with aldosterone which 
produced a larger baseline Vt, the addition of vasotocin depolarised Vt with a 
concomitant increase in conductance indicating a fall in Rt and an overall increase 
in Ieq. This is similar to what was observed in the present study and it is of note 
that the average baseline Vt in these cells is ~ -45 mV is even larger than the than 
Vt recorded across the aldosterone-treated A6 cells.  
 
Furthermore the study by Verrey highlights the differences in recording under 
short-circuit and open-circuit conditions. Under short-circuit conditions vasotocin 
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stimulated net Na
+
 absorption and Cl
-
 secretion, however under open-circuit 
conditions this hormone stimulated net Na
+
 and Cl
-
 absorption (Verrey, 1994). By 
short-circuiting Vt, the electrochemical gradient across the apical membrane will 
be altered and favour Cl
-
 secretion. Indeed several studies recording short circuit 
current from A6 cells and transimmortalized collecting duct cell lines have 
reported an increase in Cl
-
 secretion in response to AVP (Chalfant et al., 1993, 
Duong Van Huyen et al., 1998, Shane et al., 2006). However, open-circuit 
conditions represents Vt under physiological conditions and it has been 
demonstrated that under these conditions AVP can increase net Cl
-
 absorption 
(Nagy et al., 1994, Verrey, 1994, Duong Van Huyen et al., 2001). Therefore 
further work would need to be carried to determine the role of Cl
-
 in the AVP 
response seen in mpkCCDcl4 cells. 
 
The abolition of Vt by amiloride application suggests that AVP is stimulating Na
+
 
absorption which confirms findings in many previous studies (Nakhoul et al., 
1998, Butterworth et al., 2005, Shane et al., 2006). It is interesting however that 
Rt does not increase following addition of amiloride which is seen in control cells 
as well as in insulin- (3.2.4) and dexamethasone-treated cells (6.2.4). AVP also 
potently stimulates incorporation of aquaporins in collecting duct epithelia 
(Nielsen et al., 2002), so perhaps insertion of these water channels could explain 
the low resistance and mask the effect of amiloride on ENaC. Another possible 
explanation is that AVP is altering the epithelial integrity by increasing tight 
junction permeability. Overall, AVP clearly stimulates Ieq in the mpkCCDc14 cell 
193 
line and since this is sensitive to amiloride it is associated with increased ENaC-
mediated Na
+
 absorption. 
 
It is well-known that AVP acts via a cAMP / PKA pathway (Loffing and 
Korbmacher, 2009), however it was recently proposed that SGK1 is 
phosphorylated downstream of PKA which could then mediate effects on ENaC 
(Perrotti et al., 2001, Thomas et al., 2004, Vasquez et al., 2008, Inglis et al., 
2009). To test the hypothesis that AVP could stimulate ENaC activity in an 
SGK1-dependent manner the mTOR inhibitors PP242 and TORIN1 were used as 
these drugs completely abolished SGK1 activity in previous experiments (6.2.1, 
6.2.3). Neither inhibitor attenuated the response to AVP and this result clearly 
indicates that mTOR (including mTORC1 and mTORC2) and therefore SGK1 
play no role in mediating a stimulation of Ieq by AVP. The present findings are in 
contrast with a study that linked AVP stimulation of ENaC with SGK1 signalling 
(Alvarez De La Rosa and Canessa, 2003). This study showed that inducing 
constitutively active SGK1 expression in A6 cells prevented any further 
potentiation of amiloride-sensitive current with the addition of AVP (Alvarez De 
La Rosa and Canessa, 2003). This suggested that AVP signalled via the same 
SGK1-dependent pathway to stimulate ENaC, however that lack of effect of AVP 
could due to maximal stimulation of ENaC. The same study showed that inducing 
expression of a kinase dead form of SGK1 did not prevent AVP from stimulating 
ENaC-mediated Na
+
 transport thereby demonstrating this kinase was not 
necessary for the response (Alvarez De La Rosa and Canessa, 2003). Studies of 
H441 airway epithelial cells (Inglis et al., 2009, Thomas et al., 2004) and 
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submandibular gland cells (Vasquez et al., 2008) have also shown that cAMP can 
stimulate ENaC activity and this is associated with an increase in SGK1 
phosphorylation. However, it is important to note that the increase in current in all 
of these studies occured before the increase in SGK1 phosphorylation was 
observed. This suggests that SGK1 is not mediating the increase in ENaC-
mediated Na
+
 transport. Furthermore, the present data in a collecting duct cell line 
show that SGK1 activity is actually suppressed in response to AVP.  
 
This finding is in sharp contrast with a study that showed that application of 
cAMP to  COS-7 cells expressing recombinant SGK1 activated this kinase, 
measured using in vitro kinase assays (Perrotti et al., 2001), suggesting that PKA 
can act upstream of SGK1. cAMP has been found to stimulate ENaC-mediated 
Na
+
 transport in the H441 bronchiolar epithelial cell line in a PI3-kinase-, PKA- 
and MAPK-dependent manner as shown by using inhibitors of each kinase 
(Thomas et al., 2004). Whilst this study found increased phosphorylation of 
SGK1, the increase in cAMP-mediated Na
+
 transport preceded it indicating that 
cAMP does not signal via SGK1 to stimulate Na
+
 transport in these cells (Thomas 
et al., 2004). Another study has demonstrated that neither SGK1 activity nor 
expression is altered by cAMP (Shelly and Herrera, 2002). The present study 
suggests cAMP actually suppresses SGK1 activity. These inconsistent findings 
regarding SGK1 phosphorylation in response to cAMP could be due to different 
cell lines utilised. In the present study the addition of AVP stimulated PKA as 
demonstrated by an increase in the phosphorylation of CREB-Ser
133
. This 
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confirms that AVP is signalling via cAMP and PKA and accords well with 
previous studies (Shelly and Herrera, 2002). 
 
The findings from the present study indicate a lack of a role of SGK1, and it has 
been demonstrated that AVP exerts its effects on ENaC by binding V2 receptors in 
the basolateral membrane and signalling via a cAMP-dependent pathway (Morris 
and Schafer, 2002, Butterworth et al., 2005). Indeed it has been shown that the 
effects of vasopressin in the collecting duct can be mimicked using membrane 
permeable cAMP analogues including DBcAMP, phosphodiesterase inhibitors 
including IBMX as well as adenylate cyclase activators such as forskolin (Schafer 
and Troutman, 1990, Verrey, 1994). These contrasting results can be explained by 
a further study which revealed that similar to SGK1, PKA can phosphorylate 
residues on Nedd4-2 and therefore regulate ENaC-mediated Na
+
 transport (Snyder 
et al., 2004a). Therefore if AVP signals via cAMP and PKA to phosphorylate 
Nedd4-2, a constitutively active form of SGK1 could saturate Nedd4-2 
phosphorylation and AVP would not be able to further potentiate the response. 
Similarly AVP could still evoke a response with expression of kinase dead SGK1 
by phosphorylating Nedd4-2 and thereby decreasing ENaC ubiquitilation and 
internalisation. Nedd4-2 therefore marks a converging pathway between SGK1 
and PKA and their regulation of ENaC. 
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Chapter 7 – Conclusions and Future 
Work 
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7.1 Conclusions 
Treatment of type II diabetes with the insulin-sensitizing drugs thiazolidinediones 
(TZDs) has been the subject of recent studies due to reports of side effects of fluid 
retention leading to oedema and congestive heart failure. These complications 
have resulted in treatment being withdrawn in patients, particularly those at risk of 
heart failure. Initial studies proposed that fluid retention was caused by abnormal 
stimulation of ENaC in the collecting duct (Guan et al., 2005, Hong et al., 2003). 
The experiments carried out in the present study, using a murine collecting duct 
cell line, found no alteration to either basal or insulin-stimulated Na
+
 transport in 
the presence of either the TZDs pioglitazone or rosiglitazone. These data therefore 
do not support the hypothesis that TZDs alter ENaC activity in the collecting duct 
and this is consistent with a study examining  the effects of these drugs on ENaC-
mediated transport in three kidney cell lines (Nofziger et al., 2005). The present 
data furthermore unequivocally demonstrate that SGK1 activity is not increased in 
response to TZD-treatment, previously reported as a signalling molecule involved 
in increasing ENaC activity (Hong et al., 2003). 
 
One of the most interesting results to come from the work involved in this thesis 
was the evidence that spontaneous Na
+
 absorption in this cell line occurred in a 
PI3-kinase-, mTORC2- and SGK1-independent manner. Selectively inhibiting 
each kinase left ~80 % of the basal Ieq intact and this data is in sharp contrast to 
previous studies. Inhibition of PI3-kinase using LY294002 and wortmannin was 
shown to inhibit basal currents in A6 cells (Păunescu et al., 2000, Record et al., 
1998, Wang et al., 2001) and mpkCCDcl4 cells (Staruschenko et al., 2007). The 
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data from the present study utilised three different inhibitors of PI3-kinase and 
whilst each fully inhibited downstream kinase activity it was clear wortmannin 
had a substantial effect on basal Ieq that the others did not. These findings strongly 
suggest that wortmannin is inhibiting basal currents due to off-target inhibition 
consistent with previous findings with wortmannin as well as LY-294002 as 
discussed earlier (4.3.1).  
 
The proposed role of SGK1 in maintaining spontaneous Na
+
 absorption came 
from studies in A6 and M1 cells overexpressing a kinase-dead mutant of SGK1 
which completely abolished basal Na
+
 transport (Faletti et al., 2002, Helms et al., 
2003). In the present study, cells exposed to a novel inhibitor of SGK1, 
GSK650394A, showed only a modest decrease in basal Ieq. This inhibitor however 
completely abolished phosphorylation of a downstream substrate indicating that 
these cells could spontaneously absorb Na
+
 without SGK1 activity. The results in 
this thesis also provide evidence for the first time that mTORC2 does not play a 
major role in the maintenance of the basal current. This is consistent with 
mTORC2 lying downstream of PI3-kinase and upstream of SGK1, both of which 
were demonstrated to not be major contributors of the basal current. The use of 
the mTOR inhibitors PP242 and TORIN1 in conjunction with rapamycin, the 
specific inhibitor of mTORC1, allowed a novel means to target mTORC2 in a 
native system.  
 
Unlike the spontaneous Na
+
 absorption recorded from this cell line, insulin-
stimulated Na
+
 transport was found to be PI3-kinase-, mTORC2- and SGK1-
199 
dependent. Inhibiting PI3-kinase completely abolished the response and this is 
consistent with previous studies that also used chemical agents to block this 
pathway (Blazer-Yost et al., 2003, Record et al., 1998, Staruschenko et al., 2007). 
Similar to previous work was the finding that SGK1 was required for the 
natriferic effect of insulin. Studies where A6 cells expressed wild-type or 
constitutively active SGK1 showed increased rates of Na
+
 transport that could not 
further be potentiated with exposure to insulin, indicating a similar pathway 
(Faletti et al., 2002, Alvarez De La Rosa and Canessa, 2003, Arteaga and 
Canessa, 2005). Similarly in studies where SGK1 expression was silenced insulin 
could not stimulate ENaC-mediated Na
+
 transport (Lee et al., 2007). The data 
from the experiments carried out in this project confirm these findings using a 
novel drug to inhibit SGK1 in a mammalian collecting duct cell line. The role that 
Akt plays in mediating insulin-stimulated Na
+
 transport from cannot be excluded 
and remains uncertain. The present study shows that Akt remains active when 
cells are exposed to GSK650394A and therefore establishes that Akt is not 
sufficient to maintain the response to insulin. It can be concluded that Akti-1/2 is 
not a selective inhibitor of Akt as it inhibits SGK1 activity as monitored by 
phosphorylation of NDRG1. This highlights the importance of confirming the 
specificity of inhibitors employed in experiments, particularly in a native cell line. 
A novel finding from the work carried out during this thesis was the 
demonstration that insulin-stimulated Na
+
 transport is mTORC2-dependent. 
Whilst SGK1 has been shown to play an important role in this response and 
mTORC2 has recently been shown to be crucial for SGK1 activity (García-
Martínez and Alessi, 2008), the importance of mTORC2 in Na
+
 transport had not 
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previously been demonstrated. The data presented in this thesis shows that 
mTORC2 plays a vital role in mediating insulin-stimulated Na
+
 absorption. Whilst 
a paper that has just been published investigates the role of mTORC2 in mediating 
hormonally-stimulated Na
+
 transport, this study looks at the additive effect of 
insulin and aldosterone (Lu et al., 2010). Whilst this newly-published study shows 
that aldosterone and insulin require mTORC2 activity, it does not separate these 
responses and our data clearly show that mTORC2 is required for the natiferic 
effect of insulin. Since insulin and aldosterone display an additive effect on Na
+
 
transport, this suggests that they are using different mechanisms to do so; 
therefore more than one signalling pathway may be involved. 
 
Dexamethasone stimulated Na
+
 absorption in these cells in a similar manner to 
insulin but over a longer time period; the response was apparent after an hour. 
This finding is consistent with other studies that found that dexamethasone 
stimulated Na
+
 transport (Wang et al., 2001). This response could be blocked by 
the novel mTOR inhibitors PP242 and TORIN1 but interestingly also with 
rapamycin, a specific inhibitor of mTORC1. These results were unexpected as 
dexamethasone has previously been shown to increase the abundance of SGK1 in 
a similar manner to aldosterone (Wang et al., 2001, Robert-Nicoud et al., 2001). 
Therefore it was anticipated that mTORC2, a crucial component of the SGK1 
pathway, would play an important role in this response. The results from the 
present study indicate that the natriferic response to dexamethasone is in fact 
largely mTORC1-dependent. This has previously been reported in A6 cells but 
was dependent on much longer exposure to rapamycin (Rokaw et al., 1996b). 
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Another study has shown that rapamycin can inhibit basal amiloride-sensitive 
currents in fetal airway epithelial cells (Otulakowski et al., 2007). However in the 
present study, rapamycin has no effect on the basal current, therefore the acute 
mTORC1-dependence of the dexamethasone-stimulated current appears to be a 
novel finding. Of even greater interest is that whilst rapamycin can inhibit this 
natriferic response, SGK1 activity remains unaltered suggesting that activation of 
SGK1 does not provide a sufficient stimulus to explain the response. Our data 
indicate that SGK1 activity is increased in response to dexamethasone, but since 
mTORC2 activity is not increased it seems that instead of stimulating the PI3-
kinase / mTORC2 / SGK1 pathway, the increased abundance of SGK1 is feeding 
into an already active pathway. Since the current can be blocked with full SGK1 
activity, this suggests SGK1 is not a key component of this response. 
 
Vasopressin stimulated Ieq in these cells in a different manner to both insulin and 
dexamethasone by causing a large fall in Rt and an associated depolarisation of Vt. 
This response is unusual as an increase in Na
+
 absorption would give rise to a 
hyperpolarisation of Vt and the opposite is observed. The fall in Rt suggests that 
the paracellular pathway may be increased due to increased tight junction 
permeability. However, Ieq can still be blocked with amiloride consistent with an 
increase in ENaC-mediated Na
+
 absorption. The stimulated Ieq was unaffected by 
both PP242 and TORIN, a novel finding, indicating that this response is 
independent of both mTORC1 and mTORC2. Vasopressin stimulates PKA as 
demonstrated by an increase in phosphorylation of a downstream substrate and 
this is consistent with a number of studies (Shelly and Herrera, 2002, Hallows et 
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al., 2009). Another interesting finding from the present study is that vasopressin 
suppresses SGK1 activity and this is in sharp contrast to a study that showed 
SGK1 phosphorylation was increased in response to this hormone (Perrotti et al., 
2001). Furthermore, since SGK1 activity is abolished in the presence of both 
PP242 and TORIN1, SGK1 must play no role in the vasopressin-stimulated Ieq 
and that this hormone stimulates a completely different signalling pathway to 
increase ENaC activity. 
 
7.2 Future work 
Whilst the work carried out for this thesis has identified crucial steps in the insulin 
signalling pathway: PI3-kinase, mTORC2 and SGK1; the final effector that 
mediates changes in ENaC activity was not studied. Many groups have focussed 
their work on the ubiquitin ligase Nedd4-2 and have provided convincing data that 
phosphorylation by SGK1 prevents Nedd4-2 interacting with ENaC 
(Debonneville et al., 2001). With less ENaCs being targeted for internalisation 
and degradation there will be an associated increase in Na
+
 transport. This has 
been demonstrated in oocyte expression studies as well as renal cell lines where 
overexpression of Nedd4-2 reduces ENaC-mediated currents and silencing 
expression increases them (Goulet et al., 1998, Lee et al., 2007, Kamynina et al., 
2001a). Studying the role of Nedd4-2 in the murine collecting duct cell line 
utilized in the present study would provide conclusions to the signalling pathway 
investigated thus far. There are no specific inhibitors of this ubiquitin ligase 
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therefore a knockdown of Nedd4-2 would provide an insight into its role in 
hormonally regulated ENaC activity.  
 
Due to the lack of selectivity exerted by Akti-1/2 the question of the role that Akt 
plays in mediating insulin-stimulated Na
+
 transport remains unanswered. The 
simplest action would be to identify another Akt inhibitor, confirm specificity and 
then look at effects on insulin-stimulated Na
+
 transport. Alternatively, silencing 
Akt would provide a means to investigate the relative importance of this kinase in 
a mammalian collecting duct cell line. Another interesting interpretation of the 
data described here is that rather than Akti-1/2 being non-specific, there could be 
a direct interaction between Akt and SGK1. Immunoprecipitation studies could 
reveal whether Akt can physically bind SGK1. 
 
The interesting results from dexamethasone-stimulated cells opened up many 
questions. Firstly, how much of a role does SGK1 play in mediating 
dexamethasone-stimulated Na
+
 transport in the collecting duct? It seems unusual 
that this hormone would stimulate increased expression of SGK1 but the natriferic 
response can be inhibited without altering activity of this kinase. It would be 
prudent to confirm that SGK1 abundance is in fact increased in this cell line by 
measuring SGK1 transcripts. Experiments examining the effects of GSK650394A 
on dexamethasone-stimulated Na
+
 transport should also give answers to the 
importance of SGK1 in this response. Perhaps SGK1 is exerting effects on other 
transport proteins such as the Na
+
 / K
+
 ATPase, inhibitor studies could confirm 
this. It would also be interesting to verify the role of PI3-kinase in this response 
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using the more novel and specific inhibitor GDC0941. Another important 
question from the dexamethasone studies is whether this relates to aldosterone 
signalling. Whilst the present study provides information on GR-mediated Na
+
 
absorption, which is relevant in hypertensive conditions such as Apparent 
Mineralocorticoid Excess syndrome, it cannot give information regarding the 
action of aldosterone. Since this mineralocorticoid plays a vital role in mediating 
Na
+
 transport in the distal nephron it would seem prudent to repeat these 
experiments in an aldosterone-sensitive collecting duct cell line. It would be of 
great interest whether aldosterone-stimulated Na
+ 
transport is mTORC1-
dependent as this is largely an unexplored area of ENaC signalling. Could it be 
that by blocking mTORC1 and the downstream S6kinase, synthesis of protein 
molecules other than SGK1 are being blocked which make a much larger 
contribution to ENaC-mediated transport? In this respect further work into the 
roles of GILZ would be of interest as this protein inhibits the ERK pathway 
(Soundararajan et al., 2005) which could account for a non-PI3-kinase-dependent 
action. 
 
Finally, the unusual response to AVP prompted many questions. The odd fall in Rt 
and depolarisation of Vt seemed at odds with a stimulation of ENaC-mediated Na
+
 
transport. It would be interesting to look at the response in the presence of 
amiloride or Cl
-
 channel blockers such as NPBB. Furthermore it would certainly 
be of interest to investigate the response of AVP under short circuit conditions 
and compare with recordings under open circuit conditions. The Vt generated by 
these cells is very large, -45mV, therefore clamping the voltage to 0mV would 
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alter the electrochemical gradients. Any differences noted between the two 
recording conditions would certainly be useful for planning future experiments. 
The scope of the short-term experiments carried out in this thesis was to 
investigate the effects of PP242 and TORIN1. Indeed it could be concluded that 
AVP does not signal via an mTORC1/2 pathway and that SGK1 is not involved. 
Further confirmation for the lack of SGK1 involvement could be obtained by 
using GSK650394A but the present data appears unequivocal. Since PKA has 
been reported to also phosphorylate Nedd4-2 in a similar manner to SGK1, it 
would be interesting to target the ubiquitin ligase with respect to AVP. 
 
7.3 Concluding remarks 
The data presented in this thesis provides evidence that spontaneous Na
+
 
absorption in a renal collecting duct cell line is largely a PI3-kinase-, mTORC2-, 
and SGK1-independent response. Insulin-stimulated Na
+
 transport conversely 
occurs in a manner absolutely dependent on these signalling molecules. Both 
pioglitazone and rosiglitazone do not alter basal or insulin-stimulated Na
+
 
transport nor SGK1 activity and the side effects brought about by these drugs 
cannot be attributed to alterations to ENaC activity. Dexamethasone-stimulated 
Na
+
 transport was mTORC1-dependent but SGK1-independent. Vasopressin-
stimulated Na
+
 transport was mTORC1-, mTORC2- and therefore SGK1-
independent. This hormone did stimulate PKA which could therefore interact with 
Nedd4-2. All results from the work carried out in this thesis have stimulated 
further questions needing answered. The methods utilised in these studies where 
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the effects of novel inhibitors on both biophysical properties and protein 
phosphorylation in a mammalian collecting duct cell line were examined are of 
great potential in future studies. 
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Table 8.1 Electrical parameters from control and Akti-1/2-treated cells. 
Mean values ± S.E.M. of Ieq, Vt and Rt recorded from control and Akti-1/2-treated cells. Each treatment has its own unstimulated and insulin-stimulated response. 
Values are calculated as a mean of 3 min: before vehicle / insulin was added and after 30 min exposure to vehicle / insulin. 
   Ieq(µA cm
-2
) Vt (mV) Rt (kΩ cm
2
) 
Pre-vehicle / 
insulin 
Post-vehicle / 
insulin 
Pre-vehicle / 
insulin 
Post-vehicle / 
insulin 
Pre-vehicle / 
insulin 
Post-vehicle / 
insulin 
Control Vehicle -23.6 ± 2.1 -22.1 ± 2.4 -57.1 ± 2.7 -54.5 ± 3.7 2.5 ± 0.2 2.5 ± 0.2 
Insulin -23.6 ± 2.1 -30.1 ± 3.0 -54.3 ± 2.7 -63.0 ± 1.4 2.4 ± 0.2 2.2 ± 0.2 
1µM Akti-1/2 Vehicle -18.9 ± 2.1 -17.8 ± 2.3 -47.0 ± 5.0 -46.8 ± 5.1 2.6 ± 0.3 2.7 ± 0.3 
Insulin -19.0 ± 2.0 -23.3 ± 3.9 -51.1 ± 5.2 -55.6 ± 4.4 2.9 ± 0.2 2.8 ± 0.3 
Control Vehicle -13.7 ± 1.1 -13.2 ± 1.1 -26.1 ± 2.4 -25.6 ± 2.2 1.9 ± 0.2 2.0 ± 0.2 
Insulin -14.2 ± 1.4 -19.6 ± 1.8 -34.4 ± 3.1 -43.8 ± 3.8 2.5 ± 0.2 2.3 ± 0.2 
3µM Akti-1/2 Vehicle -14.6 ± 0.9 -13.5 ± 0.8 -37.7 ± 2.3 -36.6 ± 2.0 2.6 ± 0.1 2.7 ± 0.1 
Insulin -13.1 ± 0.8 -15.6 ± 1.2 -33.5 ± 1.2 -39.0 ± 1.5 2.6 ± 0.2 2.5 ± 0.2 
Control Vehicle -14.1 ± 3.2 -13.3 ± 2.8 -39.8 ± 5.9 -37.7 ± 5.2 3.1 ± 0.3 3.0 ± 0.3 
Insulin -14.4 ± 3.8 -18.9 ± 4.1 -42.8 ± 7.0 -48.7 ± 6.3 3.2 ± 0.3 2.8 ± 0.3 
10µM Akti-1/2 Vehicle -11.3 ± 1.4 -10.3 ± 1.0 -37.8 ± 4.0 -32.4 ± 2.3 3.4 ± 0.2 3.2 ± 0.1 
Insulin -10.6 ± 2.0 -10.4 ± 1.6 -32.9 ± 5.3 -31.9 ± 3.6 3.3 ± 0.4 3.3 ± 0.4 
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Table 8.2 Electrical parameters from control and GSK650394A-treated cells. 
Mean values ± S.E.M. of Ieq, Vt and Rt recorded from control and GSK650394A-treated cells. Each treatment has its own unstimulated and insulin-stimulated response. 
Values are calculated as a mean of 3 min: before vehicle / insulin was added and after 30 min exposure to vehicle / insulin. 
   Ieq(µA cm
-2
) Vt (mV) Rt (kΩ cm
2
) 
Pre-vehicle / 
insulin 
Post-vehicle / 
insulin 
Pre-vehicle / 
insulin 
Post-vehicle / 
insulin 
Pre-vehicle / 
insulin 
Post-vehicle / 
insulin 
Control Vehicle -12.0 ± 2.1 -11.3 ± 1.9 -38.7 ± 5.5 -37.7 ± 5.0 3.3 ± 0.2 3.4 ± 0.2 
Insulin -13.7 ± 1.9 -18.8 ± 2.2 -34.7 ± 6.2 -44.6 ± 5.4 2.5 ± 0.2 2.4 ± 0.1 
1µM 
GSK650394A 
Vehicle -12.6 ± 2.1 -10.9 ±2.2 -33.6 ± 3.8 -32.1 ± 3.5 2.9 ± 0.4 3.2 ± 0.5 
Insulin -11.6 ± 2.7 -13.2 ± 2.9 -32.0 ± 5.8 -30.9 ± 4.4 3.0 ± 0.4 2.7 ± 0.6 
Control Vehicle -16.5 ± 2.8 -16.0 ± 2.5 -41.9 ± 3.9 -41.2 ± 4.9 2.7 ± 0.3 2.7 ± 0.2 
Insulin -16.4 ± 3.6 -21.9 ± 3.4 -38.8 ± 4.6 -49.4 ± 3.7 2.6 ± 0.3 2.3 ± 0.2 
3µM 
GSK650394A 
Vehicle -20.9 ± 3.3 -18.9 ± 2.9 -35.7 ± 5.1 -33.7 ± 5.1 1.8 ± 0.2 1.9 ± 0.3 
Insulin -17.4 ± 2.8 -18.0 ± 2.3 -31.1 ± 3.5 -24.7 ± 7.1 2.0 ± 0.4 1.5 ± 0.5 
Control Vehicle -16.4 ± 3.1 -14.4 ± 2.5 -33.8 ± 4.4 -31.4 ± 4.4 2.2 ± 0.3 2.3 ± 0.2 
Insulin -17.7 ± 2.7 -24.3 ± 4.0 -43.7 ± 3.8 -50.3 ± 4.4 2.6 ± 0.3 2.2 ± 0.3 
10µM 
GSK650394A 
Vehicle -15.4 ± 3.9 -13.6 ± 3.1 -17.6 ± 4.4 -18.5 ± 4.3 1.2 ± 0.2 1.4 ± 0.2 
Insulin -13.9 ± 3.5 -12.5 ± 2.9 -17.8 ± 4.9 -18.1 ± 4.9 1.4 ± 0.3 1.5 ± 0.3 
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Table 8.3 Electrical parameters from unstimulated control and TORIN1-treated cells. 
Mean values ± S.E.M. of Ieq, Vt and Rt recorded from control and TORIN1-treated cells. Values are calculated as a mean of 3 min: before vehicle / TORIN1 was added 
and after 60 min exposure to vehicle / TORIN1. 
 
Treatment 
 
Ieq(µA cm
-2
) 
 
Vt (mV) Rt (kΩ cm
2
) 
Baseline 60 min exposure Baseline 60 min exposure Baseline 60 min exposure 
Vehicle -18.3 ± 1.3 -15.8 ± 1.1 -47.8 ± 3.0 -41.1 ± 2.7 2.4 ± 0.1 2.5 ± 0.1 
TORIN1 -16.8 ± 1.1 -12.9 ± 0.8 -39.8 ± 3.2 -32.1 ± 2.5 2.2 ± 0.2 2.5 ± 0.1 
Vehicle -24.0 ± 1.6 -19.9 ± 1.3 -57.2 ± 2.5 -49.2 ± 1.5 2.3 ± 0.1 2.4 ± 0.1 
PP242 -23.4 ± 2.0 -14.3 ± 1.0 -53.8 ± 2.3 -37.6 ± 1.4 2.5 ± 0.2 2.8 ± 0.3 
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Table 8.4 Electrical parameters from insulin-stimulated TORIN1- and PP242-treated cells 
Mean values ± S.E.M. of Ieq, Vt and Rt recorded from control and inhibitor-treated cells (n = 5 for each compound). Each treatment has its own unstimulated and 
insulin-stimulated response. Values are calculated as a mean of 3 min: before vehicle / insulin was added and after 30 min exposure to vehicle / insulin. 
   Ieq(µA cm
-2
) Vt (mV) Rt (kΩ cm
2
) 
Pre-vehicle / 
insulin 
Post-vehicle / 
insulin 
Pre-vehicle / 
insulin 
Post-vehicle / 
insulin 
Pre-vehicle / 
insulin 
Post-vehicle / 
insulin 
Control Vehicle -14.4 ± 1.9 -13.1 ± 1.7 -45.9 ± 2.2 -35.6 ± 3.1 2.8 ± 0.1 2.9 ± 0.1 
Insulin -17.0 ± 2.0 -22.6 ± 2.6 -39.9 ± 5.7 -43.6 ± 7.0 2.5 ± 0.2 2.5 ± 0.2 
100nM TORIN1 Vehicle -13.6 ± 1.2 -11.8 ± 1.2 -38.4 ± 6.3 -29.1 ± 4.7 2.3 ± 0.3 2.4 ± 0.3 
Insulin -14.6 ± 1.4 -14.4 ± 1.6 -39.4 ± 5.4 -40.8 ± 5.5 2.7 ± 0.2 2.8 ± 0.2 
Control Vehicle -17.5 ± 1.0 -15.8 ± 0.9 -50.2 ± 2.2 -47.2 ± 2.1 2.9 ± 0.1 3.0 ± 0.1 
Insulin -20.1 ± 1.6 -25.2 ± 1.8 -50.5 ± 4.5 -55.9 ± 3.9 2.5 ± 0.1 2.2 ± 0.1 
1µM PP242 Vehicle -13.9 ± 1.1 -11.9 ± 1.0 -41.4 ± 1.6 -36.4 ± 1.9 3.1 ± 0.1 3.1 ± 0.3 
Insulin -15.7 ± 1.3 -14.9 ± 1.3 -48.0 ± 2.4 -46.6 ± 2.7 3.1 ± 0.1 3.2 ± 0.1 
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Table 8.5 Electrical parameters from dexamethasone-stimulated TORIN1-, PP242- and rapamycin-treated cells 
Mean values ± S.E.M. of Ieq, Vt and Rt recorded from control and inhibitor-treated cells. Each treatment has its own unstimulated and dexamethasone -stimulated 
response. Values are calculated as a mean of 3 min: before vehicle / dexamethasone was added and after 2.5 h exposure to vehicle / dexamethasone. 
   Ieq(µA cm
-2
) Vt (mV) Rt (kΩ cm
2
) 
Pre-vehicle / 
dexamethasone 
Post-vehicle / 
dexamethasone 
Pre-vehicle / 
dexamethasone 
Post-vehicle / 
dexamethasone 
Pre-vehicle / 
dexamethasone 
Post-vehicle / 
dexamethasone 
Control 
(n = 5) 
Vehicle -20.7 ± 1.7 -17.6 ± 1.2 -51.7 ± 5.0 -51.9 ± 1.9 2.5 ± 0.2 3.0 ± 0.2 
Dexamethasone -22.0 ± 2.8 -32.8 ± 4.1 -47.2 ± 7.3 -60.9 ± 6.9 2.2 ± 0.3 1.9 ± 0.2 
100 nM 
TORIN1 
Vehicle -15.9 ± 1.8 -9.7 ± 0.8 -40.9 ± 3.1 -36.0 ± 2.9 2.6 ± 0.2 3.7 ± 0.2 
Dexamethasone -18.9 ± 2.2 -14.3 ± 1.8 -43.2 ± 6.3 -44.4 ± 6.6 2.3 ± 0.1 3.1 ± 0.2 
Control 
(n = 5) 
Vehicle -20.8 ± 1.0 -16.6 ± 0.9 -51.2 ± 4.5 -49.8 ± 2.1 2.4 ± 0.1 3.0 ± 0.1 
Dexamethasone -20.8 ± 1.5 -32.9 ± 2.2 -50.1 ± 5.7 -66.3 ± 4.4 2.4 ± 0.2 2.0 ± 0.1 
1 µM PP242 Vehicle -14.0 ± 1.0 -8.4 ±0.7 -40.6 ± 1.0 -32.8 ± 1.7 3.0 ± 0.2 4.0 ± 0.4 
Dexamethasone -14.7 ± 1.4 -10.1 ± 1.2 -37.6 ± 6.1 -36.2 ± 5.2 2.5 ± 0.3 3.6 ± 0.3 
Control 
(n = 3) 
Vehicle -18.7 ± 0.2 -14.1 ± 0.1 -54.5 ± 1.5 -50.9 ± 0.6 2.9 ± 0.1 3.6 ± 0.1 
Dexamethasone -19.2 ± 1.7 -30.8 ± 4.1 -41.1 ± 9.8 -60.9 ± 9.9 2.1 ± 0.5 2.0 ± 0.2 
100 nM 
rapamycin 
Vehicle -14.9 ± 1.0 -9.1 ± 0.8 -37.9 ± 5.4 -34.3 ± 3.4 2.6 ± 0.5 3.9 ± 0.7 
Dexamethasone -15.4 ± 1.9 -12.3 ± 2.2 -44.9 ± 3.4 -47.1 ± 4.5 3.0 ± 0.2 4.0 ± 0.4 
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Table 8.6 Electrical parameters from AVP-stimulated TORIN1- and PP242-treated cells 
Mean values ± S.E.M. of Ieq, Vt and Rt recorded from control and inhibitor-treated cells. Each treatment has its own unstimulated and AVP-stimulated response. Values 
are calculated as a mean of 3 min: before vehicle / AVP was added and after 30 min exposure to vehicle / AVP. 
 
   Ieq(µA cm
-2
) Vt (mV) Rt (kΩ cm
2
) 
Pre-vehicle / 
AVP 
Post-vehicle / 
AVP 
Pre-vehicle / 
AVP 
Post-vehicle / 
AVP 
Pre-vehicle / 
AVP 
Post-vehicle / 
AVP 
Control 
(n = 5) 
Vehicle -15.8 ± 0.6 -14.7 ± 0.5 -38.1 ± 4.2 -36.9 ± 3.7 2.4 ± 0.2 2.5 ± 0.2 
AVP -13.1 ± 1.0 -23.9 ± 1.7 -30.9 ± 2.8 -17.1 ± 3.0 2.4 ± 0.1 0.7 ± 0.1 
100 nM 
TORIN1 
Vehicle -12.8 ± 1.5 -12.0 ± 1.4 -28.4 ± 4.3 -27.1 ± 3.7 2.2 ±0.3 2.3 ± 0.3 
AVP -13.3 ± 2.0 -23.2 ± 1.9 -29.5 ± 3.6 -12.5 ± 2.1 2.3 ± 0.2 0.6 ± 0.1 
Control 
(n = 4) 
Vehicle -27.5 ± 2.5 -24.4 ± 2.5 -54.9 ± 2.1 -51.2 ± 2.1 2.1 ± 0.2 2.2 ± 0.1 
AVP -30.3 ± 1.4 -46.9 ± 2.7 -54.2 ± 3.0 -33.4 ± 5.6 1.8 ± 0.2 0.7 ± 0.1 
1 µM PP242 Vehicle -20.8 ± 1.8 -18.1 ± 1.6 -44.0 ± 3.1 -37.6 ± 3.6 2.2 ± 0.2 2.1 ± 0.2 
AVP -22.4 ± 1.6 -40.8 ± 4.2 -46.8 ± 5.2 -36.8 ± 5.4 2.1 ± 0.1 0.9 ± 0.1 
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